







Analysis of the transcriptome  





for the award of the degree 
“Doctor rerum naturalium” 
of the Georg-August-Universität Göttingen 
 
within the doctoral program Molecular Biology Program 






















Prof. Lutz Walter 
Primate Genetics Laboratory 
German Primate Center, Göttingen 
 
Prof Jörg Stülke 
Department of General Microbiology  
Institute for Microbiology and Genetics, Göttingen 
 
Prof. Matthias Dobbelstein 
Department of Molecular Oncology 
University Medical Center, Göttingen 
 
Members of the Examination Board 
 
Referee: Prof. Lutz Walter 
Primate Genetics Laboratory 
German Primate Center, Göttingen 
 
2nd Referee: Prof. Jörg Stülke 
Department of General Microbiology  
Institute for Microbiology and Genetics, Göttingen 
 
Further members of the Examination Board 
 
Prof. Matthias Dobbelstein 
Department of Molecular Oncology 
University Medical Center, Göttingen 
 
Prof. Steven Johnsen 
Clinic for General, Visceral and Pediatric Surgery  
University Medical Center, Göttingen 
 
Prof. Markus Bohnsack 
Department of Molecular Biology 
University Medical Center Göttingen 
 
 Prof. Holger Reichardt 
Department of Cellular and Molecular Immunology 









TABLE	  OF	  CONENTS	  
LIST	  OF	  ABBREVIATIONS	  .........................................................................................................	  5	  
ACKNOWLEDGEMENTS	  .............................................................................................................	  6	  
ABSTRACT	  .....................................................................................................................................	  7	  
1.INTRODUCTION	  .......................................................................................................................	  9	  
1.1.	  Innate	  lymphoid	  cell	  lineage	  .....................................................................................	  9	  
1.2.	  Functions	  of	  NK	  cells	  ..................................................................................................	  10	  
1.2.1.	  Cytokine	  and	  chemokine	  production	  .....................................................................................	  11	  
1.2.2.	  Cytotoxicity	  ........................................................................................................................................	  11	  
1.3.	  NK	  cell	  receptors	  .........................................................................................................	  13	  
1.4.	  Development	  of	  NK	  cells	  ...........................................................................................	  14	  
1.5.	  Licensing	  of	  NK	  cells	  and	  self-­‐tolerance	  ..............................................................	  18	  
1.6.	  Tissue-­‐specific	  characteristics	  of	  NK	  cells	  ..........................................................	  21	  
1.7.	  The	  role	  of	  high-­‐throughput	  methods	  in	  studying	  of	  lymphocyte	  
expression	  profiles	  ...........................................................................................................................	  23	  
2.	  MATERIALS	  AND	  METHODS	  ............................................................................................	  25	  
2.1.	  Chemicals,	  kits	  and	  consumables	  ..........................................................................	  25	  
2.2.	  Buffers	  .............................................................................................................................	  25	  
2.3.	  Equipment	  .....................................................................................................................	  25	  
2.4.	  Software	  .........................................................................................................................	  26	  
2.5.	  Blood	  and	  tissue	  samples	  .........................................................................................	  26	  
2.5.	  Preparation	  of	  single	  cell	  samples	  ........................................................................	  29	  
2.5.1.	  Isolation	  of	  peripheral	  blood	  mononuclear	  cells	  ..............................................................	  29	  
2.5.2.	  NK	  cell	  enrichment	  .........................................................................................................................	  30	  
2.5.3.	  Generating	  of	  cDNA	  libraries	  from	  single	  cells	  ..................................................................	  30	  
2.6.	  Sequencing	  ....................................................................................................................	  31	  
2.7.	  Statistical	  analysis	  ......................................................................................................	  31	  
2.7.1.	  Log2EX	  and	  Limit	  of	  Detection	  (LoD)	  .....................................................................................	  31	  
2.7.2.	  Principal	  component	  analysis	  ...................................................................................................	  32	  
2.7.3.	  The	  Outlier	  Identification	  Method	  ...........................................................................................	  32	  
2.7.4.	  Identification	  of	  top	  genes	  ..........................................................................................................	  33	  
2.7.5.	  ANOVA	  .................................................................................................................................................	  33	  
2.7.6.	  Hierarchical	  Clustering	  Analysis	  ..............................................................................................	  33	  
2.7.7.	  Violin	  plots	  .........................................................................................................................................	  34	  





2.7.9.	  Spearman’s	  correlation	  analysis	  ..............................................................................................	  34	  
2.7.10.	  Gene	  ontology	  analysis	  ..............................................................................................................	  35	  
3.	  RESULTS	  .................................................................................................................................	  36	  
3.1	  Clustering	  of	  different	  lymphocyte	  group:	  proof	  of	  data	  quality	  and	  the	  
method	  ..................................................................................................................................................	  36	  
3.2	  Identification	  of	  specific	  expression	  patterns	  between	  mature	  PBMC	  
populations	  .........................................................................................................................................	  41	  
3.3	  Expression	  profiling	  of	  ex	  vivo	  NK	  populations	  .................................................	  43	  
3.3.1	  Changes	  in	  expression	  landscape	  during	  NK	  cell	  development	  ..................................	  43	  
3.3.2	  Analysis	  of	  ex	  vivo	  NK	  stage	  3	  expression	  profiles	  ............................................................	  49	  
3.3.2.1	  Tissue-­‐specific	  differences	  in	  gene	  expression	  profiles	  of	  stage	  3	  ex	  vivo	  NK	  
cells	  .....................................................................................................................................................................................	  49	  
 
3.3.2.2	  Expression	  differences	  between	  stage	  3	  NK	  cells	  and	  ILC3	  ......................................	  51	  
3.3.2.3	  Heterogeneity	  of	  non-­‐bone	  marrow	  stage	  3	  samples	  ..................................................	  54	  
3.3.2	  Analysis	  of	  ex	  vivo	  NK	  stage	  4	  expression	  profiles	  ............................................................	  56	  
3.3.3	  Analysis	  of	  ex	  vivo	  NK	  stage	  5	  expression	  profiles	  ............................................................	  60	  
3.3.3.1	  Tissue-­‐specific	  differences	  .......................................................................................................	  60	  
3.3.3.2	  Functional-­‐specific	  differences	  ..............................................................................................	  62	  
3.3.3.3	  Donor-­‐specific	  differences	  .......................................................................................................	  65	  
3.3.3.4	  Correlation	  network	  of	  gene	  expression	  within	  nonlicensed,	  licensed	  and	  
memory-­‐like	  stage	  5	  NK	  cells	  ..................................................................................................................................	  68	  
3.4	  Comparison	  of	  expression	  profiles	  of	  ex	  vivo	  and	  in	  vitro	  NK	  
developmental	  stages	  ......................................................................................................................	  72	  
3.4.1	  Stage	  3	  ...................................................................................................................................................	  72	  
3.4.2	  Stage	  4	  ...................................................................................................................................................	  74	  
3.4.3	  Stage	  5	  ...................................................................................................................................................	  76	  
3.5	  Differential	  expression	  of	  protein-­‐coding	  and	  non-­‐protein	  coding	  genes	  80	  
3.6	  Regulatory	  potential	  of	  non-­‐protein	  coding	  RNAs	  ............................................	  88	  
3.6.1.	  Correlation	  between	  expression	  levels	  of	  protein-­‐coding	  and	  non-­‐protein	  coding	  
genes	  during	  NK	  development	  ................................................................................................................................	  88	  
3.6.2.	  Cis-­‐regulation	  potential	  ...............................................................................................................	  92	  
3.7.	  Transcriptome	  analysis	  of	  NK	  lymphocytes	  at	  the	  single	  cell	  level	  ........	  100	  
3.7.1.	  Identification	  of	  outliers	  ...........................................................................................................	  102	  
3.7.2.	  Heterogeneity	  of	  gene	  expression	  in	  single	  NK	  cells	  ....................................................	  102	  
3.7.3.	  Regulatory	  potential	  of	  non-­‐protein	  coding	  RNAs	  ........................................................	  106	  
3.7.4.	  Comparison	  to	  bulk	  sequencing	  data	  ..................................................................................	  109	  





4.1.	  Proof	  of	  the	  methodology	  and	  data	  quality	  .....................................................	  112	  
4.2.	  The	  specific	  NK	  cell	  expression	  profile	  .............................................................	  112	  
4.3.	  Changes	  in	  gene	  expression	  during	  NK	  cell	  development	  .........................	  114	  
4.4.	  Differences	  in	  expression	  profiles	  between	  stage	  5	  functional	  groups	  .	  116	  
4.5.	  Specific	  expression	  profiles	  of	  in	  vitro	  differentiated	  NK	  cells	  .................	  117	  
4.6.	  Identification	  of	  novel	  genes	  with	  potential	  medical	  relevance	  ..............	  118	  
4.7.	  The	  potential	  regulatory	  role	  of	  non-­‐protein	  coding	  genes	  ......................	  119	  
4.8.	  Single	  cell	  transcriptome	  analysis	  of	  lymphocytes:	  perspectives	  and	  
limitations	  ........................................................................................................................................	  122	  
REFERENCES	  ............................................................................................................................	  124	  
APPENDIXES	  ............................................................................................................................	  139	  
Appendix	  1	  Ranked	  top	  100	  genes	  differentially	  expressed	  within	  all	  analyzed	  
samples	  ..........................................................................................................................................................................	  139	  
Appendix	  2	  Genes	  differentially	  expressed	  between	  PBMC	  populations	  identified	  
using	  ANOVA	  analysis	  ..............................................................................................................................................	  140	  
Appendix	  3	  Genes	  differentially	  expressed	  between	  ex	  vivo	  NK	  developmental	  stages	  
identified	  using	  ANOVA	  analysis	  ........................................................................................................................	  144	  
Appendix	  4	  Ranked	  top	  100	  genes	  differentially	  expressed	  within	  ex	  vivo	  stage	  4	  NK	  
samples	  ..........................................................................................................................................................................	  147	  
Appendix	  5	  Genes	  differentially	  expressed	  between	  ex	  vivo	  stage	  4	  NK	  samples	  of	  
different	  tissue	  origin	  identified	  using	  ANOVA	  analysis	  ..........................................................................	  148	  
Appendix	  6	  Genes	  differentially	  expressed	  between	  BM-­‐derived	  and	  non-­‐BM	  derived	  
stage	  4	  NK	  samples	  identified	  among	  top	  400	  genes	  using	  ANOVA	  analysis	  ..................................	  150	  
Appendix	  7	  Ranked	  top	  100	  genes	  differentially	  expressed	  within	  ex	  vivo	  stage	  5	  NK	  
samples	  ..........................................................................................................................................................................	  151	  
Appendix	  8	  Genes	  differentially	  expressed	  between	  nonlicensed,	  licensed	  and	  
memory-­‐like	  ex	  vivo	  stage	  5	  NK	  populations	  identified	  from	  top	  100	  genes	  using	  ANOVA	  
analysis	  ...........................................................................................................................................................................	  153	  
Appendix	  9	  Genes	  differentially	  expressed	  between	  nonlicensed,	  licensed	  and	  
memory-­‐like	  ex	  vivo	  stage	  5	  NK	  populations	  (excluding	  samples	  from	  the	  donor	  6)	  identified	  
from	  top	  400	  genes	  using	  ANOVA	  analysis	  ....................................................................................................	  154	  
Appendix	  10	  Genes	  differentially	  expressed	  between	  ex	  vivo	  and	  in	  vitro	  stage	  3	  NK	  
populations	  identified	  from	  top	  400	  genes	  using	  ANOVA	  analysis	  .....................................................	  156	  
Appendix	  11	  Genes	  differentially	  expressed	  between	  ex	  vivo	  and	  in	  vitro	  stage	  4	  NK	  
populations	  identified	  from	  top	  400	  genes	  using	  ANOVA	  analysis	  .....................................................	  158	  
Appendix	  12	  Ranked	  top	  100	  protein-­‐genes	  differentially	  expressed	  within	  ex	  vivo	  NK	  





Appendix	  13	  Ranked	  top	  100	  non-­‐protein	  genes	  differentially	  expressed	  within	  ex	  
vivo	  NK	  samples	  ..........................................................................................................................................................	  161	  
Appendix	  14	  Correlation	  coefficients	  between	  expression	  of	  protein-­‐coding	  and	  non-­‐
protein	  coding	  genes	  ................................................................................................................................................	  162	  
Appendix	  15	  Correlation	  coefficients	  between	  expression	  of	  non-­‐protein	  coding	  and	  
those	  of	  closely	  localized	  protein-­‐coding	  genes	  ...........................................................................................	  165	  
Appendix	  16	  NK-­‐specific	  genes	  used	  for	  single	  cell	  analysis	  ................................................	  191	  
Appendix	  17	  Ranked	  top	  89	  genes	  differentially	  expressed	  within	  single	  cell	  samples
	  ...........................................................................................................................................................................................	  191	  
Appendix	  18	  Correlation	  between	  expression	  of	  non-­‐protein	  coding	  genes	  and	  those	  
of	  protein-­‐coding	  genes	  within	  single	  NK	  cells	  ............................................................................................	  192	  
Appendix	  19	  Correlation	  between	  expression	  of	  non-­‐protein	  coding	  genes	  and	  those	  
of	  protein-­‐coding	  genes	  within	  cell	  populations	  .........................................................................................	  194	  







LIST OF ABBREVIATIONS 
ADCC    Antibody dependent cellular cytotoxicity 
ANOVA   Analysis of variance 
APC   Antigen presenting cell 
BM    Bone marrow 
BSA    Bovine serum albumin 
CB  Cord blood 
ChiP Chromatin immunoprecipitation  
CLP  Common lymphoid progenitor 
cNK  Conventional natural killer cells 
DC  Dendritic cells 
EDTA  Ethylenediaminetetraacetic acid 
FACS  Fluorescence activated cell sorting 
fpkm  Fragments per kilobase of exon per million fragments mapped 
GO  Gene ontology 
HC  Hierarchical clustering 
HLA  Human leukocyte antigen 
HSC  Hematopoietic stem cells 
IFC  Integrated Fluidic Circuits 
Ig  Immunoglobulin 
IL  Interleukin 
ILC  Innate lymphoid cell 
ITAM  Immunoreceptor tyrosine based activation motif 
ITIMs  Immunoreceptor tyrosine based inhibition motifs 
KIR  Killer-cell immunoglobuline-like receptor 
LMPP  Lymphoid committed or primed progenitor  
LN  Lymph nodes 
lncRNA  Long non-coding RNA 
LoD  Limit of detection 
MC Monocyte 
MHC  Major histocompatibility complex 
miRNA  Micro RNA 
NCR  Natural killer cell receptor 
NK  Natural killer cell 
NKP  Natural killer cell restricted progenitor  
PB  Peripheral blood 
PBMC  Peripheral blood mononuclear cell 
PBS  Phosphate buffered saline 
PCA  Principal component analysis 
SLT  Secondary lymphoid tissues 







I am deeply grateful to Prof. Dr. Lutz Walter for giving me the opportunity to work 
on this project and guiding me through it. Thank you for teaching, advising and 
encouraging me during all these years.  
I want to thank my Thesis Committee members Prof. Dr. Matthias Dobbelstein and 
Prof. Dr. Jorg Stülke for advises and support throughout my PhD project. I also thank Prof. 
Dr. Steven Johnsen, Prof. Dr. Markus Bohnsack and Prof. Dr. Holger Reichardt for joining 
my extended thesis committee. 
This project became possible due to our collaboration partners. Samples 
representing cell populations were obtained from the group of Prof. Dr. Markus Uhrberg 
(University Clinic of Düsseldorf) and the group of Prof. Salim Kakoo (University of 
Southampton); RNA-seq was performed in the group of Dr. Gabriela Salinas-Riester. 
I am grateful to my colleague Angela Noll as well to my former colleague Markus 
Brameier for the support in statistical analysis. I also want to thank my colleagues Beatrix 
Petersen, Christiane Schwarz, Christian Roos, Franziska Aron, Mechthild Pohl, Nico 
Westaphal not only for the practical help, but also for creating a friendly atmosphere in the 
group and for their help in improving my German language.  
I cannot appreciate enough the support of Dr. Steffen Burkhardt and Kerstin 
Grüniger, who gave me an opportunity to study in Göttingen took care of ne during these 
years. 
Many-many thanks to my family and friends, who have been supporting me on all 
this long way from going to Germany for Master’s studies till now. They believed in me 








Natural Killer cells are large granular lymphocytes that contribute to both innate 
and adaptive immunity, as they can not only lyse infected cells or tumors, but also 
stimulate an adaptive immune response via production of cytokines and chemokines. NK 
cells function at the frontline of defense against intracellular pathogens and transformed 
cells due to their ability to respond rapidly and without prior sensitization on multiple 
signals. 
Traditionally the knowledge about NK cell function and development was obtained 
mainly from mouse models, transplantations and in vitro studies, but development of high-
throughput methods of gene expression analysis in the last years shed more light on NK 
cell developmental and functional diversity as well as on ontological relations between 
their subpopulations. However, our knowledge about NK cells remains incomplete, 
especially in comparison to T and B lymphocytes, and many questions in this field are yet 
to be answered.  
Together with our collaborators, our group collected an RNA-seq data set that, to 
our knowledge, is the most complete available for NK cell populations. This data set was 
comprehensively analyzed to elucidate the specific feature of transcriptomes of developing 
and mature NK cells.  
Typical transcription signature of NK cells that distinguishes them from other 
peripheral blood mononuclear cells (PBMCs) and changes in expression profiles of NK 
cells during their development was described. In particular, a set of novel genes was 
identified in which specific expression or function in NK cells was not described before. 
Differences in expression profiles of NK cells from tissues and functional groups were also 
described, in particular the relative immature phenotype of bone marrow-derived stage 3 
NK populations in comparison to their counterparts in tonsils.  
Further, more mature and activated phenotype of NK cells produced by in vitro 
differentiation assays in comparison to their ex vivo counterparts was stated, which can be 
explained by using a cytokine cocktail for proper growth and development of cells in vitro.  
In addition, expression levels of non-protein coding genes expressed by NK cells 
were estimated and the set of non-protein coding genes with regulatory potential in 
development and function of NK cells (e.g. LINC00299, RP11-222K16.2, RP11-212I21.4, 
RP11-456D7.1, RP11-121A8.1) was identified. 
Furthermore, the single cell expression analysis of mature human NK lymphocytes 





performed, which allows further estimation of heterogeneity level of mature NK cell, 
identification of their functional subpopulations, and studying of regulatory gene networks 







Natural Killer (NK) cells are large granular lymphocytes, which are traditionally 
described as CD3-negative, CD56-positive by surface phenotype (Kiessling et al., 1975; 
Robertson et al., 1990). Their function contributes to both innate and adaptive immunity, 
as they can not only lyse infected cells or tumors, but also stimulate an adaptive immune 
response via production of cytokines and chemokines (Herberman et al., 1975; Kiessling et 
al., 1975; Seaman et al., 1987). In the adult human organism NK cells constitute 5 to 15 % 
of peripheral blood, and also can be found in bone marrow, thymus, secondary lymphoid 
tissues (e.g. tonsils, lymph nodes, mucosa-associated lymphoid tissue, spleen) as well as in 
other organs such as liver, lungs, uterus, pancreas and joints (tissue-resident NK cells).  
In spite of NK cells being discovered more than 40 years ago (Kiessling et al., 
1975; Murphy et al., 1987), they are still studied much less than T and B lymphocytes and 
most of the knowledge about NK cell function and development is obtained from mouse 
models, transplantations and in vitro studies.  
1.1. Innate lymphoid cell lineage  
According to the recently established nomenclature, NK cells are placed in a 
diverse group of innate lymphoid cells (ILCs). ILCs are a family of cells involved in 
immunity as well as in tissue development and remodeling. Based on the cytokines that 
they produce and the transcription factors critical for their development and function, ILCs 
are separated into three groups: ILC1, ILC2 and ILC3 (Spits, 2013).  
Group 1 ILCs are characterized by production of IFN-g, but not Th2-cell- and Th17 
cell-associated cytokines (e.g. interleukin (IL)-17 and IL-22), and by dependence on T-bet 
and EOMES transcription factors during development. In mice this cell group expresses 
the cellular receptors NKp46 and NK1.1, while in humans their characteristic cell surface 
markers are CD16, CD56 and CD94 (Crellin et al., 2010b; Cupedo et al., 2009). According 
to these characteristics, NK cells were included into this group. However, a new 
nomenclature proposal puts NK cells in a separate group named cytotoxic ILCs as opposed 
to all other so-called helper-like ILCs (i.e. ILC1, ILC2, ILC3 groups) (Diefenbach et al., 
2014). In the last years more progress has been made in differentiation of conventional NK 
(cNK) cells from other ILC1 populations based on differential expression of lineage-
specific transcription factors (Ribeiro et al., 2010; Vosshenrich et al., 2006). Thus, 
differentiation of cNK cells is controlled by the transcription factors ID2, NFIL3 and 
EOMES, and in addition requires IL-15, while thymic NK cell development depends on 





2006). Development of another subset of NK cells (TRAIL+VLA-1(CD49a)+VLA-2-) 
identified in the liver is EOMES-independent, but requires T-bet and IL-15 signaling, 
while NK cells found in the uterus are both T-bet- and EOMES-independent (Sojka et al., 
2014). Besides this, NFIL3 is critical for the development of bone marrow-derived NK 
cells as well as splenic and thymic NK cells, while liver VLA-2-EOMES- NK cells do not 
require it for development (Male et al., 2012; Seillet et al., 2014).  
Unlike ILC1, group 2 ILCs express Th2-cell associated cytokines and depend on 
the transcription factor GATA3 for their development and function. In mice this group also 
produces IL-5, IL-13, IL-6 and IL-9; during development they require IL-7 and the 
transcription factor RORα for development, and their activity is regulated by IL-25 and IL-
33 (Hoyler et al., 2012; Koyasu and Moro, 2012; Moro et al., 2010; Wilhelm et al., 2011; 
Yang et al., 2013).  
Group 3 ILCs are characterized by production of Th17-related cytokines (IL-17A 
and IL-22) and by dependence on RORγt that is encoded by the RORC gene for their 
development and function and they are also dependent on IL-7Rα. The prototypical ILC3 
cell group are LTi (lymphoid tissue-inducer cells), which require RORγt and AHR during 
development and produce both IL-17 and IL-22 upon activation (Takatori et al., 2009). 
However, the ILC3 lineage is rather heterogenic and at least two other functionally 
different subgroups were identified (Luci et al., 2009; Sanos et al., 2011; Satoh-Takavama 
et al., 2008): (1) ILC3 cells that do not express NK cell receptors (NCR-) depend on 
RORγt, but not on AHR during development; in mice they are able to produce not only IL-
17 and IL-22, but also IFN-γ, while in humans they produce mainly IL-17A (Hoorweg et 
al., 2012; Luci et al., 2009; Sanos et al., 2011; Satoh-Takavama et al., 2008), and (2) 
human NCR-positive ILC3 cells, also known as NCR22 or NK22 cells, that express 
NKp30, NKp44 as well as NKp46 and are able to produce IL-17A and IL-22. In mouse 
models they were shown to produce only IL-22, but in humans NCR+ ILC3s were shown 
to produce both IL-17A and IL-22. Development of these cells is dependent on RORγt and 
AHR, but also on T-bet (as well as development of NK cells and other ILC group 1 cells) 
(Cella et al., 2009; Satoh-Takayama et al., 2010). 
1.2. Functions of NK cells 
NK lymphocytes belong to the innate immune system and are at the frontline of 
defense against intracellular pathogens (of viral as well as bacterial nature) and 
transformed cells due to their ability to respond rapidly and without prior sensitization on 





NK cells implement their functions are cell cytotoxicity and production of cytokines 
(Arase et al., 1996; Robertson et al., 1990).  
1.2.1. Cytokine and chemokine production  
The most important NK cell-derived cytokine is IFN-γ, which activates a Th1 
response and thereby triggers the adaptive immune response. Furthermore, NK cell-
derived IFN-γ activates antigen-presenting cells (APCs), stimulating them to upregulate 
major histocompatibility complex (MHC) class I expression and cytokine expression. It 
also activates macrophage killing of intracellular pathogens. 
Consistent with their function, in secondary lymphoid tissues NK cells are 
localized close to dendritic cells (DCs), where activated NK cells participate in DC 
maturation by producing TNF-a and GM-CSF, while DCs stimulate NK cell activation and 
expansion via cytokine production and secretion (e.g. IL-15, IL-12, IL-1, IL-18).  
In addition, IFN-γ production by NK lymphocytes plays a role in human 
reproduction. When an embryo implants in the uterine wall, fetal trophoblast cells activate 
maternal NK cells by expression of a unique combination of human leukocyte antigen  
(HLA) molecules: HLA-C, HLA-E and HLA-G, which are recognized by NK activating 
receptors. An activation of these NK cells leads to production of IFN-γ, which is important 
for building of placenta and proper blood supply for a developing embryo (Rajagopalan 
and Long, 1999; Trundley and Moffet, 2004; Witt et al., 2002). 
1.2.2. Cytotoxicity 
Cellular cytotoxicity. NK cells mediate cellular cytotoxicity by activation of 
apoptosis in target cells via either the action of perforins and granzymes, TNF-alpha 
release, or death receptors (e.g. TRAIL and Fas-related pathways). Cellular cytotoxicity is 
a predominant function of the CD56dim subset, while CD56bright cells have low cytotoxic 
activity (Lanier et al., 1986). NK cellular cytotoxicity plays a role in antiviral defense, as 
virus-infected cells can be lysed prior to virus replication and virion assembly (Ahmad and 
Menezes, 1996; Biron et al., 1997). Besides this, NK cells are known to be important for 
surveillance and elimination of tumors, as they can recognize multiple markers of cellular 
stress and rapidly react by cellular cytotoxicity. 
Antibody-dependent cellular cytotoxicity. Antibody-dependent cellular 
cytotoxicity (ADCC) is the process of recognition and lysis of opsonized target cells. 
Pathogen’s antigens presented on the surface of target cells are recognized by IgG 
antibodies, which in turn are recognized by Fc gamma receptors on the surface of effector 





function as a bridge between target and effector cells and provide specificity to the 
clearance reaction (Biron et al., 1997).  
Antibody-independent cellular cytotoxicity (natural cytotoxicity) requires more 
complicated regulation by a certain balance of signals from inhibitory and activating 
receptors (Lanier, 2000). Normal cells express different combinations and levels of ligands 
that engage both stimulatory and inhibitory NK cell receptors (described below in more 
detail). The affinity of activating receptors to their ligands is generally lower than that of 
their inhibitory counterparts, so under normal conditions combined signaling from both 
receptor groups does not lead to NK cell activation. Most of these ligands are MHC class I 
molecules, which are often downregulated in infected or transformed cells in order to 
avoid recognition by CD8+ T lymphocytes. This, however, makes affected cells to targets 
for NK lymphocytes, as resting NK cells become activated when they encounter target 
cells with low or missing expression of MHC class I molecules. Such recognition and lysis 
of target cells is called “missing-self recognition” (Karre et al., 1986; Ljunggren and Karre, 
1990;).  
Mechanism of cell recognition and lysis. Activation of resting NK cells is a 
complex process that requires combination of several events: cell contact, adhesion 
(formation of immune synapse), cytotoxic granule polarization and degranulation 
(exocytosis), and requires simultaneous engagement of multiple NK cell receptors 
(Leibson, 1997). Contact and adhesion provide a stable contact between NK and target cell 
and are required for formation of immunological synapse. Interaction of integrins with 
their ligands at this stage is regulated dynamically, as not only stable contact but also quick 
release from adherence is necessary for lymphocyte movement (Barber et al., 2003; 
Bryceson et al., 2005). Polarization of cytotoxic granules (secretory lysosomes) is 
accompanied by polarization of actin cytoskeleton, microtubules, and Golgi apparatus in 
the direction of target cell interface. Unlike T cell polarization (which in case of T cells is 
also required for cytotoxicity), polarization of NK cells was shown to be a relatively 
complicated stepwise process with a series of checkpoints (Bryceson et al., 2005; Wulfing 
et al., 2003). Finally, granules are exocytosed at the degranulation stage, releasing 
cytotoxic effector molecules such as perforin and granzymes to the interface space. When 
uptaken by a target cell, these molecules lead to its death by inducing apoptosis. 
Degranulation is a Ca2+ dependent process and is performed through PKC and G-protein-






1.3. NK cell receptors 
Regulation of the activation of resting NK cells is orchestrated by a balance of 
signals between numerous activating and inhibitory NK cell receptors recognizing MHC 
class I or class-I-like molecules on the surface of target cells.  
Inhibitory receptors ensure self-tolerance to healthy cells and can recognize either 
different epitopes of self-MHC class I molecules (e.g. killer-cell immunoglobulin-like 
receptors (KIRs) and NKG2A) or non-MHC ligands (e.g. KLRG1 and NKR-P1) (Lee et 
al., 1998; Ravetch and Lanier, 2000). All of these receptors use the same signal 
transduction mechanism via cytoplasmic immunoreceptor tyrosine-based inhibition motifs 
(ITIMs). Upon engagement of a ligand, the ITIM is phosphorylated and can recruit SHP-1 
(phosphatase Src homology 2-domain containing phosphatase 1). NK cells acquire 
expression of inhibitory receptors stochastically; from 10-20 inhibitory receptors encoded 
by the genome, each individual NK cell expresses only a subset of three to five receptors in 
average (Burshtyn et al., 1996; Ravetch and Lanier, 2000). 
Activating receptors also contribute to NK cell specificity. Unlike inhibitory 
receptors, most of the activating receptors are expressed by all NK cells. Also in contrast to 
inhibitory receptors activating ones do not share a common mechanism of signal 
transduction: while KIRs and NKG2C interact with the adaptor protein DAP12, which 
contains an immunoreceptor tyrosine-based activation motif (ITAM), other activating 
receptors such as NKp30, NKp44, NKp46 and CD16 are associated with the ITAM-
containing adaptor proteins CD3Z or FCERG, which transmit signals by recruitment of 
tyrosine kinase Syk and ZAP-70 (Kaiser et al., 2005; Stewart et al., 2005). One more group 
of activating NKRs including NKG2D, CD2-family members (CD2, CD244, CD319) and 
DNAM-1 do not contain ITAMs and do not involve ITAM-carrying adaptors and 
transduce signals by other various mechanisms (Bottino et al., 2005; Storkus et al., 1991).  
In particular, NKG2D transduce signals via interaction with DAP10 adaptor molecule, 
DNAM-1 contains an immunoreceptor tyrosine tail–like motif coupling DNAM-1 to 
downstream effectors, and CD244 signal transduction requires immunoreceptor tyrosine-
based switch motif-containing adaptors that interact with its cytoplasmic domain (Gilfillan, 
2002; Veillette et al., 2007; Zhang et al., 2015;) 
 No single receptor-ligand interaction is sufficient for the complex process of NK 
cell activation and elimination of target cells; there is a need of synergetic signaling from a 
bunch of different activating receptors. Only the cooperation between specific receptor 





and DNAM-1, NKG2D and 2B4, 2B4 and DNAM-1 induce degranulation associated with 
efficient target cell killing (Long et al., 2013). Furthermore, even though stimulation of 
activating receptors alone can activate cytotoxicity in resting NK cells, it is much more 
efficient upon combination with IL-stimulation (e.g. IL-2 or IL-12) (Bryceson et al., 2006). 
1.4. Development of NK cells 
Unlike T and B lymphocytes whose differentiation pathways have been already 
comprehensively described, the exact scheme and location of NK cell differentiation 
remains not completely clear.  
Bone marrow (BM) is thought to be the main source of early NK cell 
developmental stages. However, BM-derived early NK cell progenitors are believed to 
traffic through the blood stream to secondary lymphoid tissues (SLT), where commitment 
to the NK cell lineage and maturation occur (Luther et al., 2011; Warner et al., 2012). 
Already in 2005 Freud and colleagues showed that BM-derived CD34+ hematopoietic stem 
cells (HSC) migrate to lymph nodes (LN), where they develop to CD56bright NK cells. 
Later it was suggested (Eissens et al., 2012) that pre-NK cells undergo commitment in LN 
and migrate further to the spleen where their receptor repertoire develops until mature NK 
cells are released into the blood stream. However, detection of at least small amounts of all 
developmental stages in BM and LN suggests, that in situ differentiation also occurs 
outside of the main trafficking way. NK cell progenitors are also found in SLT (tonsils, 
thymus and liver), suggesting that at least some NK cells can also develop extra-medullary. 
It was also reported, that many of the mature NK cell populations that developed in extra-
medullary environment differ from most circulating NK cells in peripheral blood 
(described below) (Eriksson et al., 2004; Koopman et al., 2003). However, it is not yet 
clear, whether these differences are caused by immunophenotypic changes occurring 
during NK cell maturation or by tissue-specific development from common precursors.  
The development pathway starts from Lin-CD34+CD38-CD90+CD45RA-CD49f+ 
HSC which gives rise to the lymphoid and myeloid cell lineages, followed by Lin-
CD34+CD38-CD90+CD45RA+ lymphoid-commited or primed progenitor (LMPP), which 
is a common progenitor for lymphoid cell lineages, including T, B, NK cells and ILCs. The 
LMPP is followed by a common lymphoid progenitor (CLP), characterized as Lin-
CD34+CD38-CD123-CD45RA+CD7+CD10+, downstream in the developmental hierarchy 
(Freud et al., 2006).  
The first progenitor downstream of LMPP and CLP with developmental potential 





described by Renoux and colleagues (2015). This cell type was shown to be present in fetal 
tissues as well as in the adult human organism (in bone marrow, umbilical cord blood and 
tonsils) and is phenotypically characterized as Lin-CD34+CD38+CD123-
CD45RA+CD7+CD10+CD127-. Unlike the lymphocyte progenitors described before, NKP 
were shown to give rise to functional NK cells, but not to T- or B-lymphocytes, and not to 
ILC3s.  
According to the classical model of NK cell development, established in 2005-
2006, NK cells arise from CLP in five stages, which are distinguished based on the surface 
expression of CD34, CD117, CD94 and CD56 (Freud et al., 2006).  Later studies also 
revealed CD133, CD33, CD244 and NKG2A as important developmental markers (Eissens 
et al., 2012).  
The first two stages of NK cell development are characterized by commitment to 
NK cell lineage. Stage 1 (NK progenitor, or pro-NK) is characterized by a CD34+CD117-
CD94-CD45RA+CD10+CD161- phenotype and is multipotent (Cooper et al, 2009). 
Besides NK cells, it gives rise to T lymphocytes and plasmacytoid DCs. The part of stage 1 
cells with high CD34 expression is CD10-positive and was supposed to be the least mature 
population of NK cells in adult BM and SLT (Freud et al., 2006). 
Stage 2 (preNK) is characterized by CD34+CD117+CD94-CD45RA+CD10-
CD161+/- phenotype. All stage 2 cells typically express CD33, CD44, HLA-DR, integrin 
β7 and do not express CD1a, CD5 or CD123, but are heterogenic regarding expression of 
certain surface antigens, such as CD2, CD7, CD10, CD56, and CD161 (Freud et al., 2006). 
It was shown that every stage 2 cell has a capacity to become an NK cell, however cells 
from this population can still give rise to T cells and DCs. Stages 2 to 4 express high levels 
of the high-affinity IL-2 receptor, which allows them to successfully compete for 
picomolar levels of T-cell-derived IL-2, which has an important role for NK cell 
development in SLT (Freud et al., 2006).  
Stage 3 to stage 5 NK cell maturation is characterized by gradual loss of CD34 and 
CD117 (Kit) expression, while surface expression of CD94, CD16 and KIR molecules 
increases (Eissens et al., 2012).  
Stage 3 (immature NK cells) cells are CD34-CD117+CD94- which are usually 
described as the first population committed to NK cell development, as they are unable to 
give rise to any other lymphoid lineages (Freud et al., 2006). Indeed, they all express (on 
variable levels) NK-associated molecules, such as CD2, CD7, CD56, CD161, 2B4, and 





lymphocytes, they lack the surface molecules CD10, integrin beta 7 and HLA-DR, but 
show high expression of IL-7Rα (Freud et al., 2006). They lack two key marks of mature 
NK cells: the ability to mediate cellular toxicity and IFN-g production, however they 
contribute to immunity via production of GM-CSF and type 2 cytokines and/or mediating 
TRAIL-dependent cell death (Barton et al., 1998; Freud et al., 2006). According to the data 
of Eissens and colleagues (2012), stage 3 cells can be divided into two substages: first, 
CD34 expression is lost together with multipotency at stage 3a (CD34-CD117+CD56-
CD94-), secondly NK cell commitment is acquired together with CD56 expression at stage 
3b (CD34-CD117+CD56+CD94-).  
However, lately it has been shown, that the CD34-CD117+CD94- stage 3 population 
includes phenotypically overlapping, but functionally distinct cells: stage 3 NK cell 
progenitors themselves that express LFA-1 and are able do differentiate into mature NK 
cells upon IL-15 stimulation, ILC3 cells expressing RORC, IL-17 and/ or IL-22 and a 
minor population of ILC2 cells expressing RORα, GATA3 and type 2 cytokines (e.g. IL-5 
and IL-13).  While ILC2s can be easily identified due to a CD117-CD161+ surface 
phenotype, differentiation between NK stage 3 cells and ILC3s based on surface markers 
remains complicated (Ahn et al., 2013; Crellin et al., 2010b; Cupedo et al., 2009; Hughes 
et al., 2010; Mjösberg et al., 2011; Satoh-Takayama et al., 2011; Spits and di Santo, 2011).  
Transition of cells from stage 3 to stage 4 is characterized by acquisition of CD94-
NKG2A, NKG2D and NKp46 expression accompanied by downregulation of CD117, 
CD33 and CD127, so stage 4 NK lymphocytes are usually described as CD34-CD117+/-
CD94+CD16-. Cells of both stage 4 and 5 express CD56 molecules on the cell surface, 
however cells of stage 4 are characterized by higher expression of CD56, while stage 5 
cells show a low density of CD56. For this reason stage 4 and stage 5 NK cells are also 
called CD56bright and CD56dim NK cells, respectively. Besides this, stage 4 NK 
lymphocytes express increasing levels of the transcription factor T-bet (TBX21) and the 
high-affinity heterotrimeric IL-2 receptor alpha/beta/gamma and can thereby respond to 
picomolar IL-2 concentrations (Lanier et al., 1986). 
According to the data shown by Eissens and colleagues (2012), CD56dim cells can 
be subdivided into two developmental stages: stage 5a is characterized by downregulation 
of the CD117 expression (CD34-CD117-CD56+CD94+) which is followed by a loss of 
CD94 in the course of the development to stage 5b (CD34-CD117-CD56+CD94-). 





and granzymes) and chemokines, such as CXCL8 and Mip-1b (Eissens et al., 2012; Hanna 
et al., 2004; Koopman et al., 2003; Wendt et al, 2006; Yu et al., 2010).  
Both CD56bright and CD56dim NK cell subsets play an important role in immunity, 
however they differ dramatically in their cytotoxic potential, their capacity of cytokine 
production and their responses to cytokine activation and have different functions. They 
also have a different tissue distribution that is while the CD56dim subset is predominantly 
found in peripheral blood, CD56bright NK cells dominate in SLT, neonatal tissues and cord 
blood (Jakobs, 2001; Lanier, 1986). In the spleen the ratio between CD56dim and CD56bright 
cells is about 1:1. Consistent with their localization, CD56bright NK cells express CD62L 
and the chemokine receptors CXCR4, CCR5 and CCR7, which are involved in lymphocyte 
trafficking, allowing these cells to migrate to SLT. CD56dim NK cells express instead 
higher levels of CXCR1, CXCR2, CXCR3, CXCR4 and CX3CR1, which enables these 
cells to be recruited to sites of inflammation (Campbell et al., 2001; Eissens et al., 2012; 
Fehniger et al., 2003; Ferlazzo et al., 2004; Fu et al., 2014; Hanna et al., 2003). 
In comparison to the CD56dim population, CD56bright cells show lower expression 
levels of KIRs, but higher levels of C-type lectin receptors (CD94/NKG2 heterodimers). 
Their cytotoxic potential is lower than that of CD56dim cells and is acquired only after 
prolonged activation (Bjorkstrom et al., 2010); however, they are more potent in cytokine 
secretion (first of all, IFN-γ, and TNF-a). Furthermore, CD56bright cells have the ability to 
express high levels of GM-CSF, TARC, TGF-β3, IL-10, IL-8 and IL-13 following 
monokine stimulation, while CD56dim cells show higher expression of IGF-1 and IGFBR-3 
(Cooper et al., 2001; Hanna et al., 2004). To produce IFN-γ they need to accumulate two 
activating signals: first, they need IL-12 and secondly either another IL (e.g. IL-1, IL-2, IL-
15, IL-18) or the engagement of activating receptors (e.g. CD16 or NKG2D) is necessary. 
In addition, CD56bright cells express the c-Kit receptor tyrosine kinase (alias CD117), 
which, together with IL-2 signaling, allows them to proliferate upon activation (Bryceson 
et al., 2006; Wang et al., 2014).  
CD56dim NK cells demonstrate much higher cytotoxicity upon activation. In 
comparison to the CD56bright subset, they upregulate KIRs, cytotoxic molecules and 
chemokines. Notably, in resting NK cells, mRNA of granzymes and perforin is present, 
however translation is blocked; upon activation the mRNA level does not change, but the 
protein level increases. Recently it was shown that CD56dim cells can undergo further 
differentiation and functional modifications (Chan et al., 2007; Romagnani et al., 2007;). 





unable to proliferate even upon stimulation with high IL-2 dosages. Instead of this, they 
respond to IL-2 activation by increased cellular cytotoxicity. (Robertson et al., 1992) 
Almost all CD56dim NK cells express high levels of CD16 and are capable for ADCC, 
unlike CD56bright cells (Cooper et al., 2001; Romagnani et al., 2007). 
Memory-like NK cells are believed to be a final stage of NK cell development, 
characterized by enhanced effector response upon secondary treatment with the same 
antigen. In comparison to naïve NK cells they are able to produce higher amounts of IFN-γ 
(Miller, 2013; O’Leary et al., 2006; Sun et al., 2009). In a mouse model it was shown that 
memory-like NK cells could be derived from both CD56bright and CD56dim populations 
upon cytokine stimulation, exposure to multiple viruses and hapten treatment, however it is 
not completely clear, whether they can arise only at specific points of development, or may 
occur from different NK developmental stages depending on environmental stimuli 
(Cooper et al., 2009; Min-Oo et al., 2013; Paust et al., 2010; Romee et al., 2012). Mouse 
memory-like NK cells showed higher expression of Ly49H, Ly6C, Cd43, and Klrg1 in 
comparison to naïve NK cells, while expression of Cd27 was decreased. Besides this, 
liver-restricted NK memory cells expressed high levels of Thy1, Cxcr6, Cd49a and/or 
Ly49C/I. An existence of antigen-specific NK cell memory was also proved in rhesus 
macaques (Reeves et al., 2015). In humans a corresponding memory-like NK cell 
population was described even less, but increased expression of CD57, CD62L and 
NKG2C are supposed to mark virus-induced memory NK cells (Juelke et al., 2010; Lopez-
Verges et al., 2010; Sun et al., 2009). 
1.5. Licensing of NK cells and self-tolerance  
The simple acquisition of specific surface receptors is not enough for NK cells to 
become completely functional. In addition, they have to undergo a MHC class I-dependent 
process called “education” or “licensing”, which is different from education of T-
lymphocytes. This process ensures the tolerance of NK cells meaning that they do not 
attack healthy cells, but are able to identify efficiently pathogen-infected or transformed 
cells (Dofman et al., 1997; Kim et al., 2005; Liao et al., 1991; Yokayama and Kim, 2006). 
As mentioned above, specific ITIM-bearing inhibitory receptors, namely KIRs and 
CD94/NKG2, recognizing MHC class I molecules are necessary to inhibit NK cell 
activation upon recognition of cognate ligands. The polymorphic KIR family segregates 
independently from the MHC locus and KIR proteins are expressed in a clonal manner on 
individual cells. As KIR proteins show specificity for different MHC class I proteins and 





which does not recognize a MHC class I protein in that individual. To avoid chronic 
activation of such NK cells due to the missing-self recognition, such NK cells become 
hyporesponsive and are classified as non-licensed. Inversely, those NK cell expressing 
KIR proteins capable of interacting with MHC class I are responsive and are classified as 
licensed (Yokoyama and Kim, 2006). Therefore, in many individuals only a portion of NK 
cells possess inhibitory KIRs recognizing self-MHC class I molecules (Anfossi et al., 
2006; Fauriat et al., 2010; Sim et al., 2015). Although the exact molecular mechanism of 
NK cell licensing is unclear, it is generally appreciated that it depends on appropriate 
pairing of inhibitory receptors with their MHC ligands, which is followed by signal 
transduction. The number of inhibitory receptors engaged by MHC class I molecules and 
the strength of binding was shown to influence NK cell responsiveness for cytotoxicity and 
cytokine production (Brodin et al., 2009a; Joncker et al., 2009): the stronger the interaction 
is between inhibitory receptor and its ligand, the stronger is the effector response of the 
NK cell. It is argued that licensing occurs during transition from stage 4 to stage 5 in NK 
cell development (Cruz-Munoz and Veillette, 2010; Kim et al., 2005; Yokoyama and Kim, 
2006).  
As a result of licensing, two major subpopulations of mature NK cells can be 
distinguished; both of them are self-tolerant, although in a different manner. Those cells 
that express one or more inhibitory KIR fitting to a self-MHC phenotype and/or NKG2A 
receptors become licensed. Due to inhibition through these receptors they remain inactive 
upon normal conditions. Cells lacking inhibitory receptors to self-MHC molecules remain 
unlicensed and are tolerant due to functional incompetence. Such cells show reduced 
cellular cytotoxicity, reduced ability to lyse tumor cells and defects in cytokine production 
(Dorfman et al., 1997; Fernandez et al., 2005). Even though some studies showed that 
unlicensed cells can be activated in vitro with the help of prior treatment (e.g. with phorbol 
ester and ionomycin or by cytokine stimulation in vitro), in vivo they are hyporesponsive 
and cannot be activated. (Kim et al., 2005; Yokoyama and Kim, 2006). 
Four alternative models of the licensing mechanism were proposed: i.e. arming, 
disarming, cis-interaction and rheostat models. According to the arming model, interaction 
of NK cell receptors with cognate self-MHC class I molecules promote NK cell licensing 
in an active way by granting NK cells functional competence. NK cells that lack receptors 
against self-MHC-I molecules in accordance lack such an influence and remain 
hyporesponsive by default. According to some studies, signaling via ITIM-containing 





ITIM, proving an active influence of such interactions (Cooley et al., 2007; Peterson and 
Long, 2008).  
According to the disarming model, no active changes happen in NK cells upon 
interaction with cognate inhibitory targets and responsiveness is a default state of NK cells. 
While NK cells that possess receptors against self-MHC-I proteins avoid activation and 
show normal maturation, NK cells that lack corresponding receptors become self-tolerant 
due to persistent stimulation followed by cell anergy (Fernandez et al., 2005; Raulet et al., 
2006). 
The cis-interraction model was established in mice and is based on the ability of 
Ly49 receptors (mouse equivalent of KIRs) to bind MHC class I molecules on the same 
cell’s membrane (Andersson et al., 2007; Doucey et al., 2004;). According to this model, 
interactions between MHC class I molecules and Ly49 receptors in cis sequesters Ly49 
receptors, preventing their relocation to the immunological synapse and thus decreases 
signaling from activating receptors. However, it was not proven yet, whether all Ly49 
receptors as well as human KIRs can engage MHC class I molecules in cis. 
The rheostat model partly combines the evidence of the other three mechanisms. 
According to this model, NK cells have increased (arming-like) or decreased (disarming-
like or partially due to cis-interactions) responsiveness depending on the strength of the 
inhibitory signal that is received, but are not completely “turned on” or “turned off”, and 
that NK cell licensing happens in a quantitative manner (Brodin et al., 2009b; Johansson et 
al., 2005; Joncker et al., 2009).  
A recently published report (Thomas et al., 2013) shed some light on the licensing 
process. It was shown that licensing increases the ability of NK cells to form an 
immunological synapse, resulting in the ability to adhere to a target cell via LFA-1. As was 
described above, LFA-1 is a receptor recognizing ICAM-1; its engagement was shown to 
be sufficient for NK cell adhesion to a target cell and it can be enhanced by so-called 
“inside-out” signals from NK cell activating receptors (NKp46 and 2B4) (Barber and 
Long, 2003; Bryceson et al., 2009). Thomas and colleagues showed that licensing does not 
influence LFA-1 binding to ICAM-1 itself and thereby an initial binding to the target cell, 
but signaling from activating receptors, which in turn increases strength and stability of 
LFA-1-mediated adhesion. These data support rather an active mechanism of licensing 
and, therefore, an arming model, however details of licensing mechanism remain unclear. 
In the line with this finding, it was later shown that DNAM-1 forms a functional pair with 





changes correlate with licensing status of NK cells. Furthermore, DNAM-1 expression was 
shown to be the highest on terminally-differentiated memory-like NK cells (Enqvist et al., 
2015). It was therefore suggested, that coordinated expression and LFA-1 conformational 
changes contribute to higher responsiveness of licensed NK cells. These data support 
rather an active mechanism of licensing and the arming model. However, details of the 
molecular mechanism underlying licensing still remain unclear. 
1.6. Tissue-specific characteristics of NK cells 
Tissue- and organ-specific features of NK lymphocytes remain an extensively 
studied but still complicated topic. First of all, as earlier mentioned, NK cells can develop 
extra-medullary and many of such mature NK cell populations have specific features. 
Furthermore, distribution of NK cells is not static because they can recirculate between 
organs; under normal conditions as well as in the case of inflammation NK cells can be 
recruited to specific organs where they acquire tissue-specific features (Jiang et al., 2004; 
Liu et al., 2006; Thapa et al., 2007).  
Although it was suggested that variable characteristics of NK cells among different 
organs are due to their ability to adjust to microenvironment, the developmental location 
can also influence the NK cells’ phenotype and functional specificity (Eriksson et al., 
2004; Hamann et al., 2011; Koopman et al., 2003;).  
The first and best-described NK cell subsets are those found in peripheral blood. 
They are usually seen as prototypical NK cells, to which cells from other tissues are 
compared. In peripheral blood, NK cells usually comprise 5-15% of the total amount of 
lymphocytes. About 90-95% of the peripheral blood NK cell population are CD56dim cells, 
and the remaining 5-10% are CD56bright cells. In SLT, in contrast, CD56bright cells 
constitute an absolute majority of the NK cell population.  
It was postulated that NK cell surface phenotype and expression profiles depend on 
their developmental stage as well as on the local microenvironment (Wang et al., 2015). In 
particular, it was shown that expression of KIRs (e.g. KIR2DL2, KIR2DL3, KIR2DS2, 
KIR2DS3 and KIR3DL1) on CD56bright NK cells in lymph nodes and spleen was lower in 
comparison to corresponding populations in peripheral blood, cord blood and bone 
marrow, suggesting a more immature phenotype of CD56bright cells in these tissues. Vice 
versa, CD56bright NK cells derived from the uterus show high expression levels of KIRs 
and CD9, which was not typically seen in the CD56bright population in peripheral blood 
(Eriksson et al., 2004; Koopman et al., 2003). In another comparative study, it was shown 





marrow, cord blood and peripheral blood, higher (about 50%) in spleen and the highest in 
lymph nodes. Furthermore, the amount of CD56dim cells expressing activating receptors 
(besides NKp44) is lower in lymph nodes. Considering this and the fact that loss of 
NKG2A expression is a marker of NK cell maturation, it was suggested that NK cells 
developing in lymph nodes have a more immature phenotype in comparison to NK cells in 
other tissues (Eissens et al., 2012). 
The same is also true for earlier stages of NK cell development. In peripheral 
blood, cord blood and spleen CD33 expression was observed until stage 3b during NK cell 
development, and even until stage 4 in liver LN, although CD33 was described as a marker 
specific for stage 2 in bone marrow. Thus it was suggested, that committed NK cells in the 
spleen and lymph nodes have a more immature phenotype in comparison to cells from 
other tissues (Eissens et al., 2012). 
Even more specific features were described for NK cell populations in the liver. 
The liver is an important organ of the innate immune system, rich in NK cells, natural 
killer T cells, γδT cells and macrophages. It is an immunotolerant organ with a unique 
immunological microenvironment, where constant expression of gut-derived antigens does 
not lead to inflammation (Paust et al., 2010; Racanelli and Rehermann, 2006; Sun et al., 
2013). NK cells comprise 30-50% of the lymphocyte population in the human liver and are 
localized mainly in the hepatic sinusoids adhering to endothelial cells (Sun et al., 2013; 
Yamagiva et al., 2009). Hepatic CD56bright NK cells were shown to have a more immature 
phenotype comparing to their counterparts in peripheral blood, probably due to a specific 
immunological environment characterized by hyporesponsiveness against gut-derived 
antigens (Eissens et al., 2012; Paust et al., 2010; Racanelli and Rehermann, 2006).  
Furthermore, intrahepatic NK cells show an increased surface expression of 
CXCR6 in comparison to peripheral blood NK cells. CXCR6+ NK cells from liver were 
shown to have an immature phenotype (CD56brightCD16low/-CD57-) and correspond to the 
CD56bright subset in peripheral blood (Cooper et al., 2009).  Such cells were shown to 
develop an antigen-specific memory against haptens and virus-derived antigens (Paust et 
al., 2010). CXCR6- liver cells have a more mature phenotype and correspond to CD56dim 
NK cells from the blood (Marquadt et al., 2015; Sun et al., 2012). Furthermore, while 
peripheral blood NK cells show high expression levels of T-bet and low levels of EOMES. 
Vice versa, the liver CXCR6+ population has low expression of T-bet and high expression 
of EOMES as well as higher expression of CD49a (ITGA1) in comparison to their 






1.7. The role of high-throughput methods in studying of lymphocyte 
expression profiles  
Development of high-throughput methods of gene expression analysis in the last 
years allows comprehensive description of lymphocyte transcriptional profiles, better 
understanding of their development and activation and studying of novel potential roles of 
molecules in these processes. For these purposes methods such as large-scale mRNA 
microarrays, miRNA and DNA microarrays, multiparametric mass cytometry, FACS, 
ChiP-seq and RNA sequencing have been used (Bottcher et al., 2013; Casero et al., 2015; 
Chen et al., 2014; Choi et al., 2004; Du et al., 2006; Fu et al., 2014; Gard et al., 2012; 
Gillard-Bocquet et al., 2013; Kim and Lanier, 2013; Park et al., 2010). Furthermore, 
sophisticated bioinformatical tools, such as WGCNA, GeneMANIA, Inferelator, 
Cytoscape allow easier consolidation of available information and studying of given 
molecules in the context of their potential molecular interactions and their role in 
regulatory networks. Developing single cell technologies, including single cell mass 
cytometry, RT-qPCR and RNA sequencing, allow in addition analysis of population 
heterogeneity and individual cellular response on stimuli (Horowitz et al., 2013; Kouno et 
al., 2013; White et al., 2011;). Single cell gene expression analysis remains, however, 
challenging for NK cells due to their small size and low amount of RNA in the resting 
state. 
Studies of NK cells performed in recent years using such methods shed more light 
on different aspects of NK cell biology. In particular, using genome-wide RNA-
microarrays Bezman and colleagues demonstrate a close transcriptional relationship 
between NK cells and T cells (2012), and Dybkaer and colleagues described novel signal 
transductions pathways involved in NK cell activation by IL-2 (2007). Hanna and 
colleagues due to oligonucleotide microarrays described differences between gene 
expression profiles of CD56brightCD16- and CD56dimCD16+ NK cells, as well as changes in 
CD16+ NK cells’ expression profiles upon activation (2004); whereas Fehniger and 
colleagues identified micro-RNA transcriptome of NK cells using next-generation 
sequencing (2010). 
However, our knowledge about NK cells remains incomplete, especially in 
comparison to T and B lymphocytes (Casero et al., 2015; Chen et al., 2014) and many 
questions in this field remain unanswered.  





1. To identify the typical transcription signature of NK cells that 
distinguishes them from other PBMCs. 
2. To define, how expression profiles of NK cells change during their 
development 
3. To define, how expression profiles of NK cells differ between tissues and 
functional groups. 
4. To estimate the level of heterogeneity of mature NK cell peripheral blood 
population at the single cell level. 
5. To estimate the level of expression of non-protein coding genes 
expressed by NK cells. 
6. To define, whether expression profiles of NK cells produced by in vitro 
differentiation assays correspond to their natural counterparts. 








2. MATERIALS AND METHODS 
2.1. Chemicals, kits and consumables 
ArrayControl RNA Spikes  Life Technologies 
Biocol Seprating Solution Biochrom AG 
BSA Sigma 
C1 IFC for mRNA seq (5-10 µm)  Fluidigm 
C1 Single cell Auto Prep Reagent Kit for mRNA Seq  Fluidigm 
Conical tubes (50ml) Greiner bio-one 
EDTA Roth 
High Sensitivity DNA Assay kit Agilent Technologies 
KHCO3 Merck 
MS Columns Myltenyi Biotec 
NH4Cl Merck 
NK Cell Isolation Kit Myltenyi Biotec 
PBS Gibco 
Pipette double-filter tips (2.5ul, 100ul, 1000ul) Eppendorf 
Reaction tubes (1.5ml, 2ml) Eppendorf 
Separation tubes Luecosep (50ml)  Greiner bio-one 
SMARTer Ultra Low RNA Kit for the Fluidigm C1 System  Clontech 
Sterile piettes (5ml, 10ml, 25ml) Sarstedt 
 
2.2. Buffers 
MACS buffer: 0.5 % BSA and 2 mM EDTA in PBS. 
Erythrocyte lysis buffer: 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 8.0. 
2.3. Equipment 
BioAnalyzer 21000 Agilent Technologies 
C1TM Single cell autoprep System  Fluidigm 
Centrifuge Heraeus Multifuge 1S Thermo Scientific 
Centrifuge Heraeus Fresco 21 Thermo Scientific 
MACS multy stand Myltenyi Biotec 
Microscope Observer A1 Zeiss 









PANTHER Classification System 10.0 Paul Thomas ©  
R Bell Laboratories 
 
2.5. Blood and tissue samples  
Samples representing cell populations were obtained from our collaborators: 
Natural Immunity Group (University Clinic of Düsseldorf, Germany) and Faculty of 
Medicine (University of Southampton, UK).  
Taking blood and tissue samples with subsequent cell isolation was conducted with 
the approval of ethical authorities. Sample collection in the University Clinic of Düsseldorf 
was approved by the ethical committee of the Heinrich Heine University Düsseldorf (study 
numbers 3756, 3240, 3880, and 4723); blood and bone marrow samples were obtained 
from healthy donors, while tonsils were resected due to medical recommendations.  Liver  
sample collection was approved by the National Research Ethics Service (reference 
number 13/WA/0329).  
In all cases cells were isolated by density gradient centrifugation using Ficoll 
medium and specific lymphocyte subpopulations were selected by fluorescence-activated 
cell sorting (FACS) based on known surface markers. Details about origin and sorting 
strategy of cell populations are summarized in Table 1. 
The analyzed sample set included human NK cells (n=57), T lymphocytes (n=17), 
B lymphocytes (n=2), monocytes (n=2), and CD34+ lymphocyte precursors isolated from 
peripheral blood, umbilical cord blood, bone marrow, tonsils, and liver. Besides this, NK 
cells from two independent in vitro differentiation assays were analyzed (n=9). These NK 
cells were generated from bone marrow-derived CD34+ progenitors by induction with the 
combination of cytokines including IL-2, IL-3, IL-6, IL-7, IL-12, IL-15, IL-18, and 
trombopoetin. The differentiation assays were performed by the Natural Immunity Group 








Table 1 Characteristic of studied lymphocyte populations 
Name Source Cell Type Phenotype 
Specific 
characteristic 
pbNKst4_1 Peripheral blood NK CD56brightCD16- Stage 4 
pbNKst4_2 Peripheral blood NK CD56brightCD16+ Stage 4  
pbNKst5_1 Peripheral blood NK CD56dimKIR2DL3+ Stage 5  
cbNKst4 Cord blood NK CD56bright Stage 4  
pbNKst5_2 Peripheral blood NK KIR-NKG2A-CD56+CD3- Stage 5  
pbNKst5_3 Peripheral blood NK KIR-NKG2A-CD56+CD3- Stage 5  
pbNKst5lic_1 Peripheral blood NK KIR3DL1-NKG2A-KIR2DL1-
KIR2DL3+CD56+CD3-  
Stage 5 licensed 
pbNKst5lic_2 Peripheral blood NK KIR3DL1-NKG2A-
KIR2DL1+KIR2DL3-CD56+CD3-  
Stage 5 licensed 
cbNKst5 Cord blood NK CD56dimKIR2DL3+ Stage 5 
cbCD34pos_1 Cord blood CD34 CD34+CD38+ Lymphocyte 
precursors 
cbCD34pos_2 Cord blood CD34 CD34+CD38+ Lymphocyte 
precursors 
cbTCD4pos_1 Cord blood T CD4+  T lymphocytes 
cbTCD4pos_2 Cord blood T CD4+  T lymphocytes 
cbTCD8pos_1 Cord blood T CD8+  T lymphocytes 
cbTCD8pos_2 Cord blood T CD8+  T lymphocytes 
pbNKst5lic_3 Peripheral blood NK KIR2DL3+KIR2DL1+ 
KIR3DL1+  
Stage 5 licensed 
cbCD34_1 Cord blood CD34 CD34+  Cultured without 
feeder layer 
cbCD34_2 Cord blood CD34 CD34+ Cultured with 
feeder layer 
pbNKst5lic_4 Peripheral blood NK KIR2DL1+ Stage 5 licensed 
pbNKst5lic_5 Peripheral blood NK KIR2DL3+ Stage 5 licensed 
pbNKst5lic_6 Peripheral blood NK KIR2DL3+  Stage 5 licensed 
pbNKst5lic_7 Peripheral blood NK KIR2DL1+ Stage 5 
daNKst2_1 Differentiation 
assay 
NK CD34+CD117+CD56-CD94- Stage 2 
daNKst3_1 Differentiation 
assay 











Stage 5  
pbTKIRpos_1 Peripheral blood T CD4+KIR2DL2+  KIR-positive 
pbTKIRpos_2 Peripheral blood T CD4+KIR3DL2+  KIR-positive 






Stage 4  
daNKst2_2 Differentiation 
assay 

























Stage 5  
day 25  
pbTCKIRneg_2 Peripheral blood T CD4+KIR- KIR-negative 
pbTKIRpos_4 Peripheral blood T CD4-KIR3DL2+  KIR-positive 
pbTKIRpos_5 Peripheral blood T CD4+KIR3DL2+  KIR-positive 
stimulated 
pbTKIRpos_6 Peripheral blood T CD4+KIR3DL2+ CD3/CD28  KIR-positive 
stimulated 
pbTKIRneg_3 Peripheral blood T CD8+KIR- KIR-negative 
pbTKIRpos_7 Peripheral blood T CD8+KIR3DL2+ KIR-positiv 












pbNKst5lic_8 Peripheral blood NK CD56dimNKG2A-CD57-
KIR2DL1+NKG2C-CD3-  
Stage 5 licensed 
pbNKst5lic_9 Peripheral blood NK CD56dimNKG2A+KIR2DL1-
KIR2DL3-KIR3DL1-CD3-  
Stage 5 licensed 





pbNKst5lic_10 Peripheral blood NK CD56dimNKG2A- KIR2DL1-
KIR2DL3+KIR3DL1-CD3- 
Stage 5 licensed 
pbNKst4_3 Peripheral blood NK CD56bright  Stage 4  




cbB Cord blood B CD19+ B lymphocytes 
pbTKIRneg_4 Peripheral blood T CD4+KIR+  Stimulated  
pbTKIRneg_5 Peripheral blood T CD4+KIR+ CD3/CD28 KIR-positive 










pbNKst5lic_12 Peripheral blood NK CD56dimCD3-CD57-
KIR2DL3+NKG2C-NKG2A-
KIR2DL1-  
Stage 5 licensed 









bmNKst1_1 Bone marrow NK CD34+CD117-CD56-CD94-CD3-
CD14-CD19- 
Stage 1 
bmNKst2_1 Bone marrow NK CD34+CD117+CD56-CD94-CD3-
CD14-CD19- 
Stage 2  
bmNKst3_1 Bone marrow NK CD34+CD117+CD56-CD94-CD3-
CD14-CD19- 
Stage 3 
bmNKst4_1 Bone marrow NK CD117-CD34-
CD56brightCD94+CD3-CD14-
CD19- 





bmNKst5_1 Bone marrow NK CD117-CD34-
CD56dimCD94+CD3-CD14-CD19- 
Stage 5 
cbNKst2 Cord blood NK CD3-CD14-CD19-CD117+CD34+ Stage 2  
cbNKst3 Cord blood NK CD3-CD14-CD19-CD117+CD34-
CD56-CD94- 
Stage 3  
cbNKst4_2 Cord blood NK CD3-CD14-CD19-
CD56brightCD94+ 
Stage 4 
cbNKst5_2 Cord blood NK CD3-CD14-CD19-CD117-CD34-
CD56dimCD94+ 
Stage 5 
toNKst3_1 Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56+/-CD94- 
Stage 3 
toNKst4_1 Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56brightCD94+ 
Stage 4  
liNKCXCR6n_1 Liver NK CD56dimCXCR6-  CXCR-negative 
liNKCXCR6n_2 Liver NK CD56dimCXCR6- CXCR-negative 
liNKCXCR6p Liver NK CD56dimCXCR6+ CXCR-positive 
bmNKst1_2 Bone marrow NK CD3-CD14-CD19-CD117-CD34+ Stage 1  
bmNKst2_3 Bone marrow NK CD3-CD14-CD19-CD117+CD34+ Stage 2  
bmNKst3_2 Bone marrow NK CD3-CD14-CD19-CD117+CD34+ Stage 3  
bmNKst4_2 Bone marrow NK CD3-CD14-CD19-
CD56brightCD94+ 
Stage 4 
bmNKst5_2 Bone marrow NK CD3-CD14-CD19-CD56dimCD94+ Stage 5  
toNKst2 Tonsils NK CD3-CD14-CD19-CD117+CD34+ Stage 2  
toNKst3_2 Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56+/-CD94- 
Stage 3  
toNKst4_2 Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56brightCD94+ 
Stage 4  
toNKst5 Tonsils NK CD3-CD14-CD19-CD117-CD34-
CD56dimCD94+ 
Stage 5  
toNKst3a Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56-CD94- 
Stage 3a  
toNKst3b Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56+CD94- 
Stage 3b  








toNKst3_6 Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56+CD94-NKp44- 
Stage 3 
toNKst3_7 Tonsils NK CD3-CD14-CD19-CD117+CD34-
CD56-CD94-NKp44- 
Stage 4 
pbB Peripheral blood B CD19+ B lymphocytes 
cbMono Cord blood MC CD14+ Monocytes 
pbMono Peripheral blood MC CD14+ Monocytes 
pbNKst5lic_11 Peripheral blood NKs NKG2A+CD56dim  Stage 5 
licensed 
 
2.5. Preparation of single cell samples 
For NK cell transcriptome analysis at single cell level, mature NK cells from 
peripheral blood were selected as described below.  





 PBMCs for single cell analysis were isolated by density gradient centrifugation 
using the LeucosepTM system. First, 50 ml separation tubes containing 15 ml of Biocoll 
separation medium were centrifuged for 20 s at 1000 x g, so that the medium is localized 
below the porous barrier. After addition of 30 ml blood, diluted 1:1 with PBS, the tubes 
were centrifuged for 10 min at 1000 x g. After centrifugation, the PBMC-containing 
fraction was harvested using a pasteur pipet and washed three times with PBS for 10 min 
at 250 x g. After the second washing step all PBMCs were combined in one tube.  
To remove residual erythrocytes, additional treatment with erythrocyte lysis buffer 
was performed. For this purpose, PBS was aspirated after the last washing step and 
PBMCs were resuspended in 30 ml Erythrocyte lysis buffer. After incubation for 5 min at 
room temperature, the cells were pelleted for 10 min at 250 x g and resuspended in 
MACS® buffer. 
2.5.2. NK cell enrichment  
Enrichment of NK cells from PBMCs was performed using the MACS® magnetic 
NK Cell Isolation Kit. Due to labeling of non-target cells (i.e. T cells, B cells, stem cells, 
dendritic cells, monocytes, granulocytes, and erythroid cells) with lineage-specific 
biotinylated antibodies, this kit allows enrichment of intact, unlabeled NK cells.  
After treatment with erythrocyte lysis buffer, every 107 PBMCs were resuspended 
in 40µl MACS® buffer and incubated with 10 µl NK Cell Biotin-Antibody Cocktail for 5 
min at 8°C. Then 30 µl MACS® buffer were added and cells were incubated with 20 µl 
NK Cell MicroBead Cocktail for 10 min at 8°C. 
The mixture was adjusted to 500 µl with MACS® buffer and applied to a MS 
separation column, preliminary equilibrated with 500 µl MACS® buffer. The flow-through 
containing unlabeled NK cells was collected. Then the column was washed with 500 µl 
MACS® buffer and the flow-through was combined with the unlabeled NK cell obtained 
from the previous step.  
The NK cell suspension was washed with 5 ml PBS for 10 min at 250 x g and 
resuspended in fresh PBS before being applied to the Integrated Fluidic Circuits (IFCs). 
2.5.3. Generating of cDNA libraries from single cells 
NK cells obtained from MACS® enrichment were loaded on the IFC for mRNA 
sequencing at a final concentration of 200 cells/µl. 
Capturing of single cells, their lysis, first-strand reverse transcription on polyA+ 
RNA templates, long-distance PCR, and addition of SMARTer® universal tag sequences 





using the C1TM Single cell Auto Prep System to generate single cell tagged cDNA libraries 
for mRNA sequencing (Fluidigm Corporation ©, 2014a). Efficiency of cell capturing in 
the IFC was controlled in light microscope (Observer A1, Zeiss).  
After harvesting from the IFC, cDNA libraries (total volume of 3 µl for each) were 
diluted with 10 µl C1 DNA Dilution Reagent. DNA concentrations in the libraries were 
measured using the BioAnalyzer and the High Sensitivity DNA Assay kit; 18 samples with 
total DNA concentrations of >0.2 ng/µl were selected for preparation of sequencing 
libraries.  
2.6. Sequencing 
The preparation of sequencing libraries from complete sample transcriptomes of 
single cell samples and lymphocyte populations using Nextera DNA Library Preparation 
Kit (Illumina) as well as deep sequencing using IlluminaHighSeqTM technology was 
performed in the Transcriptome Analysis Laboratory (University Medical Center 
Göttingen). 
2.7. Statistical analysis 
Normalized expression levels used for all analysis were calculated as fragments per 
kilobase of exon per million fragments mapped (fpkm). 
Analysis of normalized data was performed using R software. Most of the analyses, 
including principal component analysis (PCA), ANOVA, unsupervised hierarchical 
clustering (HC) on gene expression, and visualizing results by violin plots was done using 
SINGuLAR Analysis Toolset, a shared-source, proprietary data analysis resource for gene 
expression data (Fluidigm Corporation ©, 2014b). 
2.7.1. Log2EX and Limit of Detection (LoD) 
The SINGuLAR Analysis Toolset performs all statistical analyses based on the 
expression values in the Log2 domain. 
Normalized levels of gene expression levels are converted to Log2 values (Log2Ex), 
as the primary interest in expression analysis is the fold change. Because small numbers 
(less than 1) can become very large negative values in the Log2 domain, a LoD is required 
to eliminate background noise. Normally in RNA-seq experiments LoD is set to 1 so that 
background expression values are zeros in the Log2 domain.  
Linear expression values are converted to Log2Ex by the following formula: 
Log2Ex = Log2(expression level) if LoD ≤ expression level, and Log2(LoD) = 0 if 






2.7.2. Principal component analysis  
The PCA is a statistical data reduction technique that uses successive orthogonal 
transformations to narrow down variation within a data set in as few variables as possible, 
while retaining most of the original variation. PCA reduces the dimensionality of a data set 
by transforming it into a new set of uncorrelated variables, called principal components, 
with decreasing degrees of variability. The number of principal components is less than or 
equal to the number of original variables. This transformation is defined in such a way that 
the first principal component has the largest possible variance (that is, accounts for as 
much of the variability in the data as possible), and each succeeding component in turn 
explains the next highest variance in the data set under the constraint that its relationship 
with the previous PC is zero (Jolliffe, 1986). 
2.7.3. The Outlier Identification Method 
The outlier analysis is based on the assumption that samples of the same type also 
have a set of commonly-expressed genes. The algorithm iteratively trims the low-
expressing genes in an expression file, until 95% of the remaining genes are expressed 
above the defined LoD value in half of the samples included in the analysis, according to 
the assumption that the sample set contains less than 50% outliers. This means that 
subsequent calculations will only include the half of the samples that have the highest 
expression for the trimmed gene list. The trimmed gene list represents the most evenly 
expressed genes. 
For the 50% of the samples that remain, a distribution is calculated that represents 
their combined expression values for the gene list defined above. For this distribution, the 
median represents the 50th percentile expression value for the set of data. 
The Outlier Threshold is defined as the expression value at which 85% of the gene 
expression values are above that line. Outliers are then identified as samples whose median 
expression values are less than the Outlier Threshold. Then, the outlier identification 
function automatically identifies outliers and displays a box plot of expression values for 
each sample, with the outlier candidates labeled. At this point it is also possible to display 
a PCA score plot of normal and outlier data points with sample names labeled to visualize 
each sample’s location in relation to each other. One can either accept an automatically 
identified list of outliers or, based on this data, indicate the list of outliers manually, if 
needed. 
In further analyses only samples identified as normal are used and only genes that 





When samples are divided into groups, an outlier analysis is performed for each 
group separately. 
2.7.4. Identification of top genes 
When an analysis is performed with SINGuLAR Analysis Toolset, the algorithm 
automatically identifies the top N PCA genes, thus, those genes that are the mostly 
differentially expressed ones among analyzed samples. Then the algorithm trims the 
expression data with those top genes. All subsequent analyses, including ANOVA, PCA, 
and HC, are performed using the edited gene list. The number of genes used for the 
analysis in a standard case was 100, however it could be raised up to 400. 
2.7.5. ANOVA 
Analysis of Variance (ANOVA) is a statistical method used to test for differences 
between two or more means. It is based on the idea that variability in the quantity being 
measured (gene expression, for example) can be partitioned into a number of identifiable 
sources. The one-way ANOVA, which is used in the SINGuLAR Analysis Toolset, 
compares the means between the groups of interest and determines whether any of those 
means are significantly different from each other. 
When ANOVA is used for gene expression data analysis, it allows identification of 
genes that are differentially expressed among analyzed groups. In this study ANOVA was 
normally used to test the set of the top 100 genes upon LoD=1. 
2.7.6. Hierarchical Clustering Analysis 
A cluster analysis or clustering is the task of grouping a set of objects in such a way 
that objects in the same group (called a cluster) are more similar to each other than to those 
in other groups (clusters). The SINGuLAR Analysis Toolset uses an algorithm of 
unsupervised HC. The goal of HC is to build a binary tree or a dendrogram of data (in this 
case – of gene expression levels) in the form of a heatmap that successively merges similar 
groups of data points. HC algorithms connect data points to form clusters based on 
distance, with a cluster being described largely by the maximum distance needed to 
connect parts of the cluster. 
Co-profiled genes are clustered together using the Pearson method and samples are 
clustered together using the Euclidean method. In each case, the complete linkage method 
is then used to find similar clusters. The data is then visualized as a heatmap with a 
dendrogram that shows both clusters of genes and samples, based on the expression levels 
of these genes. In this study two visualizing strategies were used depending on the 





The so-called "gene_z_score" display method was used in most cases to visualize 
the gene expression data. In this case expression values per gene were normalized with the 
mean and standard deviation for each gene, which better graphical demonstration of 
similarities in expression patterns between genes. The “global_z_score” display method 
was used to visualize single cell gene expression data. In this case expression values per 
gene were normalized with the global mean and global standard deviation, which allows 
better graphical demonstration of similarities between samples. 
2.7.7. Violin plots 
Violin plots depict the probability density of the data at different values and are 
used to visualize gene expression levels within the analyzed sample group. The algorithm 
included in the SINGuLAR Analysis Toolset builds histograms for multiple genes; each of 
them visualizes which portion of samples from the analyzed group expresses the gene at a 
given level. 
2.7.8. Pairwise comparison between samples and sample groups  
The algorithm allowing for pairwise comparison between sample groups was also 
included in the SINGuLAR Analysis Toolset. Pairwise scattered plots between sample 
groups allow to visualize the average gene expression values for each sample group and 
calculate the correlation coefficient between two sample groups. 
Correlations between expression levels of single samples were calculated 
separately in R using Spearman’s correlation method, which was part of the Hmisc R 
package. Scattered plots of gene expression levels used for visualization of correlation 
between individual samples were obtained from Dr. Angela Noll. 
2.7.9. Spearman’s correlation analysis 
Spearman’s rank correlation is a non-parametric test, which is used to identify 
whether there is an association between two ranked variables (in this case between 
expression levels of two genes). Spearman's coefficient ρ (rho), or r shows the strength of 
association between two variables, where the value r = 1 means a perfect positive 
correlation and the value r = -1 means a perfect negative correlation. 
The correlation analysis was performed in R. The algorithm is a part of the Hmisc 
R package, which allows calculating matrixes of Spearman's rank correlation coefficients r 
and corresponding significance tests (p-values). Only coefficients with p<0.05 were 
accepted as significant. Spearman’s correlation analysis requires at least five values to 
calculate the coefficient, meaning that groups of at least five samples have to be used to 





2.7.10. Gene ontology analysis 
Gene ontology (GO) analysis, specially a statistical the overrepresentation test, was 
performed using the PANTHER (Protein ANalysisTHrough Evolutionary Relationships) 
classification system (Mi et al., 2016). This online analysis tool was designed to classify 
proteins and genes encoding them, and is a part of the Gene Ontology Reference Genome 
Project. It allows classifying proteins and corresponding genes according to different 
characteristics, in particular according to the biological process in which they are involved. 
In this study the statistical overrepresentation test was used to determine 
representatives of which biological processes are significantly enriched in a given list in 
comparison to the reference list (in particular case - in complete human genome).  
When a list with genes of interest is given to the tool, genes are mapped to 
particular GO-slim Biological Process. Then, an expected value is calculated, which is the 
number of genes of this category expected to be present in the list, based on their presence 
in a reference list. Then, using binominal statistics, an expected value is compared to a real 
number of genes from a given category present in the list, resulting in the fold enrichment. 
If the fold enrichment is greater than 1, it indicates that the category is overrepresented in 
the analyzed list. Conversely, the category is underrepresented if it is less than 1. Fold 







3. RESULTS  
3.1 Clustering of different lymphocyte group: proof of data quality and the 
method 
To prove the data quality, PCA and HC was first performed using data from all 
samples available (n=91), including NK, T, and B lymphocytes, and monocytes. When the 
limit of detection (LoD) 1 was used, 20858 genes among the complete transcriptome were 
included in the analysis. PCA and hierarchical cluster analysis were performed using top 
100 of the mostly differentially expressed genes (Appendix 1). Based on this expression 
data, both on PCA score plot and clustered heatmap (Figure 1, 2) the following sample 
groups were observed: lymphocyte precursors (stage 1 and 2), NK cell precursors (stage 
3), NK cells stage 4 and 5, T lymphocytes; B lymphocytes, and monocytes. Thus, the 
sequencing data is complete enough and its quality is sufficient for the analysis. 
 










































































































Figure 1 PCA score plot of analyzed samples based on expression levels of the top 100 
differentially expressed genes.  
Genes were selected from the total number of 20858, LoD=1. 1 - lymphocyte precursors; 2 – immature 







As can be seen on the clustered heatmap (Figure 2), for most of these groups 
specific expression patterns were observed (Table 2). Furthermore, known functions of 
most of these specifically expressed genes were consistent to observed expression patterns. 
In particular, among genes expressed in the group of all committed NK cells (stage 3 to 
stage 5) were classical NK cell markers such as NCR1, NCR3, NCAM1, and KLRC1. 
Furthermore, genes encoding NK effector molecules, such as PRF1, IFNG, CST7, GNLY 























































































































































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)
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Figure 2 HC heatmap of analyzed samples based on expression levels of the top 100 differentially 
expressed genes  





































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)






NK cells (FCRL3, FCRL6, CX3CR1, FCGR3A, FGFBP2, S1PR5) were expressed by NK 
cells stage 4 and stage 5, but not by stage 3 NK cells.  






and NK  stage 5 
NK stages 3-5 
NK 
stages 4 and 5 
ALDH1A1 AC010468.2   BCL11B AC017104.6 ATP8B4 
ANGPT1 CACNA1I  CD247  ATP8B4  BNC2  
BCAT1 CAMK4  KZF3  B3GNT7  CLIC3  
CPA3 CCR4  PYHIN1  CCNJL  CMKLR1  
CTSG CD28 SH2D1A  CD300A  COL13A1   
EGFL7 CD5  TENM1  FAT4 CX3CR1  
FLT3 CTC-499J9.1    FGR DTHD1  
IGLL1  LEF1-AS1    GNLY  FCGR3A  
LMO2 MAL   GRIK4 FCRL3  
LPCAT2  NELL2   IL18RAP  FCRL6  
MAP7  PKIA-AS1   ITGAM   FGFBP2  
MPO SLC16A10   KLRC1  GZMA  
MSRB3  TRAT1   KRT86 GZMB  
MYB      LINC00299  GZMH  
PLD4     MLC1  GZMM  
PRTN3     NCAM1  IFNG  
SPINK2      NCR1 ITK 
TNS3     NCR3  KLRD1  
      NMUR1  L3MBTL4  
      PDGFD  LINGO2  
      PTGDR NKG7  
      RASSF4  PDGFRB 
      RGS9 PDZD4  
      RNF165  PRF1  
      RP11-104L21.3 PRSS30P  
      RP11-121A8.1   S1PR5  
      RP11-705C15.5 SLAMF7 
      SH2D1B  TBX21  
      SIGLEC17P    
      SIGLEC7    
      TRDC   
      TRDJ1    





      TYROBP    
      XCL1    
      XCL2   
 
Notably, CD56dimCXCR6- hepatic NK cells were clustered together with stage 5 
NKs from other tissues and shared a mature expression profile, while the CD56dimCXCR6+ 
sample clustered together with stage 4 NK cells. In comparison to stage 5 NK cells, 
CXCR6- samples had lower expression levels of markers of mature NK cells such as 
GNLY, GZMB, GZMH, TBX21, CX3CR1, CMKLR1, COL13A1 and FGFBP2, as well as of 
KRT86, LINGO2, PDGFRB PRSS30P. Furthermore, the expression of some genes (e.g. 
RGS9, FGFBP2, GZMB and GZMH) was lower than in both stage 4 and stage 5 NK cells. 
In the group of lymphocyte precursors hematopoiesis-related genes were expressed, 
such as MYB, CPA3, FLT3, LMO2, MPO, IGLL1 and genes involved in angiogenesis 
(EGFL7 and ANGPT1) (Su et al., 2004; Surmiak et al., 2012; Yang et al., 2002). Notably, 
stage 3 samples from bone marrow and cord blood clustered together with stages 1 and 2 
and shared with them a specific cluster of 18 highly expressed genes (Figure 2).  
Among the genes that are expressed mainly in mature T lymphocytes were classical 
T-cell markers like CD28, CD5, TRAT1 and other gens known being expressed in T 
lymphocytes such as CAMK4, CCR4, and MAL (Illario et al., 2008).  
To prove whether the obtained data are reproducible, a correlation analysis of the 
complete transcriptomic data was performed on sample pairs that were most similar 
considering the sorting strategy and the tissue origin, and were derived from the same 
donor. Two such pairs were present in the sample set: pbTKIRpos_1 and pbTKIRpos_2, 
pbNKst5lic_6 and pbNKst5lic_7. In both cases a high similarity of gene expression data 
was observed on linear regression plots (Figure 3) and corresponding correlation 
coefficients were 0.91 and 0.92 respectively, proving that the obtained data is reproducible.  
To prove that functional enrichment of immune system-related genes was 
significant, Panther GO overrepresentation test was performed. Out of the top 100 most 
differentially expressed genes, 88 were mapped to particular biological processes (Table 
3); among the significantly overrepresented ones were genes involved into immune system 







The analogical analysis, including PCA, HC and Panther GO overrepresentation 
was also performed using top 400 differentially expressed genes (data not shown). As no 
differences in distinguishing between sample groups and clustering was observed in 
comparison to analysis based on top 100 genes, it was concluded, that 100 of genes are 
sufficient for analysis. 
Table 3 Gene ontology overrepresentation among top 100 differentially expressed 
genes 
 
In summary, a successful differentiation between blood cell populations is possible 
based on the available transcriptomic data and top 100 genes are sufficient for this. The 







Cellular process (GO:0009987) 45 1.59 4.02E-02 
Response to stimulus 
(GO:0050896) 33 3.6 4.24E-09 
Immune system process 
(GO:0002376) 27 4.59 2.43E-09 
Immune response 
(GO:0006955) 18 8.2 1.35E-09 
B cell mediated immunity 
(GO:0019724) 6 10 7.20E-03 
Natural killer cell activation 





genes that were differentially expressed between the groups and defined the specific 
clustering are well-known and typical for the corresponding cell populations.  
3.2 Identification of specific expression patterns between mature PBMC 
populations 
To further investigate cell type specific gene expression patterns, expression 
profiles of the following mature PBMC sample groups were compared: stage 5 NK 
lymphocytes (n=27), T lymphocytes (n=10), B lymphocytes (n=2), and monocytes (n=2). 
As it is was suggested, that KIR+ T lymphocytes have specific features in comparison 
typical T lymphocyte phenotype (Uhrberg et al., 2001; Young et al., 2001), and also our 
data showed that they differ in their expression profiles (not shown), six KIR+ T cell 
samples were not included in this analysis. Based on LoD=1, 20180 genes were included 
into the analysis. ANOVA analysis and PCA were performed to identify top 100 genes that 
are significantly (p<0.05) differentially expressed between abovementioned groups.  
On the PCA score plot (Fig 4A) specific clusters of NK, B and T cells as well as 
monocyte samples was observed.  
Notably, among genes specifically expressed in NK samples (Figure 4B) were 
known NK cell markers (e.g. FCGR3A, FCRL6, FGR, KLRD1, KLRF1, NCAM1, NCR1, 
NKG7, PRF1, GZMA, GZMB, GZMH, TYROBP), but also genes without well-described 
function, in particular non-protein coding genes LINC00299, AC017104.6, CTC-499J9.1, 
and AC010468.2. Analogically, the group of genes specifically expressed among T cell 
samples included known T lymphocyte markers, such as CD5, CD28, CAMK4, NELL2, 
and TRAT1, but also non-protein coding genes CTC-499J9.1, AC010468.2, RP11-
203J28.8, LEF1-AS1, PKIA-AS1. 
Eleven genes were highly expressed in B lymphocytes: six of them were also 
expressed in NK cells (ITGAM, FGR, SYK, B3GNT7, AC017104.6, HBB), and the other 
five (SPI1, TNS3, JUP, ST14, CFD) were also expressed in monocytes, some NK or T 
cells.  
Due to the analysis algorithm, the relative size of a given sample group in 
comparison to other groups influences the ability to define group-specific genes. For this 
reason most of the top 100 differentially expressed genes identified for this sample set 
represented NK- and T-specific genes. Even though B lymphocyte and monocyte samples 
could be successfully differentiated from other samples, no genes expressed exclusively in 







 Despite this, when ANOVA analysis was performed, clear significant difference 
between all sample groups was observed. Among the top 100 genes, 80 genes were 
























Figure 4 PCA score plot (A) and HC heatmap (B) of mature PBMC samples based on expression levels 
of the top 100 differentially expressed genes  










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)










































































































































































































































































































































































































lymphocytes, 66 between NK lymphocytes and monocytes, 56 between T lymphocytes and 
monocytes, 32 between B and T lymphocytes, and 23 between monocytes and B 
lymphocytes (Appendix 2). 
So, despite the fact that genes specifically expressed in small sample groups are 
underrepresented, significant differences between gene expression levels within 
populations of mature PBMCs could be identified. These populations possess specific gene 
expression patterns, which include both genes with known functional relevance, as well as 
not well-described genes. 
3.3 Expression profiling of ex vivo NK populations 
The specific clustering using T and B lymphocytes as outgroups has confirmed the 
high RNA-seq data quality, as we could successfully distinguish between the different 
lymphocyte groups. However, as the main focus of my project was on NK lymphocyte 
expression profiling, in further studies I have concentrated on analysis of ex vivo NK 
subpopulations.  
3.3.1 Changes in expression landscape during NK cell development 
To check how expression profiles change during NK cell development, the analysis 
was done on ex vivo NK cell samples (n=53) including two samples from NK stage 1, four 
samples from stage 2, eleven samples from stage 3, nine samples from stage 4, and 29 
samples from stage 5. Among all analyzed genes, 20459 exceeded the threshold of LoD=1; 
PCA and HC were performed based on the top 100 differentially expressed genes. 
On PCA score plot (Figure 5) samples were grouped according to developmental 
stages and partly according to the origin of the tissue. Groups including stage 4 and stage 5 
samples were clearly separated; only one out of 30 stage 5 samples (toNKst5) was 
localized together with samples from stage 4. Also eight samples from tonsil-originated 
stage 3 were grouped together, while stage 3 samples from bone marrow were localized 
closer to earlier developmental stages. The stage 3 sample from cord blood and stage 2 
sample from tonsils had an intermediate position between the group consisting of other 
stage 3 samples and the group including stages 1 and 2 samples. For such an outlying 
position of these two samples two explanations are possible: either their expression 
phenotypes are intermediate between early progenitors (stages 1 and 2) and stage 3 NK 






According to the HC heatmap (Figure 6), a gradual change in the gene expression 
profiles was observed from stage 1 to stage 5. The following gene expression patterns were 
observed: 
• Genes with the highest expression among stage 1 and 2 samples included myeloid-
lineage related genes (MMP8, LTF, DEFA3, MPO, AZU1, CTSG, CLC, PRTN3, TAL1, 
AHSP, RHAG, SPTA1, HBD), as well as other genes known being expressed by CD34+ 
NK progenitor cells (MS4A3, CPA3, ELANE) (Lakschevitz et al., 2015; Sánches et al., 
1992; Thomas et al., 2014). 
• Among the genes, expression of which continues till stage 3, were typical markers 
of early NK cell development (MAP7, KIT, MYB, SPINK2, GNAI1, GRB10, CDH1), other 
NK-lineage specific genes (e.g. ADGRG6, CXCL8), T-lineage associated gene TGM2, and 
myeloid-specific genes CA2, CDC42BPA, PRSS57 (Eissens et al., 2012; Surmiak et al., 
2012). Besides this, VWDE, CASC15, MRC2, STAC, EREG were also expressed at the 
highest levels within stages 1 to 3. 
• Genes with the highest expression in stage 3 and lower expression at stage 4 



















































































































































































































































































































































































































































































































































Figure 5 PCA score plot of ex vivo NK samples based on expression levels of the top 
100 differentially expressed genes 






myeloid lineage (LIF and SLC4A10) and a set of genes known to be expressed in 
lymphocytes, for which, however, no specific function for NK stage 3 is yet known (IL4I1, 
B3GALT5, CSPG4, ENPP1, GPR55, KRT81) (Gurnett et al., 2008; Eissens et al., 2012; 
Takatori et al., 2009). In addition, a gene group was identified for which no specific 
function in lymphocytes was yet described (KIAA1211L, KIAA1324, LINGO4, LPAR1, 
PKDCC, RRAD, THEM5, SMIM10L2A), as well as non-protein-coding genes LINC00892, 
RP11-330A16.1, RP5-1028K7.2, and AL450992.2. 
•  A group of genes with equally high expression among stage 3 and 4 samples 
included mainly NK-lineage specific ones (DLL1, XCL1, TNFSF11, TOX2), but also IL7R 
(ILC3-specific), IGFBP4 and KRT86 (Cupedo et al., 2009; Eissens et al., 2012; Spits et al., 
2013). 
• Genes expressed among stages 3 to 5 were all typical for NK cells: CD2, GNLY, 
GPR68, TNFRSF18, XCL2 (Seillet et al., 2014). 
• Genes with the highest expression among stage 4 and 5 samples included mainly 
markers of mature NK cells: TBX21, GZMB, PDZD4, IFNG, GZMM, GZMH, GZMA, 
EOMES, FCRL6, KLRD1, TGFBR3, KLRF1, KIR3DX1, CD8A, FGFBP2, S1PR5, 
FCGR3A, FCRL3, PDZD4, but also several genes for which expression in NK 
lymphocytes was not yet described (DTHD1, PYHIN1, RP11-222K16.2, TENM1) (Eissens 
et al., 2012; Seillet et al., 2014). 
• Finally, genes expressed only among stage 5 samples included FEZ1, B3GAT1, 
AKR1C3 known to be expressed in CD56+ NK cells, as well as SLC1A7, BNC2, LGR6 
(Jakobs et al., 2001). 
Consistent to the picture observed on the PCA score plot (Figure 5), on the HC 
heatmap, the stage 3 samples of bone marrow origin were clustered together with 
developmental stages 1 and 2, and shared gene expression pattern with them, suggesting 
that they might have a more immature phenotype in comparison to stage 3 samples of 
tonsil origin.  
To check, how expression profiles change during development, pairwise 
comparisons between developmental stages were performed (Figure 7A). If gene 
expression changes sequentially from one stage to the next one, total expression profiles 
should correlate between neighboring stages, but not with those that are far from each 
other along the NK cell developmental flow. The correlation was calculated using the top 
100 differentially expressed genes selected upon LoD=1; correlation coefficients of >0.5 





stages 1 and 2, stages 2 and 3, as well as between stage 4 and 5 were highly positive, 
namely 0.74, 0.679, and 0.664 respectively, while there was no significant correlation 
between stages 3 and 4. Correlation coefficients between non-neighboring stages were in 
the range from -0.507 to 0.331.  
 
 To prove this tendency, an analogical analysis was performed based on the top 400 
mostly differentially expressed genes (Figure 7B). In that case the highest correlations 
were observed between stages 1 and 2 (correlation coefficient 0.787) and between stages 4 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)














































































































































































































































































































































































































































































-2 -1 0 1 2







Figure 6 HC heatmap of ex vivo NK samples based on expression levels of the top 100 differentially 
expressed genes 






still higher than between any of non-neighboring stages, while correlation between stages 3 
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B 
Figure 7 Pairwise comparison of gene expression levels within ex vivo NK developmental stages 
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 A plausible reason for the exceptional position of stage 3 samples is the known 
heterogeneity of stage 3. First, it is known that stage 3 cells sorted in FACS according to 
their CD34-CD117+CD94- surface phenotype are not a homogeneous population of cells, 
but also can include precursors of T lymphocytes, DCs and ILC3 cells. Another theoretical 
possibility would be heterogeneity between the analyzed stage 3 samples. To test this 
hypothesis, a correlation analysis between gene expression levels of individual stage 3 
samples was performed (Table 4). According to Spearman’s correlation analysis, 
correlation between all samples was between 0.84 and 0.93. Considering that this ratio was 
not lower than correlation rates between individual samples within other stages (not 
shown), it is unlikely that heterogeneity between stage 3 samples is the cause of the unique 
position of stage 3.  



































































bmNKst3_1 1                     
cbNKst3 0.85 1                   
bmNKst3_2 0.92 0.85 1                 
toNKst3_1 0.86 0.86 0.88 1               
toNKst3_2 0.86 0.86 0.88 0.92 1             
toNKst3a 0.86 0.86 0.88 0.91 0.93 1           
toNKst3b 0.82 0.83 0.83 0.87 0.89 0.88 1         
toNKst3_4 0.83 0.83 0.85 0.88 0.90 0.89 0.87 1       
toNKst3_5 0.83 0.83 0.84 0.87 0.90 0.89 0.87 0.91 1     
toNKst3_6 0.78 0.79 0.80 0.82 0.84 0.83 0.82 0.85 0.86 1   
toNKst3_7 0.81 0.82 0.83 0.85 0.87 0.87 0.83 0.87 0.87 0.87  1 
 
ANOVA analysis was then performed to specify the change in gene expression 
during transition from one developmental stage to the next one. Among a total of 100 of 
the most differentially expressed genes, 56 genes were differentially expressed between 
stages 3 and 4, 54 genes between stages 4 and 5, 45 genes between stages 2 and 3, and 
only 4 were differentially expressed between stages 1 and 2 (Appendix 3). In order to 
account for genes specifically expressed in small size groups, the whole analysis and 
ANOVA comparison was performed for only stage 1 and stage 2 groups separately. 






3.3.2 Analysis of ex vivo NK stage 3 expression profiles 
3.3.2.1 Tissue-specific differences in gene expression profiles of stage 3 ex vivo 
NK cells 
To study tissue-specific differences in gene expression among stage 3 NK samples, 
11 ex vivo NK samples were used: 8 of tonsil origin, 2 from bone marrow, and one from 
cord blood. Using LoD=1, 20160 genes from the complete transcriptome were included in 
the analysis; among them the top 100 of the most differentially expressed genes were 
selected to perform PCA and HC. As cord blood was represented by only a single sample, 
it was impossible to form sample groups and to compare gene expression between tissues 
with ANOVA analysis. 
The stage 3 samples from tonsil origin are further distinguished based on the 
expression of the NKp44 receptor expression and were, therefore, sorted and analyzed 
separately. Both PCA plot and HC heatmap show this heterogeneity (Figure 8A,B). 
Samples toNKst3_4 and toNKst3_5 were sorted as NKp44+ while for sample toNKst3b 
this marker was not used, but it might contain many NKp44-positive cells. NKp44+ and 
NKp44- ILC3 cells have been described to differ in function (Crellin et al., 2010b; Hughes 
et al., 2009).  
According to a clustered heatmap (Figure 8B), differences in sample expression 
profiles could be observed as well: bone marrow samples clustered closer to the sample 
derived from cord blood, while tonsil-derived samples clustered separately and could be 
also differentiated into two sub-clusters. 
Among the top 100 genes, 9 were expressed in all tonsil-derived, but much lower in 
other samples; they express ILC3 markers (KRT86, KRT81, SMIM10L2A, IL23R, GPR55), 
NK-marker XCL1, as well as GIMAP6, LPAR1, and KIAA1211L (Gurnett et al., 2008; 
Eissens et al., 2012). 
A bigger set of 31 genes was expressed in the cord blood stage 3 sample and in five 
out of eight tonsil stage 3 samples (on a lower level), but not in bone marrow and other 
tonsil samples (the same separate group as in PCA including samples toNKst3b, 
toNKst3_4 and toNKst3_5). This group included genes expressed in NK cells (DHRS9, 
PTGDR2, FCGR2B), other lymphoid lineage-related genes (FAM49A, AKAP12, SLC7A11, 
IL1RL1, MS4A2, LILRB2, CD1C, HDC), genes related to myeloid lineage (THBD, PADI2, 
CLEC10A, IL1B, ADGRE3, TMEM176B, PTX3, APOBEC3A, AGPAT9, FCER1A) as well 





DQB2, MS4A4E, RPL10P3, ANKRD55, ADGRE4P) (Chetyrkin et al., 2001; Sánches et al., 





















































































































































































Heatmap of Expression (Global Z-Score)






































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)
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B 
Figure 8 PCA score plot (A) and HC heatmap (B) of stage 3 ex vivo NK samples based on expression levels 
of the top100 differentially expressed genes  





Only 3 out of the top 100 genes were expressed by bone marrow samples 
exclusively and they were characteristic for erythroid lineage (SERPINB10, DEFA4 and 
RNASE3), while a cluster of 32 genes was expressed also by cord blood cell, but at lower 
level. This gene set mainly included genes that are characteristic for early myeloid and 
lymphoid lineages (HBD, AHSP, MYL4, RNF182, ST6GALNAC1, SELENBP1, ANK1, 
NMU, KEL, ADAMTS3, ACSM1, SPTA1, FAM178B, PKLR, KLF1, GATA1, ADD2, 
ALDH1A1, KCNH2, GFI1B, CTSE, CNRIP1, LTF, TAL1, PRTN3, ELANE, AZU1, 
RNASE2) and also RHAG, GYPA, TMEM56, SLC16A9 (Lakschevitz et al., 2015; Surmiak 
et al., 2012; Yang et al., 2002;). In addition, 11 more genes, which also were mainly 
involved in hematopoiesis, (PRSS57, CTSG, MPO, HBB, ALAS2, SLC4A1, HBG1, HBA1, 
MS4A3, HGF, and CLC) were expressed on high levels by both cord blood and bone 
marrow-derived samples, but not by any tonsil-derived ones (Kinkade et al., 1983; Perera 
et al., 2013;). 
3.3.2.2 Expression differences between stage 3 NK cells and ILC3 
As it was mentioned before, samples with stage 3 phenotype sorted by FACS are a 
heterogeneous cell mixture containing ILC3 and NK precursors. It is also known from the 
literature that ILC3 cells are present among CD34-CD117+CD94- stage 3 phenotype in 
secondary lymphoid tissues and cord blood, but not in bone marrow (Crellin et al., 2010b; 
Cupedo et al., 2009; Geremia et al., 2011; Tang et al., 2011); and one of the aims of this 
project was to find new potential gene markers that would allow differentiating 
successfully real NK stage 3 cells from ILC3. For this purpose, the difference in gene 
expression profiles between bone marrow-derived and other ex vivo samples was 
examined.  
Samples were divided into two groups: the first one contained two samples from 
bone marrow, the second one contained the other nine ex vivo stage 3 samples (cord blood 
and tonsil-derived). ANOVA analysis identified the top 100 differentially expressed genes 
and differences in gene expression between groups were visualized by violin plots.  
Consistent with expression profiles observed before in a clustered heatmap, 
differences in gene expression levels were also observed in violin plots (Figure 9). The 
following genes were clearly higher expressed in bone marrow samples than in others: 
myeloid-related RNASE3, DEF4A, SERPINB10, NMUH, AZU1, ELANE, RNASE2, 
GATA1, MPO, PRTN3, MYL4, AHSP, KLF1, CTSG, ANK1, CTSE, SPTA1, KEL, PRSS57, 
HBD; genes known to be expressed by CD34+ cells (e.g. FAM178B, PKLR, KCNH2, 





lymphocytes), ADD2 (expressed in hematopoietic tissues), and other genes, whose 
expression patterns in blood cells is not yet described (TMEM56, RNF182, RHAG, 
SLC16A9, COL6A5, ALDH1A1, MFSD2B, LIN7A) (Su, 2004; Suhre et al., 2011; Zhang et 
al., 2000). Expression levels of NK-cell markers, such as XCL1, GIMAP6, CD2, KLRC1, 
as well as ILC3-cell markers IL23R, KRT81, KRT86, GPR55, and some other genes 
(LPAR1, KIAA1211L, SORCS, and CA12) were instead higher in non-bone marrow group. 
However, for most of the samples the expression of the respective genes was observed on 
different levels. In almost half of the cases, expression levels of both groups overlapped 
completely or mainly (e.g. for TRAT1, HBA1, FCGR2B, AGPART9, RPL10P3, CLEC10A, 
IL1B, FAM49A, RNA5-8SP2, HLA-DQB2, HDC, DHRS9, SLC7A11, RP11-225N10.3, 
FCER1A, HCAR2, HCAR3, PADI2, CYPS1, AKAP12, CACNA2D3, LILRB2, SLC45A3, 


















































































Figure 9 Violin plots of top 100 gene differentially expressed within bone marrow-derived 
(BM) and non-bone marrow-derived (non-BM) stage 3 ex vivo NK samples 
 


































































































































































Even though differences in gene expression could be observed both in heatmap and 
violin plots, when ANOVA analysis was performed, no statistically significant difference 
could be identified between two sample groups. A possible reason for this might be a high 
level of heterogeneity within the “non-bone marrow” group or a low number of samples 
derived from bone marrow. Even when the analysis was extended up to 400 top genes 
(data not shown), no significant difference was found.  
However, already among the top 200 genes (Figure 10), some important differences 
between the groups were observed. In particular, among the genes with a higher expression 
in non-bone marrow group were RORC and IL22, which are typically expressed in ILC3, 
but not in NK cells.  IL23R (present already among top 100 genes) and IL7R, which were 
also highly expressed by that sample group, are important for ILC3, as IL23 and IL7 are 
required for their development, but not for the development of NK cells (Hoorweg et al., 
2012; Sanos et al., 2011).  
 
Figure 10 Violin plots of top 101-200 gene differentially expressed within bone marrow-
derived (BM) and non-bone marrow-derived (non-BM) stage 3 ex vivo NK samples 
 


































































































































































Furthermore, IL1R1, which is critical for ILC3 development, but is not expressed 
by NK cells (Killig et al., 2014), was expressed much higher by non-bone marrow 
samples, than by bone marrow (data not shown). These observations suggested that 
differences in expression profiles of the bone marrow-derived stage 3 samples from the 
other stage 3 samples could indeed be caused by absence of ILC3 cells from bone marrow.  
Besides genes already mentioned above, the non-bone marrow group had clearly a 
higher expression of NK-related genes XCL2, GIMAP7, NCR2 and IL4I1, T- and DC-
related genes TRDC, LGALS2 and ICOS, as well as KIAA1324, AL450992.2, SH2D1B, 
B3GALT5, FSD1, RP5-1028K7.2, FAM69CIGHG4, CDH17, AC092580.4, RP11-
624C23.1, and TNR.  In the bone marrow sample group a higher expression of genes 
expressed on lymphocyte precursors (CEACAM6, GAD1, CYTL1, HEMGN), myeloid-
related (CLEC5A, CA1, TRIM10, XK, SPTBN2, and NFE2) and other such as ANKRD18A, 
FAM201A, PROK2, SYTL4, CMBL, SLC25A21, AGTR1, SPTB, NPR3, CTNN, LPPR3, 
COL6A6 was observed (Ai et al., 2016; Surmiak et al., 2012; Li et al., 2004). 
In summary, these data suggest, that the difference between bone marrow and non-
bone marrow-derived stage 3 samples is more due to a less mature phenotype of the stage 
3 cells from bone marrow samples. However, the presence of ILC3 cells could make an 
influence. 
3.3.2.3 Heterogeneity of non-bone marrow stage 3 samples  
The heterogeneity of non-bone marrow stage 3 samples was examined additionally. 
Using LoD=1, 20201 genes were included in the analysis. PCA and HC were performed 
using the top 100 differentially expressed genes. Indeed, both in PCA plot and clustered 
heatmap a high level of heterogeneity between the samples could be observed (Figure 11). 
In particular, a set of 14 genes among the top 100 was highly expressed in a cord 
blood sample in contrast to tonsil samples and consisted mainly of non-NK specific genes 
e.g. genes expressed in B cells, erythrocytes, eosinophils and basophils: BCL11B, HDC, 
GATA2, CR1, CLC, TRPM6, MS4A3, GCSAML, HBG2, HBG1, RGS13, RPL10P3, RP11-
225N10.3, IGF2BP3, HBA1. 
Also the tonsil stage 3 samples were quite heterogeneous. A cluster of 16 genes 
with higher expression in 6 tonsil samples, but much lower in two NKp44- samples, as well 
as in the cord blood sample included the following genes: AC092580.3, MAS1, BFSP2-
AS1, SORCS1, CCL20, IL22, NCR2 (=NKp44), AC092580.4, REEP1, BMP7, EVC, 
SEC14L6, OPCML, TNR, SEMA3A. A set of 18 genes showed higher expression in both 





samples (including both NKp44+ samples and the CD56- sample from stage 3a): 
CLEC10A, HLA-DQB2, SIRPA, CYP2S1, CACNA2D3, PADI2, FCN1, SLC7A11, 

























































































































































Heatmap of Expression (Gene Z-Score)







































































































































Heatmap of Expression (Gene Z-Score)
-2 -1 0 1 2
Gene Z-Score




























































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)
-3 -2 -1 0 1 2 3
Gene Z-Score
Figure 11 PCA score plot (A) and HC heatmap (B) of stage 3 ex vivo N  samples of on il- and cord 
blood origin, based on expression levels of the to  100 differentially expressed genes  





Besides this, 4 out of 8 tonsil samples (toNKst3_1, toNKst3_2, toNKst3a and 
toNKst3_7) expressed a cluster of 28 genes with higher expression than in other samples. 
Most of these genes were related to the B cell lineage: 17 of them were gene segments of 
immunoglobulin chains: IGHV4-34, IGHV4-31, IGLV2-14, IGKV1-5, IGKV3-20, IGHJ6, 
IGHV3-23, IGHM, IGHGP, IGKV3-11, IGHG3, IGLC2, IGHG1, IGHV2-5, IGHV3-48, 
IGHG2, and IGKV4-1. Other genes included the specific B cell marker CD19, FCER2, 
CR2, FCRL2, KRT19, SIT1, RASSF6, IL22RA2, CD207, PDGFRB, and SLC2A5. 
Furthermore, this cluster also expressed CD22 – an inhibitory receptor and another B cell 
marker (Otipoby et al., 2001).   
Expression of these genes in abovementioned samples was between 100 and 600 
fpkm, which is lower than in B cells (3000-6000 fpkm), but still higher than average for 
stage 3 NK cells and NK cells in general. Considering that FACS sorting should have 
excluded CD19+ cells, it can be that although these genes are transcribed, their products are 
not present at the protein level. Alternatively, the phenotype of given tonsil-derived NK 
cells could differ due to immune response, as tonsils were resected due to medical 
recommendations and there is high probability of inflammation in the tonsil samples. The 
theoretical possibility of B lymphocyte contamination also cannot be completely excluded. 
3.3.2 Analysis of ex vivo NK stage 4 expression profiles 
To examine whether the gene expression landscape differs between stage 4 NK 
cells from different tissues, 9 samples from ex vivo stage 4 samples were analyzed: 2 
originated from bone marrow, 2 from cord blood, 2 from tonsils, and 3 from peripheral 
blood. Using LoD=1, 19924 genes were included in the analysis and based on the top 100 
differentially expressed genes (Appendix 4), ANOVA and PCA were performed. A HC 
heatmap was created to visualize differences in expression of selected genes.  
Similar to stage 3, also stage 4 samples turned out to be heterogeneous in their gene 
expression profiles. According to the PCA plot (Figure 12A), both bone marrow samples 
were localized far away from all other samples, samples from tonsils were also separated, 
while samples from cord blood and peripheral blood were localized relatively close to each 
other.  
According to a clustered heatmap (Figure 12B), a specific gene set expressed in 
bone marrow samples consisted mainly of genes specific for the myeloid cell lineage 
(CEACAM8, BPI, DEFA3, MMP8, CRISP3, LTF, PGLYRP1, RETN, CHI3L1, LCN2, 
PRTN3, ELANE, MPO, RNASE2, RNASE3, CTSG, DEFA4, AZU1, S100A9, S100A12, 





leukocyte groups, including NKs), MS4A3, which is normally expressed by CD34+ cells, 
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Figure 12 PCA score plot (A) and HC heatmap (B) of s age 4 ex vivo NK samples based on expression 
levels of the top 100 differentially expressed genes 










































































































































































































Besides these genes, these samples highly expressed a cluster that included 
ADAM19 (shown to be expressed by DCs), KIF21A (known to be expressed by B and NK 
lymphocytes), SLC2A5 and 12 genes encoding immunoglobulin chains (GHG1, IGLC3, 
IGHG3, IGHV3-23, IGHGP, IGLV2-23, IGHA1, IGHA2, JCHAIN, IGKV4-1, IGKV1-5, 
IGLC2) (Lakschevitz et al., 2015; Miyake et al., 2004; Su et al., 2004; Surmiak et al., 
2012; Yang et al., 2002). The same cluster was also expressed in both tonsil-derived 
samples. 
Six more immunoglobulin-coding genes (IGHV1-69, IGLV3-1, IGHG2, IGHG4, 
IGHV3-15, IGKV3-20) together with other B lymphocyte specific genes (FCRLA, FCRL5, 
FCRL1, FCRL2, CR2, GAPT, TBC1D9) and other immune system-related genes 
(COLGALT2, TAS2R64P, TNFAIP8L2, TCL1A, ABCD2, CENPQ, TLR10, and ITGA1) 
formed a cluster, that was also expressed by tonsil-derived samples, but by only one of 
bone marrow-derived. Notably, only one gene in this cluster, ITGA1, is known to be 
important for NK cells, in particular for their trafficking (Grégoir et al., 2007). 
A group of ten genes was expressed exclusively by two out of three peripheral 
blood samples. It included non-protein coding genes AC079949.1, MTRNR2L1, 
MTRNR2L12, RN7SKP291 and protein-coding genes PNLIPRP1, CYTL1, CPB1, CPA1, 
CELA1. Interestingly, among these genes only CYTL1 is known being expressed by 
lymphocytes (in particular by PBMCs and CD34+ cells), while the other protein-coding 
genes known to play a role in other tissues (e.g. pancreas and skin). The third sample from 
peripheral blood shared an expression of a specific gene cluster with cord blood- and one 
of bone marrow-derived samples. This group included CXCL8 and non-protein coding 
genes, namely BIRC6-AS1, MIR4742, RP11-380G5.2, OPA1-AS1, SLC22A20, RP11-
225N10.3, MIR1255A, RP11-286O18.1, and RP11-263C24.1. 
When ANOVA pairwise comparison between groups was performed based on the 
top 100 genes, it revealed that the number of genes whose expression significantly differed 
(p<0.05) between groups was the highest, when the bone marrow sample group was 
compared to any other: 37 genes were differently expressed between bone marrow and 
peripheral blood, 23 genes between bone marrow and cord blood, 16 genes between bone 
marrow and tonsils. When any other two groups were compared, the number of 
differentially expressed genes was lower: eleven genes were differentially expressed 
between peripheral blood and tonsils, nine genes between cord blood and tonsils, and only 
one, RPSAP53 (ribosomal protein SA pseudogene 53), was differentially expressed 





tonsils and cord blood, as well as between tonsil and peripheral blood, included mainly 
immunoglobulin coding genes (six and seven respectively), B cell specific gene CR2 and 
immature NK marker ITGA1 (CD11a). 
To specify, which genes significantly differentiate bone marrow stage 4 samples 
from other samples of the same developmental stage, an additional ANOVA analysis was 
performed. In that case, a group of two bone marrow samples was compared to a group 
containing all other stage 4 samples (n=7) and genes differentially expressed between 
groups were identified. The expression of 34 out of the top100 genes significantly differed 
(p<0.05) between groups (Table 4). All these genes were higher expressed in the bone 
marrow sample group than in another one. Among them, 21 genes were characteristic for 
the myeloid lineage (expressed normally in erythrocytes, granulocytes or monocytes), 
seven genes encoded immunoglobulin chains and one was characteristic for early stages of 
hematopoiesis. The same gene groups were also observed, when bone marrow samples 
were compared to samples from tonsil, peripheral blood and cord blood separately. 
Furthermore, when ANOVA was performed among the top 400 genes, 88 genes differed 
between bone marrow and the group of other samples (Appendix 7). Among them 75 
genes with higher expression in bone marrow-derived samples also mainly represented 
myeloid lineage and CD34+ hematopoietic cell; 13 genes with higher expression in non-
bone marrow group included seven non-protein coding genes and six protein-coding genes 
with broad expression within lymphocytes. 
Table 4 Genes differentially expressed between BM-derived and non-BM derived 
stage 4 NK samples identified among top 100 genes using ANOVA analysis. 
Expression levels are indicated in Log2 domain. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
BM non-BM BM non-BM 
ABCA13 0.006997875 10.00 2.18 IGLC3 0.031006099 8.67 2.09 
AZU1 0.000980616 12.13 3.60 IGLV2-23 0.00964024 9.31 1.49 
BPI 0.000133552 10.46 0.63 LCN2 0.001579508 11.04 2.49 
CAMP 0.001083936 11.12 1.98 LTF 0.003082246 13.25 3.42 
CEACAM8 0.000440334 9.77 0.90 LYZ 0.006791651 13.16 6.73 
CHI3L1 0.003755841 8.18 1.78 MMP8 0.002840424 9.98 1.09 
CRISP3 0.002570828 9.37 1.15 MPO 0.003409805 13.61 3.91 
CTSG 0.001571086 12.44 1.66 MS4A3 0.000812184 9.74 2.19 
DEFA3 0.001465622 11.30 1.19 PGLYRP1 0.002404518 8.73 1.45 
DEFA4 1.90E-05 11.55 0.97 PRTN3 0.002778924 12.13 1.98 
ELANE 0.0013738 12.19 1.47 RNASE2 0.000295559 9.01 0.91 
FCN1 0.02213523 10.12 2.96 RNASE3 9.08E-05 9.66 0.67 





IGHG1 0.042965989 13.01 3.81 S100A8 0.011079726 13.23 4.45 
IGHG3 0.048660702 10.87 2.56 S100A9 0.007013196 13.93 5.95 
IGHGP 0.00931305 9.39 1.58 SLC2A5 0.020687636 7.91 2.10 
IGKV1-5 0.029075362 9.17 2.21 SLPI 0.000638316 7.87 0.76 
 
Notably, when the analogical analysis was performed comparing sequentially 
peripheral blood, cord blood and tonsil samples against all others, no significant difference 
could be identified neither among the top 100, nor among the top 400 genes (not shown). 
These results suggest, that the expression landscape of stage 4 NK cells from bone marrow 
is significantly different from the other stage 4 samples that were analyzed, probably due 
to a less mature phenotype of bone marrow-derived samples. However, heterogeneity was 
also observed between stage 4 NK cells from tonsils, peripheral blood and cord blood.   
3.3.3 Analysis of ex vivo NK stage 5 expression profiles  
To study tissue- and functional-specific differences in gene expression among stage 
5 NK samples, 29 samples in total were used: two of them originated from bone marrow, 
two – from cord blood, one – from tonsils, and 24 – from peripheral blood. Eighteen 
samples were derived from licensed and five samples from nonlicensed NK cells, and for 
five samples the licensing status was not defined. Furthermore, seven among the licensed 
samples were identified as memory-like NK cells.  
Using LoD=1, 21903 genes from the complete transcriptome were included in the 
analysis; among them 100 of the most differentially expressed genes were selected for 
further analysis (Appendix 7). First, PCA and HC analysis were performed to estimate 
which factors influence the heterogeneity of samples and their clustering.  
3.3.3.1 Tissue-specific differences 
Unlike stages 3 and 4, sample groups observed in PCA (Figure 13A) plot did not 
correspond to sample origin. Even though bone marrow samples were localized together, 
they were included in a bigger group consisting of samples from cord blood and part of 
peripheral blood samples. The only sample group localized separately consisted of five 
peripheral blood samples: four of memory-like NK cells and one of nonlicensed. This 
sample group was also clearly visible on a HC heatmap (Figure 13B), as its members 
demonstrated dramatically higher expression of 79 out of top 100 genes (marked green in 









This group included genes of different specificity: typically expressed by NK cells 
(e.g. CXCL8 and DUSP4), markers of myeloid lineage (e.g. CD14, CD300E, CXCL16, 
FCAR), genes with ubiquitous expression within leukocyte populations (e.g. G0S2, 
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Heatmap of Expression (Gene Z-Score)
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Figure 13 PCA score plot (A) and HC heatmap (B) of stage 5 ex vivo NK samples based on expression 
levels of the top 100 differentially expressed genes 






GPR84, IL1RN, MAFB) or within different human tissues (e.g. ADM, EREG, PTGS2), as 
well as genes, for which a specific function in lymphocytes was not yet described (protein 
coding, such as ARSI, CAMK2A, PROK2 and three non-protein coding genes). Within all 
other stage 5 samples expression of these genes was highly variable. 
Besides this, another group of five peripheral blood samples (including 
nonlicensed, licensed and memory-like samples) expressed a smaller cluster of another 16 
genes, including those associated with erythroid lineage (ALAS2, HBA2, HBA1, HBB, 
SLC4A1, SELENBP1), T-specific (ZNF683), NK-specific (KIR3DL1), ubiquitously 
expressed among lymphocytes (GSTM1), six genes of small nuclear RNAs (RNU1-34P, 
RNVU1-18, RNVU1-6, RNU1-59P, RNU1-120P, RNU5F-1), and proapoptotic gene BOK 
(Figure 13B). 
To check, whether there is any significant difference between samples with a 
different tissue origin, ANOVA analysis based on 100 of the most differentially expressed 
genes was performed. As tonsils were represented by only one sample, it was excluded 
from the analysis, while bone marrow, cord blood and peripheral blood samples were 
compared to each other. However, no significant difference between gene expression 
groups could be detected (not shown). Furthermore, even when ANOVA was performed 
using top 400 instead of top 100 genes, still no difference could have been detected (not 
shown). 
3.3.3.2 Functional-specific differences 
At the next step of an analysis it was investigated, how the licensing status may 
influence the NK cell expression profile. For this purpose only those stage 5 samples were 
selected, where the licensing status was known. Besides this, two KIR-NKG2A- samples 
were also excluded, as they might have represented less mature cell population in 
comparison to KIR+ and/or NKG2A+ NK cells. In this case, the analysis was based on 22 
samples from peripheral blood: 3 of nonlicensed, 11 licensed, and 7 memory-like NK cells. 
Of note, when PCA and HC for these groups were performed, no group-dependent 






When these three groups were compared pairwise by ANOVA, the analysis 
revealed that there is indeed significant difference in gene expression between them (listed 
in Appendix 8). Among the top 100 genes, significantly (p<0.05) differently expressed 
between licensed and nonlicensed were 22 of them (all with higher expression in 
Figure 14 PCA score plot (A) and HCA (B) of licensed, nonlicensed and memory stage 5 ex vivo NK samples 






































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)

































































































































































































































































































































































































































































































































































































































































































































































nonlicensed group, than in licensed), and 66 genes between licensed and memory (only 
ADGRA3 was expressed higher in licensed group, all other genes had higher expression in 
memory group), and 2 genes between nonlicensed and memory group (LTF and ADGRA3). 
This, however, contradicted current knowledge about memory-like cells. As memory NK 
cells further differentiated licensed NK cells, they were supposed to share at least the same 
differences in expression landscape, as between licensed and nonlicensed sample groups, 
so the observed result was unlikely due to functional differences.  
To search for another explanation, the data were revised again. As it was shown 
before, among stage 5 was a group of five sample, the expression profile of which differed 
obviously from all other stage 5 samples, and that group included both nonlicensed (n=1), 
licensed (n=1) and memory-like (n=3) NK samples, and such prominent difference could 
have affected the analysis. Looking back at the sorting data, it was found out, that all these 
five samples came from the same donor (donor 6, Table 5). Taking this into account, it was 
suggested, that specific characteristics of the donor determined an outstanding expression 
profile of these samples; this dominating expression profile, in turn, influenced an analysis, 
so that no other differences could be identified. 
Table 5 Donor origin of selected stage 5 NK samples 
Sample Donor Sample Donor 
pbNKst5lic_1 1 pbNKst5lic_9 5 
pbNKst5lic_2 2 pbNKst5nonl_1 5 
pbNKst5lic_3 3 pbNKst5lic_10 5 
pbNKst5lic_4 1 pbNKst5nonl_2 5 
pbNKst5lic_5 1 pbNKst5mem_4 6 
pbNKst5lic_6 4 pbNKst5mem_5 6 
pbNKst5lic_7 4 pbNKst5lic_12 6 
pbNKst5mem_1 2 pbNKst5mem_6 6 
pbNKst5mem_2 2 pbNKst5nonl_3 6 
pbNKst5mem_3 2 pbNKst5lic_11 7 
pbNKst5lic_8 2     
 
To check this hypothesis, ANOVA analysis was done again excluding the five 
abovementioned samples. Indeed, the results in this case were rather different. Among the 
top 100 genes, five were expressed higher in the nonlicensed group, than in the licensed 
group (TGFBI, MS4A6A, PLD4, NAPSB, KCTD12, and CD4), nine genes were 
differentially expressed between nonlicensed and memory cells (DEFA3, LTF, MGAM2, 
SELENBP1, MPO, ADGRA3, LAG3, RP11-706O15.3, and DEFA4), and 25 genes were 





LAG3, ADGRA3, SERPINA1, S100A9, MPO, CDA, HLA-DQA2, CXCL8, FCN1, HBA1, 
RXRG, RP11-873E20.1, IL1B, HBA2, CCDC144A, CD4, RP11-706O15.3, LYZ, TNFAIP2, 
HCK, DEFA4, and DEFA3).  
However, the higher difference between licensed and memory group, than between 
nonlicenced and memory, as well as between nonlicensed and licensed groups was still 
unexpected. Furthermore, when ANOVA pairwise comparison was performed based on 
top 400 genes, the ratio between gene numbers remained comparable: 14 genes were 
differentially expressed between licensed and nonlicensed cells, 27 genes were 
differentially expressed between nonlicensed and memory cells, and 74 genes were 
differentially expressed between licensed and memory cells (Appendix 9). Also when HC 
was performed using the same sample set, no clear gene expression patterns specific for a 
certain functional group was observed, even though in a PCA plot memory-like samples 
were grouped together and rather separately from other samples (Figure 15). 
When the expression levels of the abovementioned genes were examined, it 
became clear that most of the top 100 genes were expressed relatively low in all stage 5 
samples, e.g. DEFA3 with 1.5 fpkm in nonlicensed samples and 287 fpkm in memory 
samples or ADGRA3 with average levels 205 fpkm licensed cells, 47.9 fpkm in 
nonlicensed and 7.8 in memory cell group. Mathematically, the fold change between them 
is big enough, however, the biological significance of such difference is questionable. Such 
low expressed genes might play role, when rather homogenic group of samples is 
examined, or when differences within compared groups are relatively big. As an outcome, 
no biologically significant difference can be detected.  
Considering all observations mentioned above, it was suggested, that besides tissue 
origin and functional state, also individual differences between stage 5 NK cells derived 
from different donors influence their expression profiles; and these influence is big enough 
to blur other differences.  
3.3.3.3 Donor-specific differences 
To check a role of donor-derived difference, one more round of analysis was 
performed. As it was known, from which donor every sample was derived, 21 samples 
with known licensing status were grouped according to their origin (Table 5). Two samples 
were excluded form the analysis in comparison to a previous analysis (pbNKst5lic_3 and 
pbNKst5lic_11), as these were the only samples from a particular donors, so no ANOVA 






As it could be seen in the PCA plot, the donor origin indeed influenced the 
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Figure 15 PCA score plot (A) and HC heatmap (B) of nonlicensed, licensed and memory stage 5 ex vivo NK 
samples (excluding samples from donor 6) based on expression levels of the top 100 differentially expressed 
genes  












































































































































































































16B) all five samples from donor 6 clearly clustered together, as well as both samples from 
donor 1, both samples from donor 4, and 4 out of 5 samples from donor 2. 
 
Moreover, when ANOVA pairwise comparison was performed for these donor-
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Figure 16 PCA score plot (A) and HC heatmap (B) of stage 5 ex vivo NK samples grouped according to 
donor origin, based on expression levels of the top 100 differentially expressed genes 












































































































































































































expressed (p<0.05) between different groups (Table 6). Even though most of the diversity 
was obviously derived from the donor 6-originated group, significant difference in 
expression from 2 to 22 genes was also observed between other groups.  
Table 6 Number of genes among top 100 differentially expressed between ex vivo 
stage 5 NK sample groups derived from different donors  
Donor 2 22       
Donor 4 2 17     
Donor 5 15 4 15   
Donor 6 74 72 68 75 
  Donor 1 Donor 2 Donor 4 Donor 5 
 
Taken together, all these results suggest, that expression landscapes of stage 5 ex 
vivo NK cell populations depend on all three studied factors: tissue specificity, licensing 
status and donor origin. Individual differences between donors contribute not less or even 
more than functional specificity to the sample diversity, so that transcriptional changes 
upon licensing could not be identified by the given methods. 
3.3.3.4 Correlation network of gene expression within nonlicensed, licensed 
and memory-like stage 5 NK cells 
As it was stated above, studying of transcriptional changes upon cell licensing is 
complicated due to multiple factors that influence the transcription landscape of stage 5 
NK cells. Instead, to investigate functional changes in gene expression network, the 
correlation between gene expression levels among nonlicensed, licensed and memory-like 
stage 5 NK samples was performed using Spearman’s method. 
The list of genes selected for the analysis included NK-cell specific genes 
identified in the analysis of all samples (chapter 3.1) and stage 5-specific genes identified 
in the analysis of NK differentiation stages (chapter 3.3.1). In addition, 100 genes were 
selected from the complete sequencing data that were shown to be highly and specifically 
expressed in stage 5 NK cells and are of relevance for the immune system. The total 
number of genes in the assay accounted to 192. Spearman’s correlation coefficient r was 
counted for each gene pair, correlations with value of correlation coefficient r>0.7 or r<-
0.7 (p<0.05) were considered as significantly strong and were visualized in networks of 
positive (Figure 17) and negative (Figure 18) correlations respectively. More precise 
analysis was than narrowed down to genes known being related to licensing and memory 






Even though it was claimed that transcription profiles of licensed and nonlicensed 
NK cells almost do not differ (Anfossi et al., 2006), two cell receptors, KLRD1 (CD94) 
and CD226 (DNAM-1), were previously shown to be differentially expressed between 
these groups and their expression levels correlate with licensed status of NKs (Anfossi et 
al., 2006). For this reason, correlations in which these genes were involved where analyzed 
specifically (Table 8).  
Figure 17 Correlation network of gene expression within stage 5 ex vivo NK samples 

















































































































































































































































































































Eight positive correlations with coefficients >0.8 were identified for the CD226 
gene and include correlations with genes associated with NK cell effector function and 
activation PRF1 (0.81), KLRF1 (0.8), AKR1C3 (0.86), and SH2D1B (0.87), genes involved 
in cell migration CX3CR1 (0.83) and COL13A1 (0.84), transcription activator MYBL1 
(0.82), as well as non-protein coding gene RP11-121A8.1 (0.83). Strong negative 
correlations (r<-0.8) of CD226 were observed with AHR (coefficient -0.88), which encodes 
a transcription factor important for ILC3 development; and between CD226 and TLE3 (-
0.84) that encodes a transcriptional co-repressor protein. Also multiple correlations with 










































































































Figure 18 Correlation network of gene expression within stage 5 ex vivo NK samples 






expressed in mature NK cells (FCGR3A, FCRL6, GZMA, CMKLR1, GPR65, PRSS23, 
CHST2), genes involved in cell cycle regulation (PYHIN1, NLK, SLFN12L), 
immunologically-related genes (SPON2, PALLD, PTGDR), and other genes whose 
functions are not so well defined (RASSF4, TTC38, MLC1, and lncRNA gene RP11-
705C15.5) (Tan et al., 2012). Negative correlations with coefficients between -0.8 and -0.7 
were observed between CD226 and COTL1, FOXO1, GATA3, IL1R1, TCF7, and non-
protein coding gene RP11-84D1.1 (Table 7). 
Table 7 Correlations involving markers of licensed (CD226 and KLRD1) and 







































AHR -0.88     PALLD 0.74     
AKR1C3 0.86     PDDC1     0.71 
CD244   0.72   PDGFD     0.72 
CD247   0.72   PDGFRB       
CD300A     0.71 PRF1 0.82     
CHST2 0.72     PRSS23 0.75     
CMKLR1 0.76     PTCH1       
COL13A1 0.84     PTGDR 0.71     
COTL1 -0.71     PYHIN1 0.80     
CX3CR1 0.83     RASSF4 0.77     
FCGR3A 0.76     RGS9       
FCRL6 0.70     RP11.121A8.1 0.83 0.70   
FGR     0.70 RP11.222K16.2     0.75 
FOXO1 -0.71     RP11.705C15.5 0.71     
GATA3 -0.77     RP11.84D1.1 -0.75     
GPR65 0.72 0.77   SH2D1B 0.87     
GZMA 0.79     SLAMF7   0.74   
IL12RB2       SLC1A7       
IL1R1 -0.74     SLFN12L 0.72     
IRF2     0.71 SPON2 0.76     
KLRF1 0.81     TCF7 -0.73     
MLC1 0.73     TEC       
MYBL1 0.82     TLE3 -0.84     
NLK 0.75     TTC38 0.73     
 
The KLRD1 gene expression showed three positive correlations with coefficients 
>0.7: with expression of two activating receptors CD244 (alias 2B4) and CD247 (alias 





NK receptor) and with those of non-protein coding gene RP11-121A8.1 (Kim et al., 2013; 
Krämer et al., 2013). 
Among the genes that are known to be more strongly expressed in memory-like NK 
cells are CXCR6, CD62L (SELL), and activating receptors (in particular NKG2C in 
humans) (Juelke et al., 2010; Lopez-Verges et al., 2010; Sun et al., 2009). Therefore, 
correlations in which these genes were involved were analyzed specifically.  
Six correlations with coefficient >0.7 were identified for the SELL (CD62L) gene, 
including CD300A, FGR, IRF2, PDDC1, PDGFD, and non-protein coding RP11-
222K16.2 (Table 7).  
No strong correlations were, however, observed, in which NKG2C and CXCR6 
genes were involved (not shown).  
3.4 Comparison of expression profiles of ex vivo and in vitro NK developmental 
stages 
To examine whether the in vitro differentiation assay is a good model for studying 
NK development, their expression profiles were compared to profiles of ex vivo samples 
from respective stages. 
3.4.1 Stage 3 
Within stage 3 two sample groups were formed: the ex vivo group included 11 
samples described above; the in vitro sample group included three stage 3 samples 
produced by the NK differentiation assay. ANOVA and PCA were performed using 100 of 
the most differentially expressed genes; HC heatmap and violin plots were created to 
visualize differences in expression of the selected genes.  
Despite heterogeneity between the ex vivo samples when PCA was performed, 
samples from the differentiation assay formed a clearly separated group (Figure 19A). In a 
HC heatmap as well, a branch containing all three in vitro samples was observed (Figure 
19B). A higher expression of 11 genes was observed in the in vitro samples in comparison 
to the ex vivo sample group: RP11-1094M14.5, E2F3P1, RP11-1094M14.8, KLRC2, 
TRAT1, KLRC1, IL26, GZMA, LZTS1, NTRK2, and PEG10.  
Further, to specify genes that were significantly differently expressed between ex 
vivo and in vitro stage 3 sample groups, ANOVA analysis was performed. This analysis 
showed that expression levels of 26 out of top 100 genes differed significantly (p<0.05) 
between the two groups (Table 8).  Besides the gene group mentioned above, in vitro 
samples also expressed higher levels of NCAM1, TMEM200A, B4GALNT1, TOMM20P2, 





levels of ADGRE1, AKR1C3, BTG1P1, CACNA1D, CDH1, CH25H, DTX1, IGHG4, 
IL5RA, KRT17P8.  
 
 
Notably, such genes as KLRC1, KLRC2, GZMA, and PBK are normally expressed 
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Figure 19 PCA score plot (A) and HC heatmap (B) of ex vivo and in vitro stage 3 NK samples, based on 
expression levels of the top 100 differentially expressed genes 






In order to confirm this tendency, ANOVA analysis was performed again using the 
top 400 genes. In that case, 115 out of 400 genes (28,75%) were expressed differently 
between the groups (Appendix 10); and besides already mentioned above, genes with 
higher expression in in vitro NKs included KLRC3, KLRC4, KIR2DL4, SLFN12L, which 
are normally expressed at later differentiation stages.  
Table 8 Genes differentially expressed between ex vivo and in vitro stage 3 NK 
populations identified from top 100 genes using ANOVA analysis. Expression levels 
are indicated in Log2 domain. 
GeneID p Value 
Expression 
levels 




















B4GALNT1 0.049607825 5.10 9.38 TMEM200A 0.007448746 5.14 10.23 
E2F3P1 0.007612725 3.84 8.87 TOMM20P2 0.007000877 4.27 8.76 
GZMA 5.22E-05 3.03 10.59 ADGRE1 0.017518438 4.48 0.85 
IL26 0.006537708 2.70 7.32 AKR1C3 0.021980398 5.93 1.85 
KLRC2 0.001137854 2.56 8.32 BTG1P1 0.039814816 3.19 0.49 
LZTS1 4.95E-06 2.17 9.51 CACNA1D 0.031633645 3.22 0.49 
NCAM1 0.027386606 6.02 11.53 CDH1 0.006806712 8.24 3.64 
NTRK2 8.18E-07 1.12 9.27 CH25H 0.019515034 4.64 0.00 
PBK 0.01290095 3.03 8.33 DTX1 0.003035575 6.60 0.10 
PEG10 0.000166902 2.28 9.31 IGHG4 0.036326526 5.29 0.00 
PVRL3 0.019278926 4.58 8.40 IL5RA 0.005842729 4.15 0.52 
RP11-1094M14.5 0.001449569 3.31 9.54 KRT17P8 0.042201187 3.27 0.49 
RP11-1094M14.8 0.002847264 4.08 9.47 NELL2 0.018406665 7.03 1.19 
 
3.4.2 Stage 4 
Within stage 4, nine abovementioned ex vivo samples formed one group and the in 
vitro differentiation assay group consisted of three samples. 
Hundred of the most differentially expressed genes were selected from the total 
number of 22794 genes using LoD=1 for PCA. HC heatmap and violin plots were created 
to visualize differences in expression of selected genes.  
The PCA plot showed that the ex vivo samples do not form a tight cluster as 
opposed to the in vitro differentiation samples (Figure 20A). Also in the clustered heatmap 
(besides gene clusters specific for the outlying bone marrow and peripheral blood 
samples), a group of 16 genes specifically expressed in in vitro samples can be observed 





TGFBI, NUF2, ITGA1, AFAP1L2, RP11-98G13.1, GPR15, DLGAP5, and PR11-677N16.1 
(Figure 20B). 
 
In order to specify for which genes the expression levels significantly differ 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)
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Figure 20 PCA score plot (A) and HC heatmap (B) of ex vivo and in vitro stage 4 NK samples, based on 
expression levels of the top 100 differentially expressed genes 






showed that expression levels of 32 of the top 100 (Table 9) genes differ between analyzed 
groups with a significance of p<0.05. Among them, 15 genes were significantly higher 
expressed in the in vitro sample group and corresponded to the gene cluster described 
above, excluding TGFB1 (marked in green in the Table 9), while the other 17 genes were 
higher expressed in the ex vivo sample group.  
Table 9 Genes differentially expressed between ex vivo and in vitro stage 4 NK 
populations identified from top 100 genes using ANOVA analysis. Expression levels 
are indicated in Log2 domain. 
GeneID p Value 
Expression levels 




















AFAP1L2 0.010273428 5.07 10.27 CD2 0.000342337 10.46 5.80 
AK4 1.08E-06 0.73 8.49 COL16A1 0.001670428 4.48 0.00 
CDH17 7.51E-06 0.77 7.61 DTX1 6.40E-08 8.64 0.03 
DEPDC1 0.000398382 2.47 8.54 FCRL1 0.029697826 4.36 0.18 
DLGAP5 0.005140536 4.43 9.88 FCRL3 0.008851847 7.92 1.28 
GPR15 0.000980635 2.85 8.78 HBA1 0.008359766 6.14 0.04 
ITGA1 0.04783988 5.31 10.58 HBA2 0.001886636 7.43 0.45 
LIN28B 1.81E-10 0.00 8.21 HBB 0.002754031 10.16 2.27 
LINC00599 3.08E-11 0.00 8.11 IGHM 0.009239485 7.30 2.63 
NDFIP2 0.000994266 4.06 10.93 L3MBTL4 0.000493433 7.14 0.92 
NUF2 0.007174789 3.96 9.03 LARGE 0.011181527 5.04 0.41 
PTGIS 2.48E-06 1.00 8.23 LINC00925 0.001923865 4.70 0.00 
RP11-677N16.1 0.040827167 5.00 8.52 LINGO2 0.00335457 4.23 0.03 
RP11-98G13.1 0.001003641 2.25 8.23 MS4A1 0.001711099 7.22 1.67 
SIX4 4.26E-05 1.60 8.57 NAP1L3 0.039197562 4.45 1.49 
BMP2 0.030305944 5.10 1.44 NELL2 0.032183167 7.43 3.56 
 
Furthermore, among the top 400 genes, 135 genes were differentially expressed 
between groups (Appendix 11), which are more than the highest difference within ex vivo 
samples (72 genes). These data suggest that besides high heterogeneity between different 
tissues, the in vitro differentiation assay displays important differences in gene expressions 
compared to analyzed ex vivo stage 4 NK cells. 
3.4.3 Stage 5 
To analyze differences between ex vivo and in vitro samples of stage 5 NK cells, a 
group of 30 ex vivo samples was compared to two stage 5 samples derived from the 





most differentially expressed genes, selected from a total number of 22010 genes (LoD=1). 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Heatmap of Expression (Gene Z-Score)
-3 -2 -1 0 1 2 3
Gene Z-Score
Figure 21 PCA score plot (A) and HC heatmap (B) of ex vivo and in vitro stage 5 NK samples, based on 
expression levels of the top 100 differentially expressed genes 
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Figure 22 PCA score plot (A) and HC heatmap (B) of ex vivo and in vitro stage 5 NK samples (excluding 
samples from the donor 6), based on expression levels of the top 100 differentially expressed genes 






As it is shown in Figure 21, both in PCA plot and HC heatmap the in vitro derived 
samples were not grouped together and no specific gene expression patterns could be 
identified. However, according to ANOVA analyzes, expression of 19 of the top 100 genes 
was significantly different (p<0.05) between ex vivo and in vitro sample groups, namely 
AC022182.1, GRASP, HBB, RP11-474D14.2, LMNA, RP11-372K14.2, PDK4, HBA2, 
RHOU, RP11-747H7.3, HBA1, MYOM2, RP11-61J19.5, CTD-3060P21.1, IGHM, 
IFNLR1, SIX4, COL24A1, and DUSP8, indicating that there is indeed a significant 
difference between compared groups.  
As mentioned above, five samples from donor 6 were the main source of deviation 
within the ex vivo samples. Therefore, an additional analogical comparison between ex 
vivo and in vitro groups was done, but excluding five abovementioned samples. In this 
case, both in PCA plot and clustered heatmap samples from differentiation assay were 
clustered together and clearly separated from all ex vivo samples (Figure 22A).  
Similarly, also specific patterns of gene expression were observed: a cluster of 50 
genes with higher expression in the in vitro samples and a cluster of 11 genes, the 
expression of which was higher in ex vivo samples (Figure 22B). When ANOVA analysis 
was performed with these samples, 64 were defined as differentially expressed (p<0.05) 
between groups (Table 10). Among them 42 genes were expressed at higher levels in the in 
vitro samples (marked in green in the Table 10), and 21 genes in the ex vivo samples. 
Table 10 Genes differentially expressed between ex vivo (excluding samples derived 
from the donor 6) and in vitro stage 5 NK populations identified from top 100 genes 
using ANOVA analysis. Expression levels are indicated in Log2 domain. 
GeneID p Value 
Expression levels 




















KLRF2 1.10E-09 0.55 8.67 COL9A2 0.00597699 3.64 7.24 
SIX4 5.66E-11 0.72 9.37 RP11-291B21.2 0.001434989 3.65 9.74 
AK4 2.87E-08 0.83 7.88 RP11-231I16.1 0.041534398 3.75 6.90 
ADGRL2 3.53E-07 0.87 7.46 C9orf84 0.010192002 4.26 8.57 
IGF2BP1 2.06E-05 1.09 6.97 PALD1 0.028360153 3.85 7.02 
ROBO1 7.30E-06 1.22 7.01 PTPN14 0.000132141 3.90 9.26 
ENPP1 4.91E-06 1.42 8.07 HK2 0.010709339 3.92 7.49 
LIF 
0.000199
058 1.44 7.83 GNA15 0.047382482 3.99 7.17 
KIF18B 1.34E-05 1.54 7.69 SPRY1 0.032588834 4.88 8.84 
MGAT3 
0.000524
308 1.66 6.86 MYC 0.025849789 4.89 8.19 





CDCP1 1.35E-07 1.67 8.79 RHOT1P2 0.030321807 3.77 0.00 
IQGAP3 5.45E-06 1.76 7.46 RP6-109B7.4 0.003713525 4.09 0.00 
WNT11 
0.010568
965 1.79 5.46 PRICKLE2 0.00165742 4.65 0.00 
COL24A1 6.23E-07 1.84 9.42 AC022182.1 0.00046285 4.77 0.00 
ZNF608 
0.005984
163 1.92 6.09 SNX18P13 0.013579534 4.77 0.00 
BIRC5 
0.000394
588 2.18 6.91 RP11-61J19.5 0.038777487 4.78 1.81 
UBE2C 
0.000122
274 2.25 8.26 GPA33 0.00527239 5.56 1.62 
PACSIN1 
0.003658
902 2.27 7.12 CTD-3060P21.1 0.024689696 5.89 2.39 
RASSF8 2.63E-05 2.42 9.88 DUSP8 4.25E-05 6.21 0.00 
IL1RL1 8.42E-06 2.50 9.79 COL13A1 0.000757249 6.63 0.96 
PEG10 
0.001368
468 2.52 7.84 HBA1 0.00412863 7.03 0.25 
ITGA1 4.42E-05 2.63 10.92 CYP4F29P 0.000265404 7.17 0.00 
RP11-61F12.1 
0.010771
82 2.77 6.16 SLC1A7 0.000143426 7.19 0.00 
DPP4 5.10E-05 2.79 10.46 
ANKRD20A11
P 0.000789528 8.09 0.46 
DLGAP5 2.55E-05 2.83 9.70 L3MBTL4 4.57E-08 8.51 0.00 
ID3 
0.026581
915 2.84 6.56 HBA2 0.001617629 8.78 1.31 
RP11-474D14.2 
0.003149
095 2.88 6.87 AKR1C3 1.42E-05 8.91 3.02 
NCF4 
0.013730
906 3.28 7.08 GRASP 0.002182389 8.95 2.67 
SPTSSB 
0.016473
13 3.34 8.28 LMNA 0.007507693 9.03 4.46 
GEM 
0.003847
056 3.37 7.81 PRSS23 2.04E-07 10.66 2.85 
STYK1 
0.000184
234 3.46 10.24 HBB 0.000419536 11.64 1.84 
 
In summary, these data suggest that also in NK developmental stage 5 there was a 
significant difference between ex vivo samples and samples derived from the in vitro 
differentiation assays. However, this difference was not higher, that within ex vivo group.  
3.5 Differential expression of protein-coding and non-protein coding genes 
The above-mentioned analyses clearly demonstrated that among the genes 
specifically expressed in certain cell types and in specific developmental stages both 
protein-coding and non protein-coding genes were identified. To investigate further how 
the expression landscapes of protein-coding and non protein-coding genes differ between 
NK developmental stages, these gene groups were analyzed separately. The data set for 
this analysis was the same as for chapter 3.3.1 and included 56 ex vivo NK samples from 





Genes were sorted into protein-coding and non-protein coding based on their 
Ensemble description from the complete transcriptome data. Using LoD=1, 14449 protein-
coding genes were selected for this analysis.  The group of non-protein coding genes 
included lncRNAs, miRNAs, snoRNAs, overlapping antisense and intron transcripts, 
processed and unprocessed pseudogenes. Using LoD=1, 6218 non-protein coding genes 
were included in the analysis. 
For both protein-coding and non-protein coding genes PCA, ANOVA analysis and 
HC were performed based on the top 100 differentially expressed genes (Appendices 12 
and 13 respectively).  
Both PCA and hierarchical heatmap (Figures 23 and 24) showed that successful 
distinguishing between developmental stages is possible based on expression of both 
protein-coding and non-protein coding genes.  
A clear difference could be observed between expression profiles of early 
developmental stages (stage 1 and 2), committed NK cells (stage 3) and functional NK 
cells (stages 4 and 5). While in PCA plot based on protein-coding genes groups of stages 4 
and 5 samples were separated with just a single exception (Figure 23A), in the plot based 
on non-protein coding genes these groups overlapped (Figure 23B). Similar to the analysis 
with the complete transcriptome (chapter 3.3.2), in the analysis based on only protein-
coding genes the stage 3 samples from bone marrow clustered with earlier developmental 
stages, while the stage 3 sample from cord blood and the stage 2 sample from tonsils 
clustered in between these groups (Figure 23A). 
Considering heatmaps of gene expression (Figure 24A), the samples clustered not 
only according to developmental stages, but partly according to the sample origin (for 
example stages 1 to 3 from bone marrow or stages 2 and 3 from tonsils). 
When non-protein coding genes were used, samples from stages 1 and 2 formed a 
clear cluster that also included both stage 3 bone marrow samples (Cluster 1, Figure 24B). 
This cluster had a high expression of 22 genes (Table 11). The other stage 3 samples 
formed a separate cluster, which also included stage 2 sample from tonsils (Cluster 2, 
Figure 24B). These data are in accord with published data that both stage 2 and 3 cells 
from tonsils include ILC3 cells (Crellin et al., 2010b; Mebius et al., 1997). The samples of 
Cluster 2 partly shared gene expression patterns with stage 4 and 5 samples, but also had a 
































































































































































































































































































































































































































































































































































































































Figure 23 PCA score plots of ex vivo NK samples based on top 100 protein coding genes (A) and top 100 
non-protein coding genes (B)  
Protein-coding genes were selected from the total number of 14177 and non-protein coding – from the total 






While some genes from this cluster were also expressed at lower levels among 
stage 4 samples, at least 7 genes were expressed exclusively in non-bone marrow stage 3 
samples: RP11-15B24.5, B3GALT5-AS1, RP11-567M16.1, RP11-475O6.1, RP11-389C8.2, 
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Heatmap of Expression (Gene Z-Score)






















































































































































































































































































































































































































































































Figure 24 HC heatmaps of ex vivo NK samples based on top 100 protein coding genes (A) and top 100 non-
protein coding genes (B)  
Protein-coding genes were selected from the total number of 14177 and non-protein coding – from the total 





PCA plot (Figure 23B), stage 5 samples were grouped in two clusters (Clusters 3 and 4, 
Figure 24B) with stage 4 samples intermingled in Cluster 4, suggesting that the gene 
expression differences in non-protein coding genes between stages 4 and 5 is smaller than 
in protein-coding genes. 
Table 11 Expression patterns of non-protein coding genes among ex vivo NK samples 
Cluster 1 Cluster 2 Clusters 2-4 Clusters 3-4 
AC002454.1  AC005083.1  RP11-330A16.1 AC017104.6  AC007278.2  
AC004791.2  AC010761.14 RP11-342I1.2  HCP5  AC010886.2  
AC007319.1 AC020571.3 RP11-389C8.2 LINC00299  AC092580.4 
AOX2P AC022182.1  RP11-44N11.3 LPAL2 AF131217.1  
AP001171.1  AC092667.2   RP11-456H18.2 RP3-467K16.4 AMZ2P2  
CASC15  AL356585.1  RP11-475O6.1 XXbac-BPG181B23.6 EDDM3CP  
EGFEM1P  AL450992.2  RP11-520A21.1   FCGR2C  
GATA2-AS1 B3GALT5-AS1 RP11-563D10.1   FTH1P22  
IGF2BP2-AS1 HLA-DQB1-AS1 RP11-567M16.1   RP11-104L21.2 
KIAA0087  LINC00309  RP11-624C23.1   RP11-104L21.3 
KIAA0125  LINC00877  RP11-693J15.5   RP11-1094M14.5 
LINC01268  LINC00880  RP11-6F2.5    RP11-121A8.1 
MAGI2-AS3  LINC00892   RP11-757F18.5   RP11-20I20.4 
RP1-18D14.7 LINC01132  RP11-794P6.1   RP11-222K16.2 
RP11-212I21.4 LINC01135  RP11-796E2.4   RP11-277P12.20 
RP11-305O6.3 NAPSB  RP11-98G13.1   RP11-463J10.2 
RP11-354E11.2 PLA2G4E-AS1 RP4-738P11.   RP11-47L3.1 
RP11-366L20.2 RP1-131F15.2 RP6-91H8.3    RP11-686D22.10 
RP11-424C20.2  RP1-206D15.6 RPL23AP22   RP11-693N9.2 
RP11-678G14.3 RP11-158I9.5 RPS20P2    RP11-705C15.5 
RP13-786C16.1 RP11-15B24.5 SCART1    RP11-973H7.1 
TVP23CP1  RP11-252C15.1 SRGAP3-AS2    RP5-1028K7.2 
  RP11-326C3.2     THRA1/BTR  
 
As already seen in the PCA plot (Figure 23A), the protein-coding gene clustering 
appeared more diffuse (Figure 24A). While most of stage 3, 4 and 5 samples were 
clustered according to corresponding developmental stages. Cluster 2 was mixed and 
included samples from stages 1 to 4. This Cluster contained samples from bone marrow 
and one stage 2 sample from cord blood. Specific gene expression patterns of observed 
clusters are summarized in the Table 12. Thus, different from the non-protein coding 
genes, the protein-coding genes of stages 1 to 3 of the bone marrow samples do not cluster 
according to their developmental stages. This indicates that the expression of the non-
protein coding genes more strictly follows the developmental pathway and suggests a role 





Table 12 Expression patterns of non-protein coding genes among ex vivo NK samples 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
B3GALT5  LIF  ACAN  DUSP4  B3GAT1  
B4GALNT1  LINGO4  AHSP  N4BP3 BNC2  
BCAS1  LPAR1 AZU1  TNFSF9  DTHD1  
CD200R1  LTB CLC Shared with cluster 1 EOMES  
CDH1   MAP7  CPA3   B4GALNT1  FCGR3A  
CPNE7  MYB CTSG  DLL1  FEZ1  
CSPG4   MYO7A  DEFA3  DTX1  FGFBP2  
DLL1  NCR2 ELANE  IGFBP4 GZMA  
DTX1  NELL2  HBB  IL7R  GZMB  
ENPP1 PKDCC  HBD  KRT81  GZMH  
FLT3  RORC  HBG2 KRT86 GZMM  
GPR55  SLC4A10   LTF  NELL2  IFNG  
IGFBP4  SMIM10L2A  MPO  SPINK2  KIR3DX1  
IL1R1  SORCS1  MS4A3  TNFRSF18  KLRD1  
IL22  SPINK2  PRSS57  TOX2  KLRF1  
IL23R  THEM5  PRTN3  XCL1  PDZD4  
IL4I1   TNFRSF18  RHAG XCL2  PRF1  
IL7R  TNFSF11  RNASE2  Shared with cluster 4 PRSS23  
KIAA1211L  TOX2  RNASE3  DTHD1  PYHIN1  
KIAA1324  VWDE SPTA1  EOMES  S1PR5  
KLRF2  XCL1    GZMA  TBX21  
KRT81  XCL2    GZMB  TGFBR3  
KRT86     GZMH    
      GZMM    
      IFNG    
      KIR3DX1    
      KLRD1    
      KLRF1    
      PDZD4    
      PRF1    
      PYHIN1    
      TBX21    
      TGFBR3    
 
Of the protein-coding genes, Cluster 1 (Figure 24A) includes stages 2 and 3 
samples of tonsil origin contains 46 genes. It included genes typical for early 
hematopoietic stages (e.g. LIF, MYB), as well as typical ILC3-related genes (e.g. IL1R1, 
IL23R, LTB, IL22, RORC). The abovementioned mixed cluster (Cluster 2, Figure 24A) 
included stage 1 to 4 samples from bone marrow, as well as stage 2 to 3 samples from cord 
blood. All of them expressed 19 genes at high level, most of which were associated with 





of stage 4 samples besides two of bone marrow origin clustered together (Cluster 3, Figure 
24A) and expressed high levels of DUSP4, N4BP3, and TNFSF9. Besides this they shared 
gene expressions with both Cluster 1 and Cluster 4, however both patterns were expressed 
on lower levels. Finally, Cluster 4 included only stage 5 samples and expressed mainly 
genes typical for mature NKs (e.g. KLRF1, GZMA, GZMB, GZMH, GZMM, IFNG, 
KIR3DX1, PRF1, TBX21 etc.).  
Pairwise correlation of gene expression between stages was performed based on the 
top 100 protein-coding and non-protein coding genes, respectively (Figures 25). Similar to 
the analysis of the complete transcriptome, both for protein-coding and non-protein coding 
genes the highest correlation was detected between stages following each other in 
development. The strongest correlations were observed between stages 1 and 2, and 
between 4 and 5. Correlation coefficients amounted to 0.744 and 0.69 respectively when 
protein-coding genes were analyzed, and were even higher (0.83 and 0.74 respectively) in 
non-protein coding genes. Also positive, but weaker correlation was observed between 
stages 2 and 3, and between stages 3 and 4. However, in that case a clear difference was 
observed between protein-coding and non-protein coding gene. For non-protein coding 
genes the correlation between stages 2 and 3 and between stages 3 and 4 was beyond the 
threshold (correlation coefficients 0.285 and 0.402 respectively). For protein-coding genes 
in contrast the correlation was relatively strong between stages 2 and 3 (correlation 
coefficient 0.62) and dramatically weaker between stages 3 and 4 (correlation coefficient 
0.046).  
Notably, rather strong negative correlations were detected between stages 1 and 5, 
as well as between 2 and 5 (-0.4 and -0.55) when non-protein coding genes were analyzed, 
which was not the case upon analysis based on protein-coding genes. In the latter, 
however, the strongest negative correlation was detected between stages 3 and 5 (-0.43), 
which is in accord with the analogical analysis based on the complete transcriptome. 
Higher correlations for expression of non-protein coding genes in comparison to 
protein-coding genes (Figure 26) might be due to smaller expression changes of non-
protein coding genes during development. Further, as non-protein coding genes are thought 
to be involved in the expression regulation of (protein-coding) genes, their expression 
would be expected to be more tightly regulated during either very early or during very late 
developmental stages. If an outstanding position of stage 3 is due to presence of ILC3s, 
one can suppose, that differences between stage 3 NK cells and ILC3s are more 
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Figure 25 Pairwise comparison of gene expression levels within ex vivo NK samples based on top 100 
protein coding genes (A) and top 100 non-protein coding genes (B)  
Protein-coding genes were selected from the total number of 14177 and non-protein coding – from the total 






3.6 Regulatory potential of non-protein coding RNAs 
As many of the non-protein coding genes among the studied genes were 
specifically expressed in certain lymphocyte subgroups and among certain developmental 
stages, we supposed that they might have regulatory potential for lymphocyte development 
and function.  
3.6.1. Correlation between expression levels of protein-coding and non-protein 
coding genes during NK development  
As described in chapter 3.5 the expression of both protein-coding and non-protein 
coding genes changes during NK cell development from stage 1 to stage 5. To investigate 
further relations between these two gene groups, a correlation analysis of their expression 
levels was performed. The sample set was the same as in chapter 3.5 and included 56 ex 
vivo NK samples from stages 1 to 5; the gene set included the top 100 differentially 
expressed protein-coding genes and the top 100 non-protein coding genes, described for 
this sample set above. Only correlations between protein-coding and non-protein coding 
genes were taken into account. Correlations with the value of coefficient >0.8 or <-0.8 and 
p<0.05 were considered to be significantly strong and are summarized in the Appendix 14. 
Out of the top 100 non-protein coding genes, 26 showed a significant strong 
positive (Figure 27) or negative (Figure 28) correlation to at least one of the top 100 
protein-coding genes; 42 out of the top 100 protein-coding genes were involved in these 



























Figure 26 Correlation of gene expression levels between consequent 
developmental stages based on expression of protein-coding and non-protein 






Two genes among these 26 genes, RP11-973H7.1 and RP11-20I20.4, are expressed 
specifically in stages 4 and 5 and had the highest number of correlations: 17 and 20 
respectively. Both of them correlated to following genes: S1PR5 (correlation coefficients 
0.85 and 0.91 respectively), TGFBR3 (0.85 for both), GZMA (0.84 and 0.8), GZMB (0.92 
for both), GZMM (0.82 for both), FGFBP2 (0.86 and 0.82 respectively), KLRD1 (0.82 and 
0.81), TBX21 (0.82 and 0.83), PYHIN (0.87 and 0.86), PDZD4 (0.86 and 0.84), PRSS23 























































































































































































































































































































Figure 27 Correlation network of gene expression between protein-coding and non-protein coding 
genes within ex vivo NK samples  






coefficients 0.88 and 0.87 respectively). Consistently, all of these protein-coding genes 
were also expressed by samples from stage 4 and/or 5.  
 
The expression of 3 more genes typical for mature NK cells, IFNG, GZMH and 
B3GAT1, correlated with the expression of RP11-973H7.1 (with coefficients 0.84, 0.8 and 
0.81 respectively), but not with RP11-20I20.4. At the same time, expression of RP11-
20I20.4, but not of RP11-973H7.1, strongly correlated with the expression of DTHD1 and 
BNC2 (coefficients 0.8 and 0.82 respectively). In addition, expression of RP11-20I20.4 
was negatively correlated with the expression of SPINK2 (coefficient -0.82), MAP7 (-
0.83), MYB (0.82) and VWDE (-0.8). Notably, while MAP7, MYB and VWDE were 
expressed by stages 1 to 3, SPINK2 gene was expressed mainly by stage 4 NKs. 
RP11-1094M14.5, the gene with the third highest number of correlations, was also 
expressed within stage 4 and 5 samples, but also in samples from stage 3. Strong positive 
correlations were observed for genes TGFBR3 (correlation coefficient 0.8), DTHD1 (0.84), 
















































































































Figure 28 Correlation network of gene expression between protein-coding and non-protein coding 
genes within ex vivo NK samples  






PYHIN1 (0.9), FCGR3A (0.82), KLRF1 (0.83), GZMA (0.85), BNC2 (0.8), and FEZ1 (0.8); 
all these genes were also highly expressed by mature NK cells of stages 4 and 5. The same 
was the case for another non-protein coding gene expressed within stages 4 and 5, RP3-
467K16.4. Its correlation also correlated to those of mature NK cell markers: GZMB 
(coefficient 0.83), GZMM (0.82), IFNG (0.82), PDZD4 (0.81), PRF1 (0.8). 
Three more lncRNA genes, RP11-330A16.1 (expressed mainly in stage 4 samples), 
RP11-563D10.1 (expressed in stage 3 samples from tonsils and cord blood) and RP1-
206D15.6 (expressed in stage 3 samples, but also among some samples from stage 4) 
possessed four positive correlations each. Expression levels of RP11-330A16.1 correlated 
with expression of ENPP1 (correlation coefficient 0.82), CSPG4 (0.83), IL7R (0.82), and 
LTB (0.82). RP11-563D10.1 expression correlated expression levels of ENPP1 (correlation 
coefficient 0.82), LIF (0.84), RORC (0.82), and KLRF2 (0.8). Expression of RP1-
206D15.6 correlated with expression levels of LIF (correlation coefficient 0.83), IL1R1 
(0.8), LPAR1 (0.83), and MYO7A (0.83). Expression of AC005083.1, a gene encoding 
processed transcript and expressed also mainly in stage 3 samples, correlated positively to 
expression of IL1R1 (correlation coefficient 0.82) and MYO7A (0.81) and negatively to 
S1PR5 (-0.81). 
KIAA0125 (expressed in stages 1 to 4, but not in any stage 5 sample) and RP11-
686D22.10 (expressed mainly in stages 4 and 5, but also stage 3 samples from tonsils) had 
four correlation connections each as well. The expression of KIAA0125 positively 
correlated with that of SPINK2 (correlation coefficient 0.84) and MAP7 (0,81), and 
correlated negatively with two genes expressed within stages 4 and 5, S1PR5 and GZMB (-
0.8 for both). The expression of RP11-686D22.10 positively correlated to that of TGFBR3, 
PYHIN1 and FEZ1 (correlation coefficients 0.81, 0.86 and 0.82 respectively) and 
negatively with that of FLT3 (-0.82).  
Genes RP6-91H8.3, RP11-796E2.4 and RP11-326C3.2 were expressed in stages 3 
and 4, while the latter two of them were also expressed in stage 5, but at lower levels. The 
expression of all three genes correlated significantly with that of LTB (correlation 
coefficient 0.8, 0.81 and 0.82 respectively), while RP6-91H8.3 expression also correlated 
with that of MYO7A (0.83), the expression of RP11-796E2.4 with that of XCL1 (0.85), and 
expression of RP11-326C3.2 correlated with that of DLL1 (0.84). The expression of RP11-
222K16.2, a gene expressed strictly in stage 4 and 5, correlated with that of typical mature 





Finally, the other eight non-protein coding genes correlated to only one gene each. 
Two genes, LINC00892 and RP11-520A21.1, were expressed by samples from stages 3 
and 4. While LINC00892 expression correlated with that of ENPP1 (correlation coefficient 
0.84), RP11-520A21.1 expression correlated with IL4I1 (0.86). One more gene, 
LINC00309, which was also expressed at stage 3 and at lower level in stages 4 and 5, 
correlated as well with IL4I1 expression (0.84). 
From another three genes expressed mainly at stages 4 and 5, but also partly at 
stage 3, the expression of FTH1P22 correlated significantly with that of KLRF1 
(correlation coefficient 0.82), RP11.121A8.1 correlated with PRF1 (0.83), and 
RP11.463J10.2 correlated with BNC2 (0.84). In addition, RP11-693N9.2 was expressed in 
stages 3 to 5 and correlated with PRF1 (correlation coefficient 0.83). 
The last identified non-protein coding gene, SCART1, was expressed ubiquitously 
within all analyzed samples and its expression correlated with that of ENPP1 (correlation 
coefficient 0.82). 
3.6.2. Cis-regulation potential 
As many non-protein coding genes regulate the expression of neighboring genes, 
the cis-regulatory potential of the top 100 non-protein coding genes was studied. First of 
all, their neighboring protein-coding genes were identified based on the genes’ localization 
(Table 13). To narrow down the number of potential target genes, only genes localized 
within up to 5% of the chromosome length from the given non-protein coding genes were 
considered. The result of this analysis is shown in Table 13. For the sake of clarity, the 
further analysis was restricted to 28 non-protein coding genes (marked green in Table 13) 
that are located in the neighborhood of protein-coding genes and have a known function in 
the immune system, in particularly play a role in the function and development of NK, T, 
and B lymphocytes.  
Table 13 Characteristic of top 100 non-protein coding genes differentially expressed 
within ex vivo NK samples 
GeneID Localization Gene type Neighboring genes of interest 
AC002454.1 7q21.2 antisense CDK-6, GATAD1, FAM133B 
AC004791.2 19q13.12 lincRNAS CYP4F2, OR10H4 
AC005083.1 7p21.1 processed transcript ITGB8, MACC1  
AC007278.2 2q14.3 sense intronic IL18RAP, IL18A1, IL1RL1 
AC007319.1 2q32.1 antisense CALCRL, TFP1  
AC010761.14 17q11.2 antisense PRL23A, RAB34, TLCD1 
AC010886.2 2q35 processed pseudogene DIRC3, TNS1 





AC020571.3 2q32.3 antisense STK17B, HGNC  
AC022182.1 8q12.2 lincRNA CHD7, CLVS1  
AC092580.4 2p25.1 lincRNA ID2 
AC092667.2 2q11.2 antisense NMS, LOMRF2, CHST10, AFF3 
AF131217.1 21q21.3 lincRNA BCL11B 
AL356585.1 13 miRNA FAM230C, AL356585.2 
AL450992.2 1q21.3 antisense C2CD4D, THEM5, RORC, S100A10  
AMZ2P2 6q25.3 processed pseudogene SYTL3, EZR  
AOX2P 2q33.1 pseudogene AOX1, BUW1, NIF3L1, CLK1, PPIL3  
AP001171.1 21q21.1 lincRNA - 
B3GALT5-AS1 21q22.2 antisense SH3BGR, IGSF5, HMGN1, B3GALT5  
CASC15 6q22.3 linc SRY  
EDDM3CP 2q21.3 processed pseudogene MGAT5  
EGFEM1P 3q26.2 pseudogene GOLIM4  
FCGR2C 1q23.3 pseudogene 
FCGR2C, FCRLA, FCRLB, DUSP12, 
FCGR2A, SDHC 
FTH1P22 1p13.1 processed pseudogene CD2, CD101, CD58, IGSF3, PTGFRN  
GATA2-AS1 3q21.3 antisense 
GATA2, RAB7A, ACAD9, DNSJB, 
RPN1 
HCP5 6p21.33 sense overlapping 
TCF19, AIF1, LTB, LTA, LST1, MICB, 
TNF, NCR3, BAG6, NFKBIL1, MICA  
HLA-DQB1-AS1 6p21.32 antisense HLA-DQB1A, BTNL2 
HSPE1P18 11q23.3 processed pseudogene 
IL10RA, CD3E, CD3G, CD3D, KMT2A, 
TMPRSS4, AMICA1, CXADR  
IGF2BP2-AS1 3q27.2 antisense IGF2BP2, SENP2, TRA2B  
KIAA0087 7p15.2 lincRNA SNX10, SKAP2  
KIAA0125 14q32.33 lincRNA IG locus 
LINC00299 2p25.1 lincRNA ID2  
LINC00309 2p14 lincRNA PELI1, LGALSL1  
LINC00877 3q13 lincRNA PROK2, EIF4E3, GPR227  
LINC00880 3q35.21 lincRNA TIPARP, LEKR1, CCNL1  
LINC00892 Xq26.3 lincRNA CD40LG, HTATSF1,  
LINC01132 1q42.3 lincRNA IRF2BP2  
LINC01135 1p32.1 lincRNA JUN, OMA1, MYSM1  
LINC01268 6q21 lincRNA MARCK, HDAC2  
LPAL2 6q25.3 
unprocessed 
pseudogene SLC22A3  
MAGI2-AS3 7q21.11 processed transcript MAGI2  
NAPSB 19q13.33 pseudogene 
NR1H2, KCNC3, POLD1, SPIB, EMC10, 
NAPSA  
PLA2G4E-AS1 15q15.1 antisense PLA2G4E, EHD4  
PLA2G4E-AS1 15q15.1 antisense EHD4  
RP1-131F15.2 6q23.2 processed pseudogene ENPP1  
RP1-18D14.7 1p33 antisense TAL1, PDZK1IP1, STIL  
RP1-206D15.6 1q24.2 lincRNA 
SLC19A2, BLZF1, SELL, NME7, 
SLC19A2 
RP11-104L21.2 1q24.2 sense intronic CD3Z 
RP11-104L21.3 1q24.2 lincRNA CD3Z 





RP11-121A8.1 7p14.1 lincRNA 
TRGV9, TRGC2, TRGV8, TRGVA, 
TSGA10 
RP11-158I9.5 11q23.3 antisense CXCR5, TRAPPC4, FOXR1, BCL9L 
RP11-15B24.5 9q21.32 lincRNA SPATA31D1  
RP11-20I20.4 4p16.3 antisense SPON2, FGFRL1 
RP11-212I21.4 16q lincRNA LPCAT2  
RP11-21J7.1 1q31.2 lincRNA CDC73, TROVE2, B3GALT2  
RP11-222K16.2 3p24.1 lincRNA EOMES  
RP11-252C15.1 8p23.1 lincRNA KIAA1456, LONRF1, DLC1  
RP11-277P12.20 12p13.2 antisense 
KLRC1, KLRC2, KLRC3, KLRC4, 
KLRK1, KLRD1 
RP11-305O6.3 12q14.3 sense intronic MSRB3, LEMD3 
RP11-326C3.2 11p15.5 antisense 
AP2A2, IFITM2, ATHL1, NLRP6, 
RASSF7, IFITM3, IRF7, IFITM5, ANO9  
RP11-330A16.1 6p23 lincRNA CD83  
RP11-342I1.2 4q31.1 antisense RAB33B, SETD7 
RP11-354E11.2 10p12.31 antisense MALRD1, PLXDC2 
RP11-366L20.2 12q14.3 antisense HMGA2,  
RP11-389C8.2 5q13.2 sense overlapping ZNF366, PTCD2 
RP11-424C20.2 12p12.2 processed pseudogene SLCO1C1, PDE3A  
RP11-44N11.3 8q24.13 lincRNA DERL1, ZHX2  
RP11-456H18.2 6p21.1 lincRNA HIVEP1 
RP11-463J10.2 14q22.1 antisense GNG2, NID2  
RP11-475O6.1 1p31.1 lincRNA TTLL7  
RP11-47L3.1 17q12 lincRNA 
SLFN12L, SLFN5, SLFN11, SLFN12, 
SLFN13; SLC35G3, NLE1  
RP11-520A21.1 3p22.1 lincRNA ZNF619, ZNF620, ZNF621 
RP11-563D10.1 1q31.3 lincRNA - 
RP11-567M16.1 18q23 processed transcript CTDP1, NFATC1  
RP11-624C23.1 8p22 antisense NEFM, ADAM28  
RP11-678G14.3 18p12 lincRNA ZNF493, ZNF429, ZNF100 
RP11-686D22.10 17q12 pseudogene SLFN12 




CASP12, CASP5, CASP4, CASP1, 
CARD16 CARD17, CARD18 
RP11-6F2.5 3q25.31 lincRNA LEKR1, CCNL1  
RP11-705C15.5 12p13.31 processed transcript 
KLRB1, KLRF1, KLRF2, CLECL1C, 
CLEC2D, CD69  
RP11-757F18.5 3q13.2 antisense GCSAM, SLC9C1 
RP11-794P6.1 11q23.1 sense intronic POU2AF1, COLCA1, COLCA2, BTG4  
RP11-796E2.4 12q21.33 antisense BTG1  
RP11-973H7.1 18p11.12 lincRNA PSMG2, PTPN2 
RP11-98G13.1 1q31.2 lincRNA B3GALT2, KCNT2 
RP13-786C16.1 11p13 antisense FBOXO3, CD59, LMO2  
RP3-467K16.4 1p36.21 lincRNA 
EFHD, DNAJC16, CTRC, CASP9, 
CELA2A , CELA2B  
RP4-738P11.3 1q24.2 processed pseudogene XCL2, XCL1  





RP6-91H8.3 14q24.2 lincRNA PCNX  
RPL23AP22 1q31.2 processed pseudogene - 
RPS20P2 16p13.3 processed pseudogene UBE21, BAIAP3 
SCART1 10q26.3 unitary pseudogene CYP2E1, SPRN  
SRGAP3-AS2 3p25.3 antisense SRGAP3 
THRA1/BTR 17q21.32 antisense SKAP1, NFE2L1, SNX11, CBX1  





TCF19, AIF1, LTB, LTA, LST1, MICB, 
TNF, NCR3, BAG6, NFKBIL1, MICA  
 
Then, the correlation between the expression of non-protein coding genes and the 
corresponding potential targets was calculated in the specific lymphocyte populations. 
Spearman’s correlation coefficients were calculated and compared for following sample 
groups: all available samples (n=96), ex vivo NK samples from stages 1 to 5 (n=56), stage 
3 ex vivo NK samples (n=11), stage 4 ex vivo NK samples (n=9), and stage 5 ex vivo NK 
samples (n=30). Only correlation with values of Spearman’s coefficient >0.5 or <-0.5, 
p<0.05 were considered as significant and taken into account; correlation with values of 
Spearman’s coefficient >0.7 or <-0.7 were considered as strong and are summarized in the 
Appendix 15. Expression of some non-protein coding genes also correlated to those of 
protein-coding genes that are not closely localized; most important of such correlations are 
mentioned in chapters 3.6.1 and  3.7.4, so they will not be discussed here.  
Even though it could be possible that correlation is caused by an opened or closed 
chromatin state, the close localization of genes does not necessarily lead to expression 
correlation. For example, there was no significant correlation detected in any of the sample 
groups (neither positive nor negative) between LINC011332 and IRF2BP2, which are 
localized about 66 kb apart. Also the expression of RP1-206D15.6 and SELL, of RP11-
693J15.5 and BTG1, and of AOX2P and NIF3L1 (localized 124 kb, 289 kb, and 140 kb 
apart, respectively), is not significantly correlated in any sample group. At the same time, 
expression of another non-protein coding gene, RP11-796E2.4, which is localized less than 
1kb from the BTG1 gene, correlated with the BTG1 expression in all sample groups and in 
the ex vivo NK sample groups (r=0.57 and 0.56 respectively). RP5-1028K7.2 is localized 
less than 26 kb away from the CCR7 gene and less than 20 kb away from the IGFBP4 
gene. However, no correlation was found between the RP5-1028K7.2 and the CCR7 
expression, while the expression of RP5-1028K7.2 and IGFBP4 correlated within stage 3 





When such RNA-seq data are analyzed, one should also take into account the 
expression levels of the given genes. For example, expression levels of RP11-158I9.5 and 
CXCR5 strongly correlate among all samples (0.8), among ex vivo NK samples (0.6), 
among stage 3 (0.9) and stage 4 (0.7). However, this effect seems to be achieved due to 
low expression levels of both genes in all these samples, besides B-lymphocytes. This was 
also the case for B3GALT5-AS1 (an antisense RNA of B3GALT5). Its expression correlated 
to B3GALT5 within all sample group (r=0.6), ex vivo NK cells (0.64), and at stage 3 (0.9), 
however, in all samples except for stage 3 the expression of both these genes did not 
exceed 10 fpkm. Notably, expression of another closely localized gene, IGSF5, correlated 
to B3GALT5-AS1 (r=0.91) only within stage 3, where B3GALT5-AS1 expression was 
relatively high. Between other closely located genes, HMGN1 and SH3BGR, and 
B3GALT5-AS1 no significant correlation was detected. 
In some cases among several of the protein-coding genes, which are localized in 
the neighborhood of a given non-protein coding gene, expression of only a certain one 
correlates. For example, genes of four interferon induced transmembrane proteins 
(IFITM1, -2, -3 and -5) are localized within 30 kb distance of RP11-326C3.2; SIGIRR is 
localized at the same DNA strand in less that 50 kb. However, expression of only one of 
them, IFITIM5, correlated with RP11-326C3.2 expression in both group of all samples and 
ex vivo NK cells (0.7 and 0.69 respectively), even though they are localized on opposite 
DNA strands. Expression of IFITM1, IFITM2, and SIGIRR correlates instead with RP11-
326C3.2 expression within stage 3 (Spearman’s coefficients 0.68, 0.68 and 0.72 
respectively), while between expression levels of RP11-326C3.2 and IFITM3 there was no 
significant correlation at all. 
The four genes encoding cell surface molecules CD2, CD58, IGSF3, and CD101 
(IGSF2) are localized in the neighborhood of the FTH1P22 non-protein coding gene. 
Among them, only the expression of CD2 positively correlated with that of FTH1P22 
within all samples group (0.55), ex vivo NK group (0.6), among stage 3 samples (0.68), 
and among stage 5 samples (0.63). 
Another example is two T-cell receptor segments, five of which (TRGV8, TRGVA, 
TRGC2, TRGV9, and TRAG10) are localized within 70 kb of RP11-121A8.1, which was 
expressed among NK cells from stage 3 to stage 5 with highest expression at stage 5. 
Among them TRGV8 and TRGVA were expressed in all NK, as well as in T cell samples at 
low level, however, their expression levels were strongly correlated among all samples 





besides stage 5 NK cells (0.6 to 0.81) for TRGVA, TRGC2 and TRGV9 genes were both 
expressed within stages 3 to 5 and their expression correlated with that of RP11-121A8.1 
within all sample group (0.75 and 0.8 respectively), ex vivo NK samples (0.72 and 0.65 
respectively) and weaker within stage 5 samples (0.58 and 0.56 respectively), while for 
TRGC2 the a correlation coefficient of 0,65 was also observed within stage 4 samples. The 
last examined gene from this locus, TRGA10, was relatively highly expressed within stage 
5 NK and T-cell samples, however, no correlation of the TRGA10 expression with that of 
RP11-121A8.1 was observed in any of studied sample groups.  
The same was the case for HSPE1P18: among three genes located close to it, only 
CD3E expression correlated to HSPE1P18 among stage 3 samples (r=0.8), while for 
CD3D and IL10RA no significant correlation was detected.  
Vice versa, when two non-protein coding genes localized close to the same protein-
coding gene, it is not necessary that their expression correlate in the same way. For 
example, LINC00299 and AC092580.4 are localized in the neighborhood of the ID2 gene, 
which encodes an essential factor of ILC and NK cell development (Yokota et al., 1999; 
Cherrier et al., 2012). LINC00299 is an NK- and ILC3-specific lncRNA, localized about 
270 kb from the ID2 gene; its expression correlated with ID2 expression levels, but only 
when all samples were analyzed (r=0.68), and not among ex vivo NK developmental stages 
or within specific stages. AC092580.4 is localized 207 kb from LINC00299 and in 870 kb 
distance from the ID2 gene, but in contrast to LINC00299 the expression of AC092580.4 
correlated with that of ID2 not only in all samples (0.75), but also among ex vivo NK cells 
(0.59) and – in the strongest manner – among stage 4 NK cells (0.86).  
Two other analyzed non-protein coding genes localized close to each other are 
XXbac-BPG181B23.6 and HCP5. They are located in the HLA complex, a gene-rich 
region of chromosome 6, in less than 30 kb from each other. The following protein-coding 
genes were localized within 200kb from HCP5 and XXbac-BPG181B23.6: AIF1, BAG6, 
HLA-B, HLA-C, LTS1, LTA, LTB, MICA, MICB, NCR3, NFKBIL1, and TNF; and it seems 
that in most cases correlation between their expression levels did not depend on whether 
genes were localized on the same or on opposite DNA strands. In particular, expression of 
LTB and NFKBIL1 (both localized at the same strand with HCP5) correlated with that of 
both HCP5 and XXbac-BPG181B23.6 within the same patterns (only in stages 3 and 4 
groups, but not in others) and at comparable levels. Expression levels of LTB and HCP5 
correlated with Spearman’s coefficients 0.89 and 0.68 respectively, LTB and XXbac-





of NFKBIL1 correlated with that of HCP5 with coefficients of 0.75 and 0.65, expression of 
NFKBIL1 correlated to those of XXbac-BPG181B23.6 with coefficients of 0,7 and 0, 67. 
Also expression of BAG6 correlated with both these non-protein coding genes within the 
stage 5 sample group (0.67 for HPC5 and 0.77 for XXbac-BPG181B23.6), but not in any 
other group; LTA correlated with both of them within the stage 3 group (0.95 and 0.84 
respectively). NCR3 expression (localized on the same strand as XXbac-BPG181B23.6) 
correlated with both non-protein coding genes among all samples group (0.55 and 0.5 
respectively), among ex vivo NK sample group (0.67 and 0.7), and among stage 3 NK 
samples (0.97 and 0.82). NCR3 also weakly correlated with XXbac-BPG181B23.6 
expression among stage 5 (0.5), which was not the case for HCP5, while correlation 
patterns of AIF1 and LST1 (both localized on the same strand as HCP5) differed between 
HCP5 and XXbac-BPG181B23.6. While no significant correlation was detected between 
expression of AIF1 and XXbac-BPG181B23.6 as well as between XXbac-BPG181B23.6 
and LST1, LST1 correlated positively with HCP5 among stage 3 samples, and AIF1 
expression correlated negatively with HCP5 among all sample and ex vivo NK sample 
groups  (-0.58 and -0.57 respectively). 
However, The expression of both RP11-109M14.5 and RP11-686D22.10, localized 
in the same region as SLFN12L, correlate with the SLFN12L expression in the ex vivo NK 
sample group (r=0.94 and 0.88 respectively), among all samples (0.95 and 0.94 
respectively), and among stage 5 samples (0.88 and 0.58 respectively). Besides this, RP11-
109M14.5 expression also strongly correlated with that of SLFN12L within stage 4 samples 
(0.91), but not among stage 3, while RP11-686D22.10 expression vise versa correlated 
with that of SLFN12L among stage 3 samples (0.92), but not among stage 4 samples. 
Notably, even though RP11-109M14.5 is a sense intronic RNA-encoding gene located in 
the TAF5L gene, their expression levels were not correlated in any of studied groups. 
A further very interesting correlation with regulatory potential in NK cell 
development deserves to be described separately: between RP11-222K16.2 and EOMES. 
RP11-222K16.2 is localized on the opposite DNA strand of EOMES, in about 2 kb 
distance from it. EOMES is an important transcription factor in NK cell development, and 
correlation between its expression levels to expression level of RP11-222K16.2 was 
observed among all samples and ex vivo NK cells (0.87 and 0.8 respectively), but not 
among stage 3, stage 4 or stage 5 NK groups. These data were consistent with differences 





positive role of RP11-222K16.2 in the regulation of EOMES expression in early NK cell 
developmental stages.  
The expression of RP11-567M16.1 - localized on the same DNA strand and in 
about 131 kb distance from NFATC1 - strongly correlated with that of NFATC1 of stage 3 
samples (0.98), while correlation within all samples and ex vivo NK cells was weaker (0.51 
and 0.54 respectively) and completely absent within stages 4 and 5, suggesting that a 
potential regulation could take place at developmental stage 3, but not later.  
Also a rather strong correlation within the stage 3 sample group was detected 
between expression of RP4-738P11.3 and two cytokine genes, XCL1 and XCL2 (0.75 and 
0.7 respectively). Their expressions correlated within all samples (0.84 and 0.87) and 
within the ex vivo NK group (0.71 and 0.79), but not within the stage 4 and 5 groups.  
Among other genes of interest was AC007278.2, a sense intronic RNA of 
IL18RAP, and the expression of both genes expectedly correlate, but to different extent in 
different groups: the correlation coefficient was 0.9 among all samples, 0.8 among ex vivo 
NK cells, 0.6 among stage 3, 0.67 among stage 5, but negatively among stage 4 (-0.6; 
although not significantly, p=0.07). On the same DNA strand in less than 70 kb from 
AC007278.2 are the IL18R1 and IL1RL1 genes localized.  While there is no significant 
correlation between AC007278.2 and IL1RL1 expression in any of the analyzed groups, 
IL18R1 expression correlated with AC007278.2 in the group of all samples and even 
stronger in stage 3 NK sample group (0,64 and 0,86 respectively), but not in any other. 
AL450992.2 is localized about 20 kb from the RORC gene (a highly important 
marker of ILC3 cells, which is normally not expressed in NK lymphocytes) and 67 kb 
from the S100A10 gene (both are localized on the opposite DNA strand of AL450992.2). 
While the expression of AL450992.2 and RORC slightly correlated in both all sample 
group and ex vivo NK cells (0.56 and 0.64 respectively), there was no significant 
correlation between AL450992.2 and S100A10 in either of these groups. Among stage 3 
samples, correlation between AL450992.2 and RORC was even higher (0.82), while 
AL450992.2 and S100A10 were strongly negatively correlated in stage 4 samples (-0.76).  
Two immunologically relevant genes are localized in the neighborhood of 
LINC00892: CD40LG localized on the same DNA strand in less than 6 kb, and HTATSF1, 
which is located on the opposite strand at 77 kb distance of LICN00892. While no 
significant correlation in any groups was detected between LINC00892 and HTATSF1, 
expression of LINC00892 and CD40LG correlated within stage 5 group (r=0.57) and even 





Expression of lncRNA RP11-330A16.1 and that of the CD83 gene, localized in 44 
kb distance on the opposite DNA strand, were negatively correlated among stage 4 
samples (-0.67), while no other correlations were observed within other groups. 
Among three genes localized close to GATA2-AS1, only GATA2 expression itself 
correlated with that of GATA2-AS1 among all samples (0.64) and ex vivo NK samples 
(0.91). Expression of the other two genes, ACAD9 (localized on the same DNA strand in 
315 kb distance) and RAB7A (localized also on the same DNA strand in 195 kb distance) 
did not correlate with that of GATA2-AS1 in any of those sample groups. However, the 
expression of DNAJB8, (localized on the opposite DNA strand of GATA2-AS1 in about 20 
kb distance) correlated with that of GATA-AS1 among ex vivo NK samples (0.66) and 
among stage 5 samples (0.55). 
The RP11-277P12.20 non-protein coding gene is localized in the locus of NK cell 
receptors, including KLRC1, -C2, -C3, -C4, -K1, and -D1. Its expression correlated with 
that of all mentioned KLR genes among all samples (correlation coefficients from 0.69 to 
0.92), and among stage 3 samples it correlated with that of all KLR genes except for 
KLRD1 (0.72 to 0.97). However, among ex vivo NK samples its expression strongly 
correlated with that of KLRC4, KLRK1, KLRC2, and KLRC3 (coefficients 0.9, 0.87, 0.77, 
0.84 respectively), and weaker with that of KLRD1 (0.53), but not with that of KLRC1. 
Among stage 4 samples, the expression of RP11-277P12.20 was strongly correlated with 
that of KLRC4 and KLRC1 (0.7 and 0.9 respectively), and among stage 5 samples with that 
of KLRC3, KLRC4, and KLRK1 (0.6, 0.83, 0.66 respectively).  
One more non-protein coding genes localized in the KLR locus was RP11-
705C15.5, while the distance to above-mentioned KLR genes was more than 400 kb, 
KLRB1, -F1 were localized in less than 100 kb distance from it, and KLRF2 in about 150 
kb. The expression of both KLRB1 (localized on the opposite DNA strand of RP11-
705C15.5) and KLRF1 (localized on the same DNA strand) correlated with that of RP11-
705C15.5 among all sample group and ex vivo NK group (0.72 and 0.53 respectively for 
KLRB1, 0.7 and 0.71 for KLRF1), while the expression of KLRF1 also correlated strongly 
with that of RP11-705C15.5 among stage 5 with a coefficient of 0.85. At the same time, no 
significant correlation between KLRF2 and RP11-705C15.5 expression was detected. 
Another immunologically relevant gene in that locus was CD69 (expressed by NK cells 
upon activation), localized less than 30 kb away from RP11-705C15.5 on the opposite 
DNA strand, but no significant correlation was detected. 





Sequencing libraries were prepared from 18 intact cells obtained from NK-cell 
enriched peripheral blood for single cell transcriptome analysis. Similar to bulk RNA 
sequencing, library preparation and Illumina sequencing was performed in the 



























































































































Heatmap of Expression (Global Z-Score)
























































































































Heatmap of Expression (Global Z-Score)



































Figure 29 PCA score plot (A) and HC heatmap (B) of single-cell NK samples  














































































































Heatmap of Expression (Gl bal Z-Score)






The gene set used for analysis included protein-coding and non-protein coding 
genes that were identified as specifically expressed within mature NK cells (chapter 3.2). 
The number of genes from this set that were expressed in single cell samples counted to 86 
(Appendix 16). 
3.7.1. Identification of outliers 
As the cells used for the experiment were not sorted by FACS, but enriched by 
MACS-sorting, the obtained libraries were checked for the presence of contaminating T 
and B lymphocytes. For this purpose, typical B cell markers (e.g. CD19, and multiple 
immunoglobulin-genes), as well as T cell markers (e.g. CD3D, CD3E, NELL2, CD82, 
IL32, IL6ST, IL7R, IL27RA) were added to the gene set described above. The total number 
of genes included in the analysis was 171; PCA and HC were performed with the top 89 
differentially expressed genes that acceded LoD=1 threshold (Appendix 17). 
When PCA and clustered heatmaps were performed using this gene set, two 
samples (s19 and s92) were identified as outliers (Figure 29A,B). Sample s92 expressed 
high levels of genes encoding immunoglobulin chains and B cell marker CD19, while 
sample s19 expressed high levels of CD3E, CD3D, IL7R, ITK, IL32, IL6ST. Furthermore, 
both of them expressed low levels of typical NK cell markers such as TYROBP, GZMB, 
CX3CR1, FCGR3A and PRF1. Thus, samples s19 and s92 were suggested to be 
contaminating T and B cells, respectively, and were excluded from further analysis.  
3.7.2. Heterogeneity of gene expression in single NK cells 
Upon exclusion of the outlying samples s19 and s92, the analysis was performed 
using the set of NK-cell specific genes (n=86); 52 of these genes exceeded the threshold of 
LoD=1 and were used for PCA and HC. Gene expression levels were visualized using 
violin plots and the Spearman’s correlation analysis was performed using all 86 genes. 
As can be see on violin plots (Figure 30A), for all 52 selected genes different 
subpopulations of cells were observed that expressed the given genes on different levels. 
Consistent with this, also the clustered heatmap (Figure 30B) showed different gene 
expression patterns. Some genes such as GNLY, GZMA, NKG7, and KLRD1 were 
expressed ubiquitously in every single cell, while other genes were expressed only in 
certain cells. For example, genes PRF1 and CTS7 were expressed higher in nine cells (s23, 
s83, s69, s18, s64, s65, s49, s55, s68) than in the other eight, and TYROBP, SH2D1B and 
GZMB were expressed in cells s23, s83, s69, s18, s64, s65, s49, s55, s68, s56 and s2, but 





To investigate further relations between the analyzed genes, Spearman’s correlation 
analysis was performed. Only correlations with an absolute value of correlation coefficient 
of > 0.7, p<0.05 or with a coefficient of <-0.7, p<0.05 were assumed as significantly 
strong. When the network of strong positive correlations was visualized (Figure 31), four 
correlation nods and several additional correlations were observed.  
 




















































































































































































Heatmap of Expression (Global Z-Score)


















































































Heatmap of Expression (Global Z-Score)
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Figure 30 Violin plots (A)  and HC heatmap (B) of single-cell NK samples  






The biggest nod included 14 genes expressed only or on higher levels in the sample 
s8: PDGFD, AC017104.6, SLC1A7, RP13-516M14.2, RP11-305L7.1, RASSF4, SIPR5, 
RP11-18316.2, PCDH1, PDGFRB, SLC4A4, KIR3DX1, FAT4 and CMKLR1 genes.  
The second nod included mainly genes typical for mature NKs that were expressed 
in most of samples: NKG7, GZMA, KLRD1, GNLY, FCGR3A, SH2D1A, CLIC3, and 




































































































































































































































































































































Figure 31 Correlation network of gene expression within single-cell NK samples 






The third nod consisted of five genes expressed in the cell s65 (RNF165, 
COL13A1, FCRL6, LINC01108, U91324.1). 
In addition, the following correlations were observed:  
• between PRF1 and CST7 (r=0.75); 
• between L3MBTL4 and AF131217.1 (r=0.82); 
• between NME8 and LINGO2 (r=1); 
• between PLCB1-IT1 and CXCR2 (r=1); 
• between ADAMTS1 and PTGDR (r=0.73); 
• between CCNJL and SIGLEC7 (r=0.73). 
Notably, no strong negative correlations were identified within the given set of 
genes. However, several correlations were observed with coefficients lower that -0.5 
(Figure 32), which were also considered as significant:  
• SLAMF7 was negatively correlated with FGFBP2, CST7, TRDC and PRF1; 
• DTHD1 was negatively correlated with ATP8B4 and ITK; 



























































Figure 32 Correlation network of gene expression within single-cell NK samples 






3.7.3. Regulatory potential of non-protein coding RNAs 
To further examine the potential regulatory role of non-protein coding genes, the 
correlation between expression of protein-coding and non-protein coding genes were 
analyzed at the single cell level. The gene set included the set used for analysis protein-
coding and non-protein coding genes identified as specifically expressed in NKs in the 
chapter 3.2 as well as protein-coding and non-protein coding genes identified as 
differentially expressed within NK developmental stages in the chapter 3.3.1. From this set 
only those genes expressed in more than one single cell sample were used for analysis, 
counting for 69 protein-coding and 26 non-protein coding genes. 
Correlations with Spearman’s coefficient r>0.5 or <-0.5 (p<0.05) were considered 
as significant (Appendix 18) Correlation with values of correlation coefficient >0.7 or <-
0.7 (p<0.05) were considered as strong. The strongest positive correlations between 
protein-coding and non-protein coding genes are summarized in Table 15. 
Table 15 The strongest positive correlations between protein-coding and non-protein 
coding genes detected at the single cell level (r>0.7, p<0,05) 














































AF131217.1         0.82         
CASC15       0.77           
GS1.115G20.1                 0.75 
LINC01108 0.72                 
MAGI2.AS3 0.84 0.72       0.72 1.00 1.00   
RP11.277P12.20     0.71             
RP11.693N9.2 0.84 0.72       0.72 0.99 0.99   
 
When the network of strong positive correlations was visualized (Figure 33), five 
groups of correlations were observed. Two non-protein coding genes were in the center of 
the constellation-like structure: pseudogene RP11-693N9.2 and MAGI2-AS3 antisense 
RNA. Both of them correlated with five protein-coding genes: CAMK2A (regulator of cell 
cycle; correlation coefficients 0.84 for both), PDGFD (mitogenic factor; 1 and 0.99 
respectively), CMKLR1 (0.72 for both), VWDE (1 and 0.99), and NELL2 (cell growth 
regulation; 0.72 for both). Besides this, the CAMK2A gene expression also correlated with 
that of LINC01108. Interestingly, three of these genes, CAMK2A, PDGFD and NELL2, are 
involved in cell cycle regulation, and CMKLR1 encodes a receptor of the chemoattractant 





reduction of immune responses (Kaur et al., 2010; Matsumoto et al., 2002). Notably, 
RP11-693N9.2 was also detected in the analysis of bulk sequencing samples (chapter 
3.6.1), where it was ubiquitously expressed among NK samples from stages 3 to 5 and its 
expression strongly correlated with that of PRF1.  
Besides this, the following correlations were observed: 
• between GC1-115G20.1 and XCL1 (r=0.75); 
• between RP11-277P12.20 and GNLY (r=0.71); 
• between AF131217.1 and L3MBTL4 (r=0.82); 
• between CASC15 and KIR3DX1 (r=0.77). 
 
 
 Also weaker positive correlations (with coefficients 0.5> r <0.7, p<0,05) were 
detected (Appendix 18), that were also considered being significant. In particular, the 
expression of LINC00299 lncRNA (expressed in NK cells starting from stage 3 and in 
ILC3 stage 3 cells) correlated with that of other mature NK cell markers such as CST7, 






















































































Figure 33 Correlation network of gene expression between protein-coding and non-protein coding 
genes within single-cell NK samples 






The RP11-222K16.2 gene expression correlated with that of typical NK cell genes 
such as CXCR1 and NCAM1 (0.57 and 0.54 respectively), as well as with that of Corf21 
(0.52). Interestingly, although the expressions of RP11-222K16.2 and EOMES did not 
correlate in the single cell data (but was the case for bulk sequencing data), the expression 
of RP11-222K16.2 correlated with that of NFIL3 (coefficient 0.59) at the single cell level. 
NFIL3 is required for the formation of EOMES-expressing NK cells (Seillet et al., 2014), 
suggesting that RP11-222K16.2 might indeed have a role in NK development.  
The expression of RP11-277P12.20, besides GNLY mentioned above, also 
correlated with that of genes typical for mature NK cells such as CX3CR1, FCGR3A, 
FEZ1, GZMA, KLRD1, and SH2D1A (coefficients 0.52, 0.69, 0.51, 0.59, 0.52, 0.65), as 
well as CLIC3 (0.65), which is known to be tightly regulated in NK cells, but its function 
remains unclear (Kaur et al., 2010; Liu et al., 2002; Matsumoto et al., 2002;). Interestingly, 
as it was shown in the chapter 3.6.2, RP11-277P12.20 gene is localized in the same locus 
as the KLR genes and according to the analysis of bulk sequencing data the expression of 
this non-protein coding gene was correlated not only with that of KLRD1, but also to some 
extend of KLRC1, -C2, -C3, -C4, and –K1. 
The expression of both MAGI2-AS3 and RP11-693N9.2, in addition to the 
abovementioned genes CAMK2A, PDGFD, CMKLR1, VWDE, and NELL2, correlated with 
that of three more genes: NCAM1 (0.69 and 0.7 respectively), TBX21 (0.61 for both) and 
TTC38 (0.62 for both). NCAM1 (alias CD56) is a very important NK cell marker and 
TBX21 is an essential transcription factor of TH1, ILC1 and NK cells (Montaldo et al., 
2015). 
Although no strong negative correlations were observed, several genes showed 
correlation coefficients of <-0.5 (p<0.05), which were also considered to be significant 
(Figure 34 and Table 16). In particular, the expression of the FCGR2C (mentioned above 
in the chapter 3.7.2) non-protein coding gene was negatively correlated with that of 
protein-coding genes IL18RAP and TRGV9 (coefficients -0.69 and -0.53), while TRGV9 
was also correlated with AC022182.1 (stage 5, differentially expressed between ex vivo 
and in vitro) (coefficient -0.52). Besides this, the expression of RP11-456D7.1 (antisense 
RNA of SKAP1 gene) correlated negatively with that of FOSL2 (-0.56), which encodes a 
component of transcription factor AP-1 that is involved in regulation of cell proliferation, 






Table 15 The strongest negative correlations between protein-coding and non-protein 
coding genes detected at the single cell level (r<-0.5, p<0,05) 
Gene name FOSL2 IL18RAP TRGV9 
AC022182.1     -0.52 
FCGR2C   -0.69 -0.53 
RP11.456D7.1 -0.56     
 
 
3.7.4. Comparison to bulk sequencing data 
The correlations discovered in the bulk sequencing data (chapters 3.6.1 and 3.6.2) 
were compared to those of the single cell data. No corresponding relations between genes 
were identified, besides the one between RP11-277P12.20 and KLRD1. However, this does 
not appear to be surprising, as correlations detected for populations show rather differences 
between NK developmental stages, tissues of origin, and eventually between donors, while 
the single cell data are all from mature NK cells from peripheral blood of a single blood 
donor.  
Instead, the novel correlations were identified in single cells between genes that 
were not analyzed together before. These newly identified correlations were further tested 
on the bulk sequencing data. For this purpose, different data sets were used including the 
whole available data set (described in chapter 3.1), ex vivo NK samples from stages 1 to 5 
(corresponding to the data set used in chapter 3.3.1), ex vivo NK samples from peripheral 
blood stages 4 and 5 (n=28), ex vivo from stage 5 in general, as well as separated 













Figure 34 Correlation network of gene expression between protein-coding and non-protein coding 
genes within single-cell NK samples 






chapter 3.3.3). Only correlations with values of Spearman’s coefficients >0.5 or <-0.5, 
p<0.05 were considered as significant; correlations with values of Spearman’s coefficients 
>0.7 or <-0.7 were considered to be strong (Appendix 19). 
Some of the corresponding correlations could be found only among the group of all 
samples, suggesting that particular non-protein coding genes might be important for NK 
cells, and correlations between them and corresponding protein genes differ between NK 
cells and other samples. In particular, correlations identified between AC092580.4 and 
GZMB (correlation coefficient 0.61), as well as between LIN00299 and XCL1 or XCL2 
(0.69 and 0.67 respectively).  
In some other cases correlations between gene expression could be also identified 
in the ex vivo NK sample group, but were still higher in the group of all samples, for 
example the correlation between AF131217.1 and CCNJL (coefficients 0.62 and 0.73 
respectively), the correlation between RP11-222K16.2 and NCAM1 (0.69 and 0.76 
respectively), correlation between RP11-277P12.20 and KLRD1 (0.53 and 0.71 
respectively), as well as between RP11-277P12.20 and GNLY (0.61 and 0.73 respectively). 
In other cases, the correlations between particular genes were observed in all or 
almost all examined samples groups. In particular, LINC00861 expression level correlated 
with that of NCR1 among all samples (0.65), ex vivo NK sample group (0.73), stage 5 
samples (0.63) and at the highest level among nonlicensed and memory samples (0.83 and 
0.89 respectively). Unexpectedly, however, the correlation between them was lower when 
only NK samples from peripheral blood were analyzed (0.51) and completely absent 
among licensed samples.  
Strong correlations between another lncRNA gene, RP11-81H14.2, and CMKLR1 
was detected among all samples (0.73), ex vivo NK samples (0.79), peripheral blood NKs 
(0.7), licensed NKs (0.77) and memory NKs (0.86), while it was lower among all stage 5 
samples (0.52) and absent among nonlicensed NKs. The expression of AF131217.1 
correlated with that of L3MBTL4 within all analyzed groups (coefficients between 0.62 and 
0.83), besides licensed and memory NKs, with the highest correlation within nonlicensed 
stage 5 samples (r=0.83). Strong correlation was also observed between the genes 
LINC01108 and CAMK2A within ex vivo NK cells and peripheral blood NK cell sample 
groups (0.78 and 0.76 respectively).  
In many other observed cases corresponding correlations were identified only for 
specific stage 5 NK groups or where much higher than among broader groups (for example 





nonlicensed NK samples), suggesting that such non-protein coding genes might play a role 
during licensing or functioning of mature NKs. The expression of AC092580.4 strongly 
correlated with that of GZMA, NCAM1, PYHIN1 and C1orf21 among memory samples 
(coefficients 0.93, 0.93, 0.78 and 0.82 respectively), and with GNLY among nonlicensed 
samples (0.83). Analogically, HCP5 expression correlates with both CMKLR1 and ITGAM 
expression only among memory NK samples (coefficients 0.82 and 0.86 respectively). 
The expression of ANKRD20A11P correlated with that of CLIC3 and KLRD1 
expression in the strongest manner in memory NK samples (0.86 and 0.96 respectively). 
Interestingly, the expression of another typical NK gene, FCGR3A (alias CD16), correlated 
with that of ANKRD20A11P only in broader sample groups, especially high in ex vivo NK 
samples and peripheral blood NK samples (0.72 and 0.7). This likely corresponds to the 
known increase of FCGR3A expression during transition from stage 4 to stage 5 and 
suggests a possible role of ANKRD20A11P in NK cell maturation. 
The expression of RP11.456D7.1 was negatively correlated with that of FOSL2 in 
the ex vivo NK samples (coefficient -0.6) and stronger in the nonlicensed and licensed 
sample groups (-0.94 and -0.79), and this in accord with a negative correlation between 
them observed at the single cell level. Within the memory NK cell group, however, 
correlation between RP11-456D7.1 and FOSL2 was strongly positive (0.78), suggesting 
that RP11-456D7.1 might play a role in the memory status of NK cells or in their 
proliferation.  
Expression of the abovementioned LINC00299 correlates with that of CST7 and 
TGFBR3 only in the memory NK cell samples, and with that of PRF1 in peripheral blood 
NK cell samples, within stage 5 and in the stronger manner in memory samples (0.75, 0.71 
and 0.96 respectively), but not within nonlicensed and licensed samples. 
Interestingly, two non-protein coding genes RP11-693N9.2 and MAGI2-AS3 that 
were so closely related in single cell data, showed different correlation profiles in the cell 
populations. While RP11-693N9.2 correlated with CMKLR1, PDGFD, TBX21, and TTC38 
in the strongest manner within ex vivo NK samples (coefficients 0.75 to 0.77) and weaker 
in all samples and peripheral blood, MAGI2-AS3 correlated in a strong manner only with 
CAMK2A in memory samples (0.78) and with PDGFRB in licensed samples (0.71), and 








4.1. Proof of the methodology and data quality 
The large RNA-seq data set and the analyses described in this work is, to our 
knowledge, the most complete that was yet performed on human NK cell populations. The 
data are reproducible and sufficient for successful distinguishing between the studied 
sample groups, namely NK cells, B and T lymphocytes, lymphocyte precursors as well as 
monocytes. Furthermore, genes identified as differentially expressed between groups 
corresponded to genes known to be involved in the immune response and to be expressed 
in corresponding lymphocyte populations, such as classical markers of NK cells (NCR1, 
NCR3, NCAM1, KLRC1) or lymphocyte precursors (MYB, CPA3, FLT3, LMO2, MPO), or 
classical T cell markers (CD28, CD5, TRAT1) (Eissens et al., 2012; Illario et al., 2008; 
Surmiak et al., 2012; Yang et al., 2002). The high reliability of the data set and the 
consistency of the observed expression patterns of known genes that are described in the 
literature allowed the identification of expression patterns not only of well-known genes 
but also of novel genes, whose function and/or expression in particular cell populations 
was not yet known and will be described below. 
The only limitation of the applied analysis methods is the low detection level of 
genes that are expressed only in small subset of samples in comparison to the whole data 
set. In particular, genes expressed exclusively in B cell or monocyte samples were not 
observed due to the low number (n=2) of samples for each population. A plausible reason 
for this is the analysis algorithm according to which genes expressed in a small number of 
probes in comparison to the whole sample set might be underrepresented. First of all, the 
bigger the number of samples within a sample group, the more significant are conclusions 
about their common expression profile. This means that for sample groups with small 
numbers of samples, less genes can be significantly identified as specifically expressed. In 
addition, the bigger the group size, the higher the number of genes contained in the section 
of top selected genes that are differentially expressed between groups. However, this effect 
decreased when more homogeneous sample groups (such as separate NK cell 
developmental stages) were analyzed.  
4.2. The specific NK cell expression profile  
Previous studies on human NK cell expression profiles were performed using 
microarrays (Watkins et al., 2009), which limited the analysis to already known (protein-





instead, allowing for an unbiased analysis of all genes (protein-coding and non-protein 
coding) that are expressed in a certain cell population. 
Among the 100 most differentially expressed genes, 41 genes turned out to have a 
significantly higher expression in mature NK cells (= stage 5 sample group) than in all 
other studied cell types, namely T and B lymphocytes as well as monocytes. Classical NK 
cell markers and genes described as being expressed by NK cells composed indeed the 
larger portion of this gene group (28 of 41) and included the well-known NK cell marker 
genes GZMA, GZMB, GZMH, KIR3DX1, KLRD1, KLRF1, NCAM1, NCR1, NKG7, 
TYROBP, PRF1, GNLY, ADGRG1, B3GAT1, CST7, FCRL6, FGFBP2, S1PR5, SH2D1B, 
BNC2, CLIC3, COL13A1, PRSS23, FEZ1, LINGO2, PTGDR, HOPX, and MLC1 (Peng et 
al., 2011; Della et al.; Chiesa et al., 2010; Lozano et al., 2011; Watkins et al., 2009).  
The expression profile and/or function of the other 13 genes were not yet defined in 
NK cells. Three of these 13 genes, TRDC, TRDJ1, and TRGV9, encode T cell receptor 
chains. Indeed, rearrangement and expression of T cell receptor genes is known for NK 
cells, although they were shown not to play a role in NK cell function Leiden et al., 1988). 
Seven further protein-coding genes, PCDH1, RNF165, FAT4, SLC1A7, LGR6, SLCO4C1, 
and TTC38, were described in immune-related studies before. However, their expression 
was never strictly connected to NK cells. PCDH1, a gene encoding a membrane protein 
found at cell-cell boundaries, was previously described to be ubiquitously expressed 
among human tissues and was suggested to be involved in neuron development (AI et al., 
2004). In addition, it was shown to be associated with autoimmune pathologies such as 
bronchial hyperresponsiveness (Koppelman et al., 2009) and asthma (Toncheva et al., 
2012). Ring finger protein 165 (RNF165) was detected as one of the genes whose 
expression decreases in the course of the Gulf War Illness (GWI). GWI is a syndrome 
characterized by a variety of symptoms including fatigue, musculoskeletal discomfort, skin 
rashes, and cognitive dysfunction, and recently was shown to be associated with impaired 
immune function, in particular with the inability of NK cells and CD8 T cells to respond to 
"stress-mediated activation" (Whistler et al., 2009). Together with other NK cell-related 
genes such as GZMB and CCL4, RNF165 was shown to be downregulated in GWI patients 
in comparison to healthy donors, suggesting its possible role in NK cell activation. The 
expression of the SLC1A7 and TTC38 genes were previously shown to be significantly 
lower in PBMCs upon chronic antibody-mediated rejection after kidney transplantation, 
compared to kidney transplant recipients with normal graft function and histology (Rascio 





FCGR3A, CST7, NCAM1, KLRK1, GZMA, was shown to be lower expressed in PBMCs of 
smokers (Charlesworth et al., 2010).  
Besides these protein-coding genes, three non-protein coding genes, the long non-
coding RNA gene LINC00299 and the pseudogenes SIGLEC17P as well as PRSS30P 
completed the NK cell-specific transcription signature. The LINC00299 non-coding RNA 
gene is of particular interest as it was found to be disrupted in a developmentally delayed 
patient and, thus, is thought to be involved in developmental processes (Talkowski et al. 
2012). LINC00299 was also demonstrated by these authors to be expressed in 
lymphocytes. The RNA-seq data presented here showed that LINC00299 is specifically 
expressed in stage 3 ILC3 precursors and in CD56bright (= stage 4) and CD56dim (= stage 5) 
NK cells. Thus, LINC00299 might play a role in the development of innate lymphoid cells 
of the ILC3 and NK cell type. Support for this hypothesis comes from the correlation data, 
as the expression of LINC00299 is positively correlated with that of the ID2 gene, a well-
known factor involved in the development of these lymphocytes (Cherrier et al. 2012; 
Yokota et al. 1999;) but also in brain development (Park et al. 2013). 
4.3. Changes in gene expression during NK cell development 
A strong correlation of gene expression between neighboring stages of NK cell 
development was observed, indicating sequential changes of the gene expressions during 
development of these lymphocytes. The only exception was developmental stage 3, which 
did not correlate to the stage 4 sample group and correlated only weakly with the stage 2 
sample group. Two explanations of this phenomenon are suggested: (1) the individual 
samples within stage 3 differ substantially (technical variation) and (2) the phenotype 
(CD34-CD117+CD94-) used to sort stage 3 cells detects different cell types. The first 
hypothesis was rejected because the results of the Spearman’s correlation analysis between 
expression profiles of individual samples indicated a high level of correlation (correlation 
coefficients between 0.85 and 0.93, p<0.05) and, thus, homogeneity of replicated 
experiments. Indeed, the second hypothesis was supported by previously published studies 
showing that the CD34-CD117+CD94- cells represent a heterogeneous population (Ahn et 
al., 2013; Crellin et al., 2010a; Mjosberg et al., 2011). It is known, that these cell 
population can give rise to T lymphocytes, DCs, and ILC3s (Eissens et al., 2012); 
furthermore, ILC3 precursors represent a specific subpopulation with specific 
characteristics within CD34-CD117+CD94- cells (Ahn et al., 2013; Hughes et al., 2010). 
Our further analysis also supported this explanation due to the specific expression of ILC3 





(known to contain also ILC3s) as compared to bone marrow stage 3 samples. It is already 
known that bone marrow does not include ILC3s (Ahn et al., 2013; Cupedo et al., 2009; 
Hughes et al., 2010; Killig et al., 2014) and, therefore, CD34-CD117+CD94- cells in the 
bone marrow should represent stage 3 NK cell progenitors. 
NK cells develop from hematopoietic stem cells and become more and more 
restricted to NK cell development upon progression through the various developmental 
stages. Stage 1 and 2 cells still can give rise to the erythroid lineage and various 
granulocytes and cells of stage 3 are also able to give rise to T lymphocytes and DCs. 
According to Wang and colleagues, hematopoietic pluripotent cells selectively loose their 
pluripotency together with the expression of erythroid and granulomonocytic lineage genes 
and start to selectively express NK cell and T cell commited genes (Wang et al., 2015). 
This corresponded to the expression patterns described here (see chapter 3.3.1). While cells 
from stages 1 and 2 expressed a broad variety of genes related to the myeloid linage, such 
as MMP8, LTF, MPO, AZU1, and DEFA3, the expression of these genes decreased in stage 
3. Indeed, the expression of myeloid-lineage related genes was completely lost in samples 
originated from tonsils, while it was still retained in cells of stage 3 samples from bone 
marrow and cord blood. For some of these genes the expression was retained even in cells 
of stage 4 samples from bone marrow. Cells of stage 3 samples from tonsils, instead, partly 
share the expression pattern with cells of stage 4 samples, in particular genes known to be 
expressed by cytotoxic NK cells, e.g. XCL1, XCL2, CXCL8, and TOX2. All in all, this 
leads to the conclusion that cord blood and bone marrow cells have an immature 
phenotype in comparison to the tonsil samples, and, at least for bone marrow, this 
difference remains until stage 4. 
Two samples differed from the rest of their developmental group: the tonsil-
originated sample from stage 2 and the cord blood-originated stage 3 sample. Both showed 
an intermediate position between the group of lymphocyte precursors (including also stage 
3 samples from bone marrow) and stage 3 samples from tonsils. A possible explanation 
could be either that their expression phenotypes are intermediate between early progenitors 
(stages 1 and 2) and stage 3 NK cell precursors, or cells included in them represent a 
mixture of several cell types. A possible explanation for the position of the tonsil-derived 
sample was given by Luetke-Eversloh and colleagues, who identified ILC3 precursor cells 
among stage 2 and stage 3 cells of tonsil samples (Luetke-Eversloh et al., 2013). This also 
corresponds to the high expression of ILC3-related genes, such as IL23R and RORC, by 





ILC3 cells are known to be present among stage 3 cells from the cord blood as well as 
tonsil-derived samples (Yu et al., 2013); on the other hand the sample from the cord blood 
expressed genes typical for earlier developmental stages (including such as MPO, ELANE, 
RNASE2, and RNASE3), suggesting that it had a less mature phenotype in comparison to 
tonsil-derived stage 3 samples. 
4.4. Differences in expression profiles between stage 5 functional groups 
Unlike cells of stages 3 and 4, no significant difference between samples from 
different organs was identified for cells of stage 5. Instead, a combination of at least three 
factors might influence the gene expression profiles: the tissue of origin, the licensing 
status, and the donor origin. This variability made it more or less impossible to identify 
exact changes that happen during licensing and education of NK cells with the available 
data set. This finding is in accord with previous findings and suggests that there are no 
major transcriptomic differences between these populations (Anfossi et al., 2006; Guia et 
al., 2011), showing that licensed and nonlicensed cells differ rather in their organization of 
cellular receptors than in their transcriptome signatures.  
It is known however, that some genes (or protein epitopes such as CD57) are more 
strongly expressed in licensed NK cells, namely CD226 (alias DNAM-1) and KLRD1 
(alias CD94) as well as in memory-like NK cells, namely CD57 and SELL (alias CD62L) 
(Anfossi et al., 2006; Enqvist et al., 2015; Juelke et al., 2010; Lopez-Verges et al., 2010; 
Sun et al., 2009). Using these genes, correlation networks of gene expression within stage 
5 NK cells were build to check whether other genes show co-expression and might play a 
role in the licensing and memory phenotype of NK cells. Among the genes that are 
significantly (p<0.05) co-expressed with either CD226 or CD94 were other effector NK 
cell genes such as PRF1 and GZMA as well as other genes typically expressed by mature 
NK cells such as activating receptors CD244 (2B4), CD247 (CD3z), FCGR3A (CD16), and 
SLAMF7 and the cytokine receptor CX3CR1 (Kim and Lanier, 2013; Krämer et al., 2013). 
In addition, among the genes that correlated with CD226 expression were proliferation 
regulators PYHIN, NKL, and SLFN12L, and the transcription activator MYBL1 (Tan et al., 
2012), while the expression of the transcription co-repressor TLE3 was negatively 
correlated with that of CD226. Furthermore, the expression of GPR65 (G-protein coupled 
receptor) and lncRNA RNARP11-121A8.1 correlated with the expression of both, CD226 
and CD94. 
Taken into account that the molecular mechanism of NK cell licensing is not yet 





whether silencing or over-expression of any of the above mentioned genes influences the 
function of NK cells. 
4.5. Specific expression profiles of in vitro differentiated NK cells 
As it is impossible to study human lymphocytes in vivo and the sample source for 
ex vivo studies is limited (e.g. stage 2 or stage 3 cells), an established in vitro 
differentiation assay is commonly used as a model system for NK cell development and 
function. However, the extent of differences in gene expression between in vitro 
differentiated NK cells and ex vivo NK cells was unknown so far. 
As shown in chapter 3.1, the transcription profiles of cells from in vitro samples 
corresponded to those of cells from the ex vivo samples of the same developmental stages. 
This indicates that the in vitro differentiation assay generally produces cells that 
correspond to ex vivo progenitors and mature NK cells. However, upon specific 
comparison of ex vivo and in vitro samples it became obvious that there are significant 
differences for earlier developmental stages. In particular for stages 3 and 4 the number of 
genes differentially expressed between cells of ex vivo and in vitro stage 5 samples was 
lower than the number of genes differentially expressed between the most different ex vivo 
stage 5 sample groups. Furthermore, among the genes that were highly expressed by cells 
of the in vitro samples from stage 3 and partly stage 4 were such genes as KLRC1, KLRC2, 
KLRC3, KLRC4, GZMA, NCAM1, KIR2DL4, SLFN12L, and PBK, which correspond to 
later NK cell developmental stages, and even T lymphocytes (such as AK4, TRAT1, 
DEPDC1). An obvious reason for such differences is the cytokine cocktail that is 
necessary for proper growth and development of cells during the in vitro differentiation 
assay. Indeed, to grow and maintain NK lymphocytes in culture, a cocktail of cytokines 
including stem cell factor, granulocyte-macrophage colony-stimulating factor, 
thrombopoetin and various Interleukins is used, which is critical for NK cell development 
from CD34+ precursors and their maintenance (Kao et al., 2007). Although these growth 
factors correspond to those that NK cells face upon normal in vivo development, their 
concentrations are substantially higher in the culture medium than in the natural NK cell 
developmental niche. This cytokine treatment might lead to partial activation of immature 
NK cells and their more mature phenotype in comparison to their in vivo counterparts. The 
fact that culturing of NK cells with various cytokines leads to their activation is well 
known and the effect of different cytokines on NK cells alone and in combination was 





cells without their excessive activation (Agaugué et al., 2008; Guven et al., 2003; 
Hromadnikova et al., 2013; Kuribayashi et al., 1981).  
Nevertheless, the data clearly show the consistencies and differences between in 
vitro differentiated NK cells and their ex vivo counterparts and form a highly important 
basis for future experiments to study the role of certain genes - either protein-coding or 
non-protein coding - in human NK cell development. 
4.6. Identification of novel genes with potential medical relevance 
The data described here identified also some novel genes for which a specific 
function or even expression in NK lymphocytes is not yet known. The potential 
importance of non-protein coding genes will be described below. However, also novel 
protein-coding genes are of interest. Description of their specific expression during NK 
cell development or in mature NK cells may for example shed light on the etiology of 
autoimmune diseases. Among the novel candidates that are expressed in NK cells were 
genes with known medical relevance in systemic sclerosis, rheumatoid arthritis, asthma, 
psoriasis, and even in schizophrenia. 
The G0S2 (G0/G1 switch gene 2) gene is reported to be over-expressed in psoriasis 
(Koczan et al., 2005) and turned out in the study presented here to be also highly expressed 
in KIR-positive T lymphocytes and most of stage 5 NK cell samples, and on lower level in 
CD8+ T lymphocytes. G0S2 was originally identified in PBMCs and is involved in cell 
cycle regulation. Initially it was believed to mediate re-entry of cells from the G0 to G1 
phase of the cell cycle. However, recently its pro-apoptotic function by antagonizing BCL-
2 became clear (Welch et al., 2009). Silencing of the G0S2 gene by DNA methylation is 
thought to be an important feature of various cancer types, such as squamous lung cancer 
(Kusakabe et al., 2009). In particular, it is known to be highly expressed in proliferating 
lymphocytes in bone marrow, and is suggested to be one of the key regulators of the cell 
cycle in T lymphocytes (Kusakabe et al., 2009; Sivozhelezov et al., 2006; Yamada et al., 
2012). However, its specific expression in mature NK lymphocytes from peripheral blood 
as well as the differential expression in different T cell subpopulations was not yet 
described. Even though the role of activated lymphocytes and monocytes in the peripheral 
blood in the pathogenesis of psoriasis is known (Abrams et al., 2000), the exact etiology 
remains unclear. The fact that two genes, over-expressed in psoriasis, are specifically 
expressed in KIR-positive lymphocytes might be helpful for a better understanding of the 





Several genes, known to participate in the regulation of the cell cycle or cellular 
growth control in other cell types (not known for NK cells), were also identified in the 
current analysis. For example CAMK2A, which in the current analysis was shown being 
expressed in mature NK cells and was also detected in NK cells at the single cell level. The 
product of this gene is a protein involved in the regulation of the G1 phase of the cell cycle 
as well as in G1/S transition; its expression and critical role in cell cycle regulation was 
demonstrated for brain tissue, and its presence was declared in PBMCs, however the 
specific role in NK cells was not described (Esteras et al., 2012; Uhlen et al., 2015;).  
The FOSL2 gene encodes a leucine zipper protein that can dimerize with proteins 
of the JUN family and, thereby, forming the transcription factor complex AP-1, which 
participates in the regulation of cell proliferation, differentiation, and transformation. 
FOSL2 was previously shown to be expressed in PBMCs and to be downregulated in 
autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus (Mandel 
et al., 2004). The current study allowed specifying its expression pattern, as the highest 
expression was seen in mature NK cells (both, in bulk RNA and single cell sequencing) in 
comparison to earlier developmental stages as well as to other PBMCs. A further gene 
implicated in an autoimmune disease is defensin alpha 4 (DEFA4). It was shown before to 
be up-regulated in peripheral blood of patients with systemic sclerosis in comparison to 
healthy donors and was suggested to be involved in the IFN-γ response (Bos et al., 2009). 
According the current analysis, it was specifically expressed in bone marrow NK cell 
samples in all stages, suggesting its specific and precise regulation. 
In summary, specific expression patterns of various genes were newly described, in 
particular, genes relevant for immune pathologies. This new knowledge of gene expression 
may shed more light on the respective pathogenesis of the diseases.  
4.7. The potential regulatory role of non-protein coding genes  
It is currently clear, that non-protein coding genes such as long non-coding RNAs 
(lncRNA) play a distinct role in the regulation of the expression of other genes (Fatica and 
Bozzoni, 2014). A role of lncRNAs in T and B cell development (Casero, 2015) as well as 
in monocyte and DC function (Carpenter et al., 2013) was demonstrated. In NK cells, 
however, only the role of microRNAs was so far described (Bezman et al., 2010; Fehniger 
et al., 2010), while the role of lncRNAs in NK cell development and function was not 
known. Here, we broadened our studies to all non-protein coding genes, including 





are high within specific patterns, there is a high probability that they have a regulatory 
function in NK cells. 
Both, negative and positive regulation of gene expression has been described for 
lncRNAs (Fatica and Bozzoni, 2014). For example lncRNAs are involved in histone 
modifications or may recruite corresponding regulatory proteins to specific DNA loci 
(Carpenter, 2013; Keller, 2013). Also natural antisense transcripts can increase the levels 
of the target mRNA by stabilizing its molecules (Matsui, 2008). Therefore, in the current 
study both, positive and negative correlations between expression of non-protein coding 
genes and protein-coding genes with immunological relevance were evaluated. 
As shown in chapter 3.5, expression levels of non-protein coding genes change 
during NK cell development. This generally indicates that the expression of non-protein 
coding genes is also highly regulated. Unlike protein-coding genes, the expression of 
which is rarely limited to only one of the different stages, most of the described non-
protein coding genes were expressed either during early development (stages 1, 2, and 
partly 3) or in mature NK cells (stages 4 and 5) and with lower expression among stage 3 
samples. Smaller differences in gene expression between neighboring developmental 
stages were also supported by a higher pairwise correlation of gene expression profiles in 
comparison to expression profiles of protein-coding genes in most cases. The specific 
expression profile of stage 3, however, is due to the heterogeneous mixture of cells of 
different type as discussed above. 
The strict expression profiles of non-protein coding genes in the various 
developmental stages suggest, that they play an important role during the cells’ 
development. For example, non-protein coding genes expressed during early stages (e.g. 
KIAA0087, RP11-212I21.4, or RP11-395O6.3) might be important for turning the 
development towards NK cell development. In contrast, lncRNAs that are constantly 
expressed within committed NK cells (e.g. LINC00299 and RP11-222K16.2) might be 
important for the function of mature NK cells. This is also consistent with a known role of 
lncRNAs in B and T cell development (Casero et al., 2015). 
Taking into account the big variety of the examined non-protein coding genes as 
well as multiple potential mechanisms of their regulatory influence, different explanations 
can be suggested for the observed correlations in the expression of protein-coding and non-
protein coding genes. Some of the identified non-protein coding genes might be important 
at particular developmental stages, e.g. RP11-973H7.1 and RP11-20I20.4 that are 





cell’ signature (e.g. TBX21, KLRD1, FCGR3A, PRF1, and granzymes). Other genes 
correlated more specifically to one or two protein-coding genes, e.g. ANKRD20A11P, 
which is expressed in mature NK cells and correlated with stage 5 marker FCGR3A 
(CD16), when their expression in all developmental stages are compared, i.e. during 
acquisition of FCGR3A by NK cells. Furthermore, their expression was also correlated in 
mature NK cells in the single cell analysis, supporting the co-expression of these genes. 
Other correlations observed upon a closer look within stages could play a role in 
the function of NK cells, the same as was shown for activation of monocytes and DCs 
(Carpenter et al., 2013). In particular, an interesting candidate for such a role is the non-
protein coding gene RP11-456D7.1, the expression of which is negatively correlated with 
the cell cycle regulator gene FOSL2 based on single cell data as well as in cells of the stage 
5 sample group; however, only within non-licensed and licensed samples their correlation 
was negative, while within memory samples it changed to be strongly positive. Taking into 
account that memory-like NK cells have a dramatically longer lifespan than naïve NK cells 
and the ability of self-renewing, it could be supposed that a specific regulation of the cell 
cycle with contribution of RP11-456D7.1 and FOSL2 might play a certain role in their 
specific properties (Reeves et al., 2015; Sun et al., 2009). A plausible mechanism could be 
that RP11-456D7.1 is directly involved in the negative regulation of FOSL2 expression. 
This could easily explain the positive regulation in naïve NK cells as well as the negative 
regulation in memory NK cells. 
Another potential regulator is the non-protein coding gene RP11-121A8.1, the 
expression of which strongly correlated with that of KLRD1 and CD226 in cells of the 
stage 5 samples. As both, KLRD1 and CD226, were previously shown to be more strongly 
expressed in licensed than in non-licensed cells (Anfossi et al., 2006), it is suggested that 
RP11-121A8.1 might be associated with the licensing status of NK cells. Unfortunately, 
the expression of this gene was not detected in the single cell samples, so that its role in 
individual cells could not yet be checked. A possible reason for this lack of detection in 
single cells is the generally low level of expression of non-protein coding genes compared 
to protein-coding genes (Djebali et al., 2012; Fatica and Bozzoni, 2014). Similarly, the 
expression of RP11-222K16.2 correlated with that of the SELL (alias CD62L). This 
correlation might be important for the function of mature NK cells, in particular for the 
function of memory-like NK cells. Notably, RP11-222K16.2 arose in the analysis 
independently several times, which marks it as one of the most potent regulators identified 





cells markers as NCAM1 (alias CD56), KLRF1, GZMA, and EOMES. At the single cell 
level the correlation with NCAM1 was confirmed, and also the correlation with another 
important transcription factor, NFIL3, was shown. 
Finally, in the case of closely localized genes such as for example RP11-277P12.20 
that maps to the locus of KLR genes, it could be possible that their co-expression is caused 
by an opened conformation of the DNA locus, particularly, if the genes are localized on the 
same DNA strand. However, it was also suggested by Carpenter and colleagues, that 
expression of lncRNAs in regions where also high expression of immune genes is 
encountered might be caused by their co-regulation (Carpenter et al., 2013). The fact that 
the expression of RP11-277P12.20 correlates with that of only certain genes from this 
locus (KLRC2, -C3, -C4 and -K1, but not with KLRC1 in ex vivo NK cells) supports the 
hypothesis of co-regulation, rather than simple accidental co-expression due to open 
conformation of chromatin.  
The next logical step in this project is to define the biological significance of the 
identified correlations. In future studies, the impact of over-expression and silencing of the 
respective lncRNAs on NK cell development and function should be performed. The first 
step to check the real influence of the lncRNAs is the transcription analysis at the single 
cell level either by RNA-seq or qRT-PCR, which allows for a more precise analysis of the 
correlations in individual cells and not biased by averaging within the cell population. 
4.8. Single cell transcriptome analysis of lymphocytes: perspectives and 
limitations 
Transcriptome sequencing on the population level is a good tool to determine 
typical expression profiles of cell groups and major differences between cell populations, 
as it was demonstrated here for mature NK lymphocyte populations and distinct stages of 
NK cell development. However, it does not allow for the analysis of variations inside the 
analyzed cell population, for example in cases of cell heterogeneity such as the stage 2 and 
stage 3 samples from tonsils and cord blood that contained NK cell and ILC3 precursor 
cells. Furthermore, in those cases where the average expression levels are biased by the 
presence of cells with very high or low expression of certain genes, the average expression 
level of those genes do not represent the true expression in individual cells. Therefore, 
RNA-seq of single cells is becoming more and more popular. 
During this study single cell expression analysis of mature human NK lymphocytes 
using the microfluidic Fluidigm© technique was established and a pilot experiment was 





and was successfully used for transcriptome analysis of various cell types including 
hematopoietic stem cells, T lymphocytes and lymphocytic leukemia cells (Arsenio et al., 
2014; Benavides-Garcia et al., 2014; Landau et al., 2014; Li et al., 2013), it was not used 
for the analysis of NK lymphocytes before. The main complication for this application is 
the small size of resting lymphocytes in general and for NK cells (5-6µm in average) and 
the corresponding low amount of mRNA in these cells. In the current study, NK cells, 
freshly isolated from peripheral blood by MACS-sorting, were directly used for the 
analysis, avoiding FACS-sorting or any additional staining to preserve the most natural 
transcription profile. It was shown, that RNA-seq of single NK cells is indeed possible, and 
the expression of genes associated with a typical ‘mature NK cell’ signature (e.g. GNLY, 
GZMA, GZMB, PRF1, CTS7, NKG7, KLRD1, and TYROBP), was confirmed. However, 
there was also a high heterogeneity of gene expression levels among single cells and this 
interfered with the correlation studies, in particular the correlation of expression of non-
protein coding genes and protein-coding genes expressed by NK cells (in particular 
LIN00299, RP11-222K16.2, and RP11-2777P12.20 mentioned above).  
A clear disadvantage of using MACS-NK cell isolation in comparison to FACS 
sorting is the incomplete elimination of other cell types and, therefore, the presence of 
contaminating cells among the sequenced libraries. Taking this into account, the next step 
should be to use FACS-sorted cells and to specifically analyze certain NK cell populations: 
not only mature NK cells, but also earlier developmental stages, as well as a separate 
analysis of licensed and non-licensed cells. Furthermore, the new high-throughput dynamic 
arrays are expected to come to the market in the next months, which allows simultaneous 
analysis of up to 800 single cells in a single run. In future, the combination of these 
advanced techniques and the established knowledge will allow a fast acquisition of 
information about NK cell subpopulations and gene regulatory networks within them. This 
will not only foster basic research with human NK cells, but also studies using NK cells as 
therapeutic tools in the treatment of various diseases, in particular treatment of cancer, 
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Appendix 1 Ranked top 100 genes differentially expressed within all analyzed 
samples  
Genes identified from the total number of 20858 genes using LoD1. 
GeneID Score (PC1-3) Rank GeneID Score (PC1-3) Rank 
SH2D1B 0.046211855 1 PRTN3 0.030322462 51 
GZMB 0.040545715 2 BCAT1 0.030315395 52 
NMUR1 0.040207182 3 FAT4 0.030211952 53 
FCRL6 0.040197263 4 TBX21 0.03012797 54 
NCAM1 0.038953949 5 TNS3 0.030106641 55 
GNLY 0.038288605 6 CD247 0.030077825 56 
KLRD1 0.037813562 7 SLAMF7 0.030052784 57 
NCR1 0.037653283 8 IGLL1 0.030017484 58 
FCGR3A 0.037649381 9 FCRL3 0.029920427 59 
MPO 0.037251151 10 IKZF3 0.029797926 60 
AC017104.6 0.036800003 11 ITGAM 0.029513769 61 
PTGDR 0.036258052 12 LMO2 0.029462625 62 
TRDC 0.036126767 13 RASSF4 0.029388897 63 
CLIC3 0.036004902 14 ANGPT1 0.029335414 64 
SIGLEC7 0.035499688 15 CD300A 0.029213044 65 
S1PR5 0.035409046 16 PDGFRB 0.02917724 66 
CX3CR1 0.034972368 17 L3MBTL4 0.029160946 67 
FGR 0.034625771 18 BNC2 0.02915969 68 
BCL11B 0.034583362 19 CAMK4 0.029086805 69 
XCL2 0.03455931 20 MYB 0.029067877 70 
CD28 0.034289992 21 AC010468.2 0.029043678 71 
FLT3 0.034002569 22 PLD4 0.028976966 72 
DTHD1 0.033973869 23 PDZD4 0.028938765 73 
CPA3 0.033922611 24 MSRB3 0.028857116 74 
LINC00299 0.033912246 25 MAP7 0.028810967 75 
CMKLR1 0.033562424 26 CD5 0.028809729 76 
PRF1 0.033299088 27 PDGFD 0.028803034 77 
XCL1 0.033258596 28 SH2D1A 0.028796607 78 
NKG7 0.03300908 29 RGS9 0.028767589 79 
FGFBP2 0.032872492 30 CCR4 0.028723691 80 
GZMH 0.03281785 31 CTSG 0.028711259 81 
MLC1 0.032537178 32 TRAT1 0.028709552 82 
IFNG 0.032480375 33 COL13A1 0.028656065 83 
GZMM 0.032363887 34 NELL2 0.028652299 84 
SLC16A10 0.0322795 35 ALDH1A1 0.028585352 85 
CACNA1I 0.032252599 36 ATP8B4 0.028576339 86 
LEF1-AS1 0.032234284 37 KLRC1 0.028537801 87 
TRDJ1 0.032179722 38 RNF165 0.028528544 88 






TYROBP 0.031777736 40 EGFL7 0.028399162 90 
PYHIN1 0.031688328 41 KRT86 0.028397972 91 
B3GNT7 0.031598814 42 ITK 0.028382932 92 
GZMA 0.031564505 43 LINGO2 0.02833046 93 
TRGV9 0.031166321 44 PKIA-AS1 0.028317236 94 
CCNJL 0.030822052 45 CTC-499J9.1 0.02823147 95 
RP11-121A8.1 0.03081529 46 IL18RAP 0.028185366 96 
SPINK2 0.030793462 47 LPCAT2 0.028134425 97 
SIGLEC17P 0.030705875 48 
RP11-
104L21.3 0.028116524 98 
NCR3 0.030591624 49 GRIK4 0.028057238 99 
TENM1 0.030418915 50 HOPX 0.027980855 100 
 
Appendix 2 Genes differentially expressed between PBMC populations 
identified using ANOVA analysis 
Expression levels are indicated in Log2 domain. 
2.1 Genes differentially expressed between NK and T lymphocytes. Genes 
higher expressed in NK cells are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
NK  T NK  T 
GNLY 8.16E-13 14.27 6.47 LGR6 8.17E-13 8.68 2.33 
PRF1 8.30E-13 14.18 7.78 FEZ1 8.25E-13 8.51 2.01 
NKG7 8.16E-13 13.82 5.80 CMKLR1 7.95E-12 8.47 1.22 
KLRD1 8.16E-13 12.74 4.40 L3MBTL4 3.63E-12 8.42 2.20 
GZMB 8.16E-13 12.56 3.65 RNF165 8.16E-13 8.35 1.79 
ITGAM 8.16E-13 12.17 5.32 GPR141 8.16E-13 8.12 0.83 
FGFBP2 9.18E-13 12.13 4.87 KIR3DX1 8.16E-13 8.11 1.19 
CST7 8.16E-13 12.09 5.46 DAB2 8.16E-13 7.91 0.94 
S1PR5 8.16E-13 11.93 3.94 TRGV9 8.16E-13 7.90 1.43 
GZMA 8.17E-13 11.81 4.92 PDGFRB 8.17E-13 7.88 0.50 
FCGR3A 8.16E-13 11.60 2.88 B3GAT1 1.72E-12 7.79 1.37 
KLRF1 8.19E-13 11.58 4.99 PCDH1 8.16E-13 7.68 0.68 
TTC38 8.16E-13 11.47 4.83 NME8 8.16E-13 7.62 0.73 
SH2D1B 8.16E-13 11.35 1.96 CXCR2 8.16E-13 7.45 0.85 
GZMH 8.25E-13 11.32 3.70 PRSS30P 1.08E-12 7.44 1.58 
FGR 8.16E-13 11.14 4.16 SIGLEC17P 8.16E-13 7.20 0.30 
ADGRG1 8.18E-13 11.05 4.29 SLC1A7 1.36E-11 6.98 0.60 
CD300A 8.16E-13 10.72 4.30 SIGLEC7 8.17E-13 6.79 0.24 
HOPX 8.16E-13 10.70 3.43 LINGO2 8.21E-13 6.69 0.11 
CX3CR1 1.19E-10 10.63 3.72 TRDJ1 8.16E-13 6.54 0.08 
TRDC 8.16E-13 10.60 3.12 COL13A1 1.01E-11 6.32 0.22 
PRSS23 8.16E-13 10.59 3.18 HCK 0.025926292 4.38 1.98 





SYK 8.16E-13 10.18 3.29 CAMK4 8.16E-13 5.30 12.80 
ATP8B4 8.16E-13 10.17 2.43 NELL2 1.42E-12 4.11 11.97 
TYROBP 8.16E-13 10.06 2.88 CCR7 8.28E-13 3.91 11.54 
FCRL6 8.16E-13 10.06 1.32 CD5 8.26E-13 3.73 11.65 
PTGDR 8.16E-13 10.02 2.83 TRAT1 7.61E-12 3.55 10.53 
LINC00299 8.16E-13 9.93 3.06 CD28 8.16E-13 2.96 12.34 
BNC2 8.16E-13 9.89 1.50 SLAMF1 8.58E-13 2.69 9.02 
NCR1 8.16E-13 9.87 2.47 AXIN2 9.18E-13 2.03 8.56 
B3GNT7 8.17E-13 9.83 1.97 SLC16A10 8.20E-13 1.43 8.58 
MLC1 8.16E-13 9.74 1.58 ALS2CL 8.19E-13 1.40 7.80 
PDGFD 8.16E-13 9.51 2.16 SIT1 8.20E-13 1.36 8.12 
RASSF4 8.16E-13 9.37 2.71 CCR4 8.16E-13 0.81 9.08 
NMUR1 8.16E-13 9.35 0.88 LEF1-AS1 8.16E-13 0.80 8.48 
FAT4 8.16E-13 9.15 0.66 FAAH2 8.16E-13 0.71 7.40 
SLCO4C1 8.16E-13 9.07 2.01 MAL 8.16E-13 0.69 8.72 
CLIC3 8.19E-13 8.97 2.59 CACNA1I 8.16E-13 0.37 8.05 
AC017104.6 8.16E-13 8.88 1.07 
CTC-
499J9.1 8.16E-13 0.23 6.94 
 
2.2 Genes differentially expressed between NK and B lymphocytes. Genes 
higher expressed in NK cells are marked in green. 
GeneID p Value NK B GeneID p Value NK B 
GNLY 2.38E-12 14.27 3.87 CLIC3 3.91E-06 8.97 3.29 
PRF1 3.41E-08 14.18 6.45 LGR6 2.64E-10 8.68 0.34 
NKG7 1.82E-09 13.82 4.88 FEZ1 5.24E-08 8.51 0.97 
KLRD1 8.14E-10 12.74 3.18 CMKLR1 0.000204057 8.47 1.56 
GZMB 3.76E-09 12.56 4.10 RNF165 1.15E-10 8.35 1.34 
ITGAM 0.014038922 12.17 9.87 GPR141 2.08E-09 8.12 0.34 
FGFBP2 2.28E-08 12.13 2.49 KIR3DX1 5.89E-08 8.11 1.50 
CST7 1.51E-12 12.09 3.29 DAB2 3.82E-05 7.91 3.06 
S1PR5 5.77E-10 11.93 2.83 TRGV9 1.13E-11 7.90 1.00 
GZMA 5.61E-11 11.81 2.49 PDGFRB 0.007194957 7.88 4.33 
FCGR3A 2.75E-07 11.60 3.56 B3GAT1 2.36E-05 7.79 1.24 
KLRF1 3.81E-09 11.58 3.56 PCDH1 3.59E-11 7.68 0.00 
TTC38 1.70E-09 11.47 6.44 NME8 8.75E-08 7.62 1.57 
SH2D1B 4.81E-11 11.35 2.16 CXCR2 3.20E-08 7.45 0.97 
GZMH 4.08E-08 11.32 2.35 PRSS30P 1.40E-07 7.44 0.00 
ADGRG1 1.35E-08 11.05 3.37 SIGLEC17P 2.44E-08 7.20 1.00 
CD300A 2.95E-05 10.72 6.03 SLC1A7 0.000146564 6.98 0.63 
HOPX 0.000263012 10.70 6.52 SIGLEC7 3.36E-07 6.79 0.34 
CX3CR1 7.81E-06 10.63 1.76 LINGO2 1.82E-06 6.69 0.34 
TRDC 8.28E-13 10.60 1.63 TRDJ1 8.20E-13 6.54 0.00 
PRSS23 1.86E-10 10.59 1.69 COL13A1 0.000155986 6.32 0.34 
NCAM1 1.57E-12 10.42 2.02 CYBB 0.007079707 6.20 12.16 





TYROBP 1.72E-07 10.06 4.23 HCK 0.009445927 4.38 10.03 
FCRL6 6.09E-10 10.06 1.57 SPI1 0.049981251 4.05 9.01 
PTGDR 5.40E-10 10.02 2.00 CD86 0.046443612 3.96 8.91 
LINC00299 1.20E-10 9.93 1.84 CCR7 0.000103201 3.91 9.99 
BNC2 1.71E-10 9.89 2.07 TNS3 0.000213329 3.58 10.32 
NCR1 1.33E-12 9.87 2.10 CD1D 0.046105377 3.05 8.17 
MLC1 9.86E-08 9.74 2.78 SLAMF1 0.000472038 2.69 7.46 
PDGFD 2.74E-08 9.51 3.83 AXIN2 0.039476765 2.03 5.26 
RASSF4 1.08E-05 9.37 4.50 DGAT2 0.013581184 1.99 6.83 
NMUR1 8.41E-13 9.35 1.13 SIT1 1.71E-09 1.36 10.13 
FAT4 8.47E-13 9.15 1.26 FAAH2 0.007946423 0.71 3.23 
SLCO4C1 6.11E-11 9.07 1.82         
 
2.3 Genes differentially expressed between NK and monocytes. Genes higher 
expressed in NK cells are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels  
NK MC NK  MC  
GNLY 2.31E-10 14.27 5.53 LGR6 3.67E-10 8.68 0.44 
PRF1 4.51E-11 14.18 4.21 FEZ1 5.72E-06 8.51 2.48 
NKG7 4.02E-06 13.82 7.47 L3MBTL4 0.000628966 8.42 3.13 
KLRD1 4.68E-10 12.74 2.98 RNF165 2.37E-07 8.35 3.19 
GZMB 9.21E-12 12.56 1.98 KIR3DX1 3.48E-10 8.11 0.00 
FGFBP2 4.57E-09 12.13 1.84 TRGV9 2.88E-11 7.90 1.23 
CST7 9.79E-09 12.09 5.86 PDGFRB 0.00960803 7.88 4.43 
S1PR5 4.38E-10 11.93 2.73 B3GAT1 8.92E-07 7.79 0.00 
GZMA 1.60E-11 11.81 2.06 PCDH1 3.59E-11 7.68 0.00 
KLRF1 5.43E-12 11.58 1.34 PRSS30P 1.27E-06 7.44 0.73 
TTC38 9.44E-06 11.47 8.07 SIGLEC17P 6.73E-05 7.20 3.04 
SH2D1B 9.07E-11 11.35 2.37 S100A9 0.005111889 7.14 15.46 
GZMH 3.02E-09 11.32 1.34 SLC1A7 3.27E-05 6.98 0.00 
ADGRG1 1.64E-07 11.05 4.15 LINGO2 6.31E-07 6.69 0.00 
HOPX 3.13E-12 10.70 1.10 TRDJ1 8.20E-13 6.54 0.00 
TRDC 8.17E-13 10.60 0.44 COL13A1 6.70E-05 6.32 0.00 
PRSS23 1.42E-10 10.59 1.60 CYBB 0.000289019 6.20 14.04 
NCAM1 1.39E-12 10.42 1.94 FCN1 0.001716661 5.68 14.99 
SYK 0.036299499 10.18 12.57 TNFAIP2 0.001055934 5.36 14.37 
TYROBP 0.02847195 10.06 12.55 MPEG1 0.002874598 5.05 12.48 
FCRL6 4.16E-08 10.06 2.88 SERPINA1 0.000392649 4.76 13.47 
PTGDR 2.74E-09 10.02 2.48 HCK 9.97E-05 4.38 12.62 
LINC00299 1.37E-09 9.93 2.54 SPI1 0.000333274 4.05 12.34 
BNC2 1.27E-10 9.89 1.98 CD86 0.00034272 3.96 12.13 
NCR1 2.20E-10 9.87 3.57 TNS3 9.86E-05 3.58 10.68 
B3GNT7 5.01E-07 9.83 2.48 RBM47 0.000203469 3.56 11.32 
MLC1 0.007189711 9.74 6.32 CFD 0.000147124 3.44 11.59 





NMUR1 8.25E-13 9.35 0.73 JDP2 0.000237226 3.06 10.80 
FAT4 8.46E-13 9.15 1.25 CD1D 0.000554689 3.05 11.18 
SLCO4C1 0.000225536 9.07 5.50 THBD 0.002397956 2.43 10.54 
CLIC3 1.62E-07 8.97 2.35 DGAT2 5.58E-05 1.99 9.63 
AC017104.6 5.16E-08 8.88 1.98 ALS2CL 0.000105678 1.40 6.16 
 
2.3 Genes differentially expressed between T lymphocytes and monocytes. 
Genes with higher expression in T lymphocytes are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
T MC T MC 
AXIN2 2.83E-06 8.56 1.25 CYBB 1.23E-05 3.98 14.04 
CACNA1I 8.33E-10 8.05 0.00 DAB2 1.03E-05 0.94 6.45 
CAMK4 3.05E-11 12.80 3.38 DGAT2 3.97E-05 1.42 9.63 
CCR4 1.19E-06 9.08 1.54 FCGR3A 0.000193193 2.88 8.78 
CCR7 4.90E-05 11.54 4.83 FCN1 0.000182095 3.36 14.99 
CD28 2.22E-09 12.34 1.91 FGR 2.12E-11 4.16 13.52 
CD5 0.000298924 11.65 5.54 GPR141 5.65E-07 0.83 7.29 
CTC-499J9.1 8.93E-13 6.94 0.00 HCK 2.78E-06 1.98 12.62 
FAAH2 4.19E-11 7.40 0.00 ITGAM 6.55E-12 5.32 13.02 
GZMA 0.043966888 4.92 2.06 JDP2 0.0001538 2.41 10.80 
IL7R 1.52E-07 13.59 1.75 MLC1 0.000282552 1.58 6.32 
KLRF1 0.006778523 4.99 1.34 MPEG1 0.00031325 3.13 12.48 
LEF1-AS1 9.97E-13 8.48 0.00 NME8 2.93E-05 0.73 5.48 
MAL 6.20E-12 8.72 0.00 PDGFRB 0.004413248 0.50 4.43 
NELL2 1.52E-06 11.97 2.34 RASSF4 4.79E-10 2.71 10.71 
PRF1 0.012864422 7.78 4.21 RBM47 3.96E-05 2.25 11.32 
SIT1 1.49E-07 8.12 0.44 S100A9 0.000440521 4.66 15.46 
SLAMF1 0.006804697 9.02 5.05 
SERPINA
1 1.63E-05 2.22 13.47 
SLC16A10 0.000303481 8.58 3.27 
SIGLEC17
P 0.016930394 0.30 3.04 
TRAT1 1.04E-07 10.53 0.00 SIGLEC7 2.99E-07 0.24 7.07 
TRDC 0.004786652 3.12 0.44 SLCO4C1 0.000607553 2.01 5.50 
ANPEP 5.47E-05 2.18 11.87 SPI1 8.11E-05 2.74 12.34 
ATP8B4 4.73E-06 2.43 8.96 SYK 3.88E-12 3.29 12.57 
CD1D 0.000104203 1.56 11.18 THBD 0.001983222 1.86 10.54 
CD300A 2.96E-06 4.30 9.91 TNFAIP2 0.000217891 3.69 14.37 
CD86 0.000149182 3.02 12.13 TNS3 5.44E-06 1.82 10.68 
CFD 9.88E-06 1.49 11.59 TTC38 5.35E-05 4.83 8.07 
CXCR2 1.54E-05 0.85 5.90 TYROBP 1.84E-12 2.88 12.55 
 
2.4 Genes differentially expressed between T and B lymphocytes. Genes with 
higher expression in T lymphocytes are marked in green. 
GeneID p Value T B GeneID p Value T B 





AXIN2 0.048211056 8.56 5.26 CD1D 0.009631394 1.56 8.17 
CACNA1I 5.78E-08 8.05 1.26 CD86 0.019394662 3.02 8.91 
CAMK4 8.17E-08 12.80 5.87 CYBB 0.000325067 3.98 12.16 
CCR4 3.32E-06 9.08 1.92 DGAT2 0.007955644 1.42 6.83 
CD28 3.82E-09 12.34 2.13 FGR 3.73E-07 4.16 10.51 
CD5 0.005121458 11.65 6.83 HCK 0.000291421 1.98 10.03 
CTC-499J9.1 1.15E-12 6.94 0.34 HOPX 0.013661026 3.43 6.52 
FAAH2 2.18E-05 7.40 3.23 ITGAM 2.53E-06 5.32 9.87 
IL7R 0.000173187 13.59 5.50 JDP2 0.040610676 2.41 7.32 
LEF1-AS1 8.29E-12 8.48 1.00 MPEG1 0.003950965 3.13 10.72 
MAL 2.67E-08 8.72 2.38 PDGFRB 0.00585475 0.50 4.33 
NELL2 3.08E-07 11.97 1.57 RBM47 0.036521636 2.25 7.19 
SLC16A10 0.003422509 8.58 4.23 SPI1 0.012959867 2.74 9.01 
TRAT1 2.03E-06 10.53 1.38 SYK 7.50E-12 3.29 12.33 
AC017104.6 1.06E-07 1.07 8.11 TNS3 1.16E-05 1.82 10.32 
 
2.5 Genes differentially expressed between B lymphocytes and monocytes. 
Genes with higher expression in B lymphocytes are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
B MC B MC 
AC017104.6 0.000183343 8.11 1.98 CXCR2 0.001110193 0.97 5.90 
B3GNT7 0.008095343 7.73 2.48 FCGR3A 0.014748615 3.56 8.78 
CCR7 0.022474728 9.99 4.83 GPR141 2.12E-05 0.34 7.29 
FAAH2 0.014169341 3.23 0.00 NME8 0.009836482 1.57 5.48 
HOPX 0.000550519 6.52 1.10 RASSF4 3.67E-05 4.50 10.71 
ITGAM 0.014035438 9.87 13.02 
SERPINA
1 0.016392762 5.04 13.47 
PDGFD 0.004142158 3.83 0.00 SIGLEC7 5.60E-05 0.34 7.07 
SIT1 2.89E-07 10.13 0.44 SLCO4C1 0.006585699 1.82 5.50 
ALS2CL 0.007455837 1.56 6.16 THBD 0.038578435 2.44 10.54 
ATP8B4 0.000674948 2.75 8.96 TNFAIP2 0.026581098 5.52 14.37 
CD300A 0.014802003 6.03 9.91 TYROBP 6.82E-08 4.23 12.55 
CX3CR1 0.029098815 1.76 7.99         
 
Appendix 3 Genes differentially expressed between ex vivo NK developmental 
stages identified using ANOVA analysis 
Expression levels are indicated in Log2 domain. 
3.1 Genes differentially expressed between stage 1 and stage 2 ex vivo NK 
samples. All identified genes are higher expressed by stage 1 samples. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
Stage 1 Stage 2 Stage 1 Stage 2 
CA2 0.008581077 11.98 7.36 PDZD4 0.01072162 3.95 0.95 






3.2. Genes differentially expressed between stage 2 and stage 3 ex vivo NK 
samples. Genes with higher expression in stage 2 samples are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
Stage 2 Stage 3 Stage 2 Stage 3 
ADGRG6 0.014087346 9.35 6.30 IL7R 0.000242399 6.10 12.98 
CPA3 0.040783765 10.98 6.90 KIAA1211L 3.87E-05 1.30 7.48 
HBD 0.04314571 7.75 2.73 KIAA1324 1.35E-08 1.53 9.46 
MAP7 0.04423324 9.77 7.83 KRT81 0.005183573 1.53 6.43 
MPO 0.024955782 12.96 5.48 KRT86 0.001308175 1.29 7.29 
PRSS23 0.011445942 3.81 1.40 LIF 0.000665343 4.25 9.78 
PRSS57 0.001368987 10.58 5.01 LINC00892 4.51E-05 1.20 6.74 
SPINK2 0.009062321 10.28 7.79 LINGO4 7.56E-05 2.65 8.15 
TAL1 0.016399197 9.23 4.68 PDZD4 4.42E-05 0.95 3.99 
AL450992.2 0.005320224 2.05 6.45 PKDCC 3.46E-05 2.21 7.89 
B3GALT5 1.35E-06 0.81 6.95 RORC 0.000155328 3.71 10.72 
CD2 0.000343415 3.79 8.97 
RP11-
330A16.1 0.003430403 2.23 5.80 
CSPG4 0.003126537 1.96 5.46 
RP5-
1028K7.2 0.011937266 0.75 5.20 
DLL1 0.005091447 4.53 9.16 SLC4A10 0.000151548 0.68 7.75 
ENPP1 3.01E-06 2.47 9.37 
SMIM10L2
A 0.001883157 1.51 5.96 
EOMES 0.011641871 0.81 3.02 TGFBR3 0.000278677 3.64 5.71 
GNLY 0.001305565 5.94 9.04 THEM5 0.006462324 1.80 5.89 
GPR55 0.00898273 2.17 6.72 TNFRSF18 4.45E-05 3.89 9.13 
GPR68 0.001166204 5.05 9.27 TNFSF11 4.60E-05 1.97 8.80 
IGFBP4 0.045589771 3.77 7.02 TOX2 0.002858866 3.60 8.19 
IL1R1 0.00270958 5.22 10.39 XCL1 0.000106199 1.61 8.08 
IL23R 0.000206492 2.01 8.95 XCL2 0.000116576 1.70 7.03 
IL4I1 0.001311971 3.73 9.17         
 
3.3 Genes differentially expressed between stage 3 and stage 4 ex vivo NK 
samples. Genes with higher expression in stage 3 samples are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
Stage 3 Stage 4 Stage 3 Stage 4 
ADGRG6 6.41E-06 6.30 2.27 BNC2 2.22E-05 1.81 4.93 
AKR1C3 0.029933829 5.93 3.16 CD8A 0 3.14 8.20 
AL450992.2 0.044095866 6.45 3.78 DTHD1 0 1.05 8.28 
B3GALT5 1.05E-09 6.95 0.69 EOMES 0 3.02 9.34 
CA2 5.45E-07 9.23 4.87 FCGR3A 0 1.95 8.53 
CDC42BPA 1.18E-06 8.00 3.99 FCRL3 0.00435096 4.44 7.92 
CDH1 2.06E-07 8.24 2.81 FCRL6 1.49E-08 3.25 8.04 
CPA3 0.001761078 6.90 2.57 FEZ1 2.94E-06 0.74 4.15 
EREG 0.021786606 9.71 5.82 FGFBP2 0 1.05 7.36 





GRB10 1.55E-07 8.07 3.84 GZMA 0 3.03 10.29 
IL1R1 0.000149211 10.39 5.49 GZMB 0 4.85 10.30 
IL23R 0.00354844 8.95 4.62 GZMH 0 0.98 9.01 
IL4I1 0.002282303 9.17 5.16 GZMM 0 1.79 9.47 
KIAA1211L 0.001281245 7.48 3.69 IFNG 0 1.17 8.11 
KIAA1324 1.80E-05 9.46 5.01 KIR3DX1 0 1.07 7.19 
KIT 1.66E-06 12.49 8.88 KLRD1 0 4.31 12.12 
LIF 0.002490478 9.78 5.93 KLRF1 0 2.87 11.15 
LINGO4 4.17E-10 8.15 1.04 PDZD4 0 3.99 8.47 
MAP7 5.16E-08 7.83 4.19 PRF1 1.36E-11 6.73 12.49 
MRC2 1.16E-08 9.04 4.18 PRSS23 4.04E-09 1.40 5.63 
MYB 3.22E-08 9.17 4.74 PYHIN1 0 2.92 8.65 
PKDCC 4.40E-08 7.89 1.96 
RP11-
222K16.2 0 0.37 7.07 
RORC 1.04E-05 10.72 4.44 S1PR5 0 0.79 8.40 
STAC 0 7.91 2.73 TBX21 0 3.88 10.52 
TGM2 8.13E-07 9.13 3.41 TENM1 0 2.58 8.89 
VWDE 4.43E-08 7.69 3.29 TGFBR3 0 5.71 11.00 
ACAN 0.002163214 2.82 6.18 XCL2 0.017352484 7.03 9.77 
 
3.4 Genes differentially expressed between stage 4 and stage 5 ex vivo NK 
samples. Genes with higher expression in stage 4 samples are marked in green. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
Stage 4 Stage 5 Stage 4 Stage 5 
ACAN 2.58E-06 6.18 1.92 STAC 1.78E-05 2.73 0.40 
CA2 0.019618121 4.87 3.02 TNFSF11 0.000349946 7.48 3.56 
CDC42BPA 0.035914272 3.99 2.36 TOX2 0.000167189 6.82 3.16 
CSPG4 1.31E-07 4.83 0.81 VWDE 0.000384224 3.29 0.92 
DLL1 0.000257419 9.23 5.44 XCL1 9.93E-05 10.71 6.49 
ENPP1 1.12E-10 8.00 1.35 XCL2 0.018317172 9.77 7.47 
GNAI1 0 6.19 1.05 AKR1C3 6.02E-08 3.16 8.54 
GPR55 0.000555762 4.91 1.18 B3GAT1 0 1.78 7.79 
GRB10 0.007817987 3.84 1.96 BNC2 0 4.93 9.89 
IGFBP4 1.65E-10 8.81 2.47 CD8A 0.00046797 8.20 9.97 
IL1R1 0.016830891 5.49 2.67 DTHD1 5.74E-07 8.28 10.67 
IL23R 0.024566706 4.62 1.62 FCGR3A 1.31E-06 8.53 11.60 
IL7R 2.11E-06 11.65 5.85 FCRL6 0.005243711 8.04 10.06 
KIT 7.81E-12 8.88 4.17 FEZ1 5.05E-11 4.15 8.51 
KRT81 0.016064946 5.09 2.25 FGFBP2 0 7.36 12.13 
LIF 5.20E-05 5.93 1.70 GZMA 0.04406799 10.29 11.81 
LINC00892 4.30E-05 5.42 1.81 GZMB 0.000106211 10.30 12.56 
LPAR1 5.30E-08 6.80 1.48 GZMH 0.000228603 9.01 11.32 
MAP7 4.68E-07 4.19 1.38 GZMM 0.004292417 9.47 10.84 
MRC2 0.012626141 4.18 2.32 IFNG 0.001285718 8.11 9.86 





PRSS23 0 5.63 10.59 PDZD4 5.73E-05 8.47 10.42 
RORC 0.026651162 4.44 1.49 PRF1 0.019104451 12.49 14.18 
RP11-
330A16.1 6.77E-11 5.95 0.54 PYHIN1 7.26E-05 8.65 10.65 
SLC4A10 0.013550666 7.23 4.02 S1PR5 3.16E-12 8.40 11.93 
SMIM10L2
A 9.28E-05 4.53 0.97 SLC1A7 8.04E-11 1.11 6.98 
SPINK2 0 6.66 0.72 TGFBR3 2.67E-05 11.00 12.55 
 
Appendix 4 Ranked top 100 genes differentially expressed within ex vivo stage 
4 NK samples 
Genes identified from the total number of 20160 genes using LoD1. 
GeneID Score (PC1-3) Rank GeneID Score (PC1-3) Rank 
HLA-U 0.044872866 1 CPA1 0.028576064 51 
PPBP 0.042793137 2 MMP8 0.02856053 52 
HBG1 0.041395926 3 RN7SKP291 0.028503449 53 
HBG2 0.041259942 4 S100A12 0.028286044 54 
CTSG 0.040896323 5 ABCD2 0.028237051 55 
RPSAP53 0.040235825 6 TCL1A 0.028144963 56 
IGHG1 0.040112401 7 RP5-857K21.11 0.028035752 57 
ELANE 0.039878047 8 CENPQ 0.027890947 58 
RP11-380G5.2 0.038727222 9 PGLYRP1 0.027885592 59 
DEFA4 0.037676366 10 KIF21A 0.027829581 60 
IGHG2 0.037580756 11 CXCL8 0.027425628 61 
LTF 0.036850387 12 IGLC3 0.027378225 62 
PRTN3 0.036692085 13 CPB1 0.027368866 63 
COLGALT2 0.036618122 14 AZU1 0.027278489 64 
MTRNR2L1 0.035658654 15 TLR10 0.027253323 65 
CELA1 0.035132499 16 MTRNR2L12 0.027102442 66 
PF4 0.034670961 17 RP11-263C24.1 0.027003067 67 
S100A8 0.03419542 18 TAS2R64P 0.026991588 68 
FCRL5 0.033676034 19 CRISP3 0.026955824 69 
BIRC6-AS1 0.033640429 20 LYZ 0.026891252 70 
DEFA3 0.033612078 21 FCRL2 0.026886044 71 
CAMP 0.033589194 22 CHI3L1 0.026870583 72 
IGHA1 0.033359998 23 SLC22A20 0.02676414 73 
MPO 0.033142477 24 GP9 0.02674691 74 
RNASE3 0.032762949 25 RP11-726G1.1 0.026689902 75 
IGHG3 0.032494735 26 CYTL1 0.026634354 76 
BPI 0.032218286 27 MTRNR2L10 0.026615115 77 
MIR4742 0.032112952 28 MIR1255A 0.026588787 78 
ITGA1 0.032095342 29 SLPI 0.026578227 79 
RNU2-64P 0.032058646 30 TBC1D9 0.026558456 80 
MDGA1 0.031874738 31 IFIT1B 0.026538442 81 





IGKV3-20 0.031693363 33 TNFAIP8L2 0.026509954 83 
IGLV3-1 0.031495208 34 FCRLA 0.026485506 84 
ITGB3 0.031253428 35 IGKV4-1 0.026483515 85 
IGHV1-69 0.030969613 36 RP3-465N24.5 0.026481947 86 
OPA1-AS1 0.030330073 37 MS4A3 0.026453607 87 
CEACAM8 0.030115459 38 IGHV3-15 0.026358545 88 
AC079949.1 0.030039327 39 IGLV3-19 0.026255917 89 
LCN2 0.029988944 40 RP11-319G9.3 0.02623054 90 
IGLV2-23 0.029916983 41 RN7SKP137 0.0262097 91 
ABCA13 0.029850262 42 RP11-286O18.1 0.026191232 92 
RNASE2 0.029780793 43 CPA2 0.026183614 93 
RP4-591B8.2 0.029394141 44 ADAM19 0.026148029 94 
CR2 0.029237168 45 RP11-225N10.3 0.026123355 95 
JCHAIN 0.028958795 46 RP11-513M16.7 0.026107061 96 
IGKV1-5 0.02877502 47 SLC2A5 0.026048112 97 
S100A9 0.028721833 48 RN7SL753P 0.025948049 98 
IGHGP 0.028692624 49 RP11-394O4.5 0.025946907 99 
PNLIPRP1 0.028650991 50 FCN1 0.025789268 100 
 
Appendix 5 Genes differentially expressed between ex vivo stage 4 NK samples 
of different tissue origin identified using ANOVA analysis 
Expression levels are indicated in Log2 domain. 
5.1 Genes differentially expressed between PB- and BM-derived stage 4 NK 
samples. All identified genes are higher expressed by BM-derived samples. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
BM PB BM PB 
ABCA13 0.040775111 10.00 0.64 IGLC3 0.008147998 8.67 0.54 
AZU1 0.03521059 12.13 3.58 IGLV2-23 0.007418155 9.31 0.00 
BPI 0.002510486 10.46 0.00 JCHAIN 0.036939929 10.06 1.61 
CAMP 0.004808829 11.12 0.40 LCN2 0.030612573 11.04 1.77 
CEACAM8 0.006281595 9.77 0.00 LTF 0.009246428 13.25 1.62 
CHI3L1 0.016231377 8.18 0.54 LYZ 0.030318717 13.16 5.37 
CRISP3 0.004488564 9.37 0.00 MMP8 0.019786435 9.98 0.20 
CTSG 0.009180755 12.44 0.54 MPO 0.030080094 13.61 2.44 
DEFA3 0.022124486 11.30 0.70 MS4A3 0.028057495 9.74 2.01 
DEFA4 0.002021867 11.55 0.73 PGLYRP1 0.030652781 8.73 0.64 
ELANE 0.012103025 12.19 0.00 PLBD1 0.01528074 9.35 1.77 
IGHA1 0.007347146 10.59 1.40 PRTN3 0.027559544 12.13 0.67 
IGHA2 0.000142033 8.11 0.20 RETN 0.015686867 8.04 0.54 
IGHG1 0.007268767 13.01 1.02 RNASE2 0.005186584 9.01 0.20 
IGHG3 0.005615043 10.87 0.00 RNASE3 0.002182448 9.66 0.20 
IGHGP 0.00213222 9.39 0.00 S100A12 0.028312931 9.92 1.57 





IGKV1-5 0.041200739 9.17 1.02 SLC2A5 0.007586502 7.91 0.54 
IGLC2 0.027201772 8.59 0.80 SLPI 0.00935506 7.87 0.00 
 
5.2 Genes differentially expressed between BM- and tonsil-derived stage 4 NK 
samples. Genes with higher expression in BM-derived samples are marked in green 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
BM Tonsils BM Tonsils 
BPI 0.003804809 10.46 0.00 RETN 0.017197016 8.04 0.00 
CAMP 0.016920463 11.12 2.35 RNASE2 0.022826538 9.01 2.20 
CEACAM8 0.013070427 9.77 0.74 RNASE3 0.008358835 9.66 1.98 
CRISP3 0.006732058 9.37 0.00 S100A12 0.032073791 9.92 1.06 
DEFA3 0.024648072 11.30 0.00 S100A9 0.021420888 13.93 3.68 
DEFA4 0.003370746 11.55 0.95 SLPI 0.041410376 7.87 1.90 
FCN1 0.043941761 10.12 0.00 CR2 0.01843573 0.00 8.36 
LTF 0.023714767 13.25 3.09 ITGA1 0.021789257 5.27 11.42 
MMP8 0.026281099 9.98 0.00         
 
5.3 Genes differentially expressed between BM- and CB-derived stage 4 NK 
samples. All identified genes are higher expressed in BM-derived samples. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
BM CB BM CB 
AZU1 0.045469492 12.13 3.38 IGHV3-23 0.014803247 8.13 0.00 
BPI 0.010797969 10.46 2.20 IGKV1-5 0.038088192 9.17 0.06 
CAMP 0.038327985 11.12 3.98 IGLC2 0.026430575 8.59 0.00 
CEACAM8 0.029997395 9.77 2.41 IGLC3 0.0094361 8.67 0.06 
CTSG 0.013021856 12.44 0.42 IGLV2-23 0.01100207 9.31 0.00 
DEFA4 0.004014637 11.55 1.35 MS4A3 0.041255488 9.74 2.09 
ELANE 0.030275333 12.19 1.53 RNASE2 0.009809633 9.01 0.67 
IGHA1 0.007040331 10.59 0.42 RNASE3 0.003090902 9.66 0.06 
IGHA2 0.000256057 8.11 0.42 RPSAP53 0.028849284 8.23 0.00 
IGHG1 0.011762502 13.01 1.26 SLC2A5 0.015613447 7.91 1.09 
IGHG3 0.008381973 10.87 0.00 SLPI 0.021009958 7.87 0.76 
IGHGP 0.003239692 9.39 0.00         
 
5.4 Genes differentially expressed between CB- and tonsil-derived stage 4 NK 
samples. All identified genes are higher expressed in tonsil-derived samples. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
CB Tonsils CB Tonsils 
CR2 0.036908257 1.35 8.36 IGHGP 0.030686376 0.00 5.54 
IGHA1 0.023729829 0.42 8.04 IGHV3-23 0.022368078 0.00 7.36 
IGHA2 0.001257025 0.42 5.94 IGLC3 0.032341008 0.06 6.44 
IGHG1 0.030808707 1.26 10.54 ITGA1 0.007386238 3.47 11.42 






5.5 Genes differentially expressed between PB- and tonsil-derived stage 4 NK 
samples. All identified genes are higher expressed in tonsil-derived samples. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
PB Tonsils PB Tonsils 
CR2 0.023055852 1.14 8.36 IGHV3-23 0.017286332 0.20 7.36 
IGHA1 0.028465654 1.40 8.04 IGLC3 0.03074734 0.54 6.44 
IGHA2 0.000679536 0.20 5.94 ITGA1 0.002921869 2.49 11.42 
IGHG1 0.019333371 1.02 10.54 SLC2A5 0.039414738 0.54 5.47 
IGHG3 0.01300668 0.00 8.95 TLR10 0.041480249 1.21 7.26 





5.6 Genes differentially expressed between PB- and CB-derived stage 4 NK 
samples. The only identified gene is higher expressed in PB-derived samples. 
GeneID p Value Expression levels CB PB 
RPSAP53 0.014617274 0.00 8.88 
 
Appendix 6 Genes differentially expressed between BM-derived and non-BM 
derived stage 4 NK samples identified among top 400 genes using ANOVA analysis 
Expression levels are indicated in Log2 domain. 
GeneID p Value 
Expression levels 
GeneID p Value 
Expression levels 
CB PB CB PB 
ABCA13 0.006997875 10.00 2.18 LPCAT2 0.012541798 7.57 2.69 
ANXA3 0.003571723 8.33 2.02 LTF 0.003082246 13.25 3.42 
AZU1 0.000980616 12.13 3.60 LYZ 0.006791651 13.16 6.73 
BEX1 0.000858393 5.99 0.78 MCEMP1 0.00097922 6.27 0.79 
BPI 0.000133552 10.46 0.63 MGST1 0.00012882 6.11 0.64 
CAMP 0.001083936 11.12 1.98 MMP8 0.002840424 9.98 1.09 
CD177 0.009211566 7.15 1.11 MNDA 0.00343195 8.41 2.33 
CEACAM6 4.82E-05 8.95 1.33 MPO 0.003409805 13.61 3.91 
CEACAM8 0.000440334 9.77 0.90 MS4A3 0.000812184 9.74 2.19 
CHI3L1 0.003755841 8.18 1.78 OLFM4 0.003013909 8.15 0.87 
CHIT1 0.002575087 7.63 1.79 PADI2 0.00555747 7.30 1.95 
CLC 0.002836451 6.66 0.87 PGLYRP1 0.002404518 8.73 1.45 
CLEC4D 0.000468154 6.69 0.70 PLBD1 0.004602579 9.35 3.13 
CLEC5A 0.000225758 6.51 0.83 PRRT4 5.81E-07 6.57 0.19 
CRISP3 0.002570828 9.37 1.15 PRTN3 0.002778924 12.13 1.98 
CSF3R 0.022993957 9.24 4.19 RAB44 5.36E-05 6.91 0.62 





CTSG 0.001571086 12.44 1.66 RNASE2 0.000295559 9.01 0.91 
CYP4F3 0.000587681 8.15 1.19 RNASE3 9.08E-05 9.66 0.67 
DEFA3 0.001465622 11.30 1.19 S100A12 0.013417495 9.92 2.67 
DEFA4 1.90E-05 11.55 0.97 S100A8 0.011079726 13.23 4.45 
ELANE 0.0013738 12.19 1.47 S100A9 0.007013196 13.93 5.95 
FCAR 0.009551089 8.22 2.27 S100P 0.001243559 9.16 2.96 
FCN1 0.02213523 10.12 2.96 
SERPINB
10 0.000448408 7.45 0.84 
GLT1D1 0.002676796 6.71 1.74 SIRPB1 0.009921931 5.97 1.48 
H1F0 0.001628369 8.81 3.70 SLC2A5 0.020687636 7.91 2.10 
HK3 0.010539678 8.12 1.96 SLPI 0.000638316 7.87 0.76 
IGHA1 0.031039151 10.59 3.02 SPI1 0.041546652 7.77 2.95 
IGHA2 0.020810183 8.11 1.90 SPP1 0.004740411 5.13 0.21 
IGHG1 0.042965989 13.01 3.81 TCN1 0.002764109 7.89 0.89 
IGHG3 0.048660702 10.87 2.56 VSTM1 6.74E-06 7.25 0.16 
IGHGP 0.00931305 9.39 1.58 
CTD-
2228K2.7 0.007793918 2.07 6.44 
IGHV3-21 0.027836493 7.43 1.76 CYCSP40 0.008757902 0.00 4.70 
IGKV1-5 0.029075362 9.17 2.21 FAM129C 0.010387984 2.57 7.24 
IGKV1-9 0.001005592 7.28 0.82 KCND3 0.031720814 0.85 4.11 
IGKV3-11 0.018213792 8.03 1.46 LRRC48 0.017006933 2.33 6.19 
IGLC2 0.027538621 8.59 2.01 MFAP1 0.03774401 3.63 7.72 
IGLC3 0.031006099 8.67 2.09 PHKG1 0.046158696 2.71 6.48 
IGLV2-11 0.015224378 5.84 1.23 
RP11-
533E19.3 0.0157923 1.53 5.47 
IGLV2-23 0.00964024 9.31 1.49 
RP11-
567M16.5 0.041374679 1.45 5.46 
JDP2 0.008172979 7.08 2.50 
RP11-
701H24.4 0.038097903 3.84 8.22 
KCNH2 0.006150404 6.84 1.53 
RP11-
702F3.1 0.00184513 0.00 4.61 
LCN2 0.001579508 11.04 2.49 
RP11-
802E16.3 0.02451216 2.77 6.77 
LIN7A 0.003364205 6.82 1.75 UBAP1L 0.016958663 3.05 7.46 
 
Appendix 7 Ranked top 100 genes differentially expressed within ex vivo stage 
5 NK samples 
Genes identified from the total number of 21903 genes using LoD1. 
GeneID Score (PC1-3) Rank GeneID Score (PC1-3) Rank 
CXCL8 0.048725036 1 SPI1 0.029533229 51 
G0S2 0.043684424 2 MAFB 0.029496721 52 
HBA1 0.042841837 3 ANPEP 0.029383244 53 
HBA2 0.041642666 4 ALAS2 0.029269775 54 
HBB 0.040229567 5 LTF 0.029251677 55 
THBD 0.040130548 6 RNU1-120P 0.029196621 56 
AQP9 0.039567551 7 SLC4A1 0.029129114 57 





FCAR 0.038887971 9 LILRA5 0.028954611 59 
IL1B 0.038283023 10 FAM20C 0.028944054 60 
FCN1 0.037708582 11 IL31RA 0.02882478 61 
TSIX 0.037573964 12 CD1D 0.028817054 62 
C5AR1 0.037082444 13 CYP27A1 0.028736263 63 
ARSI 0.036744692 14 MNDA 0.028558618 64 
EREG 0.036421824 15 RNU1-59P 0.02851339 65 
MPEG1 0.036171307 16 TBC1D9 0.028397372 66 
SEMA6B 0.035340882 17 CXCL3 0.028318437 67 
HBEGF 0.03524662 18 RAB20 0.028281443 68 
SERPINB2 0.034846779 19 SERPINA1 0.028269283 69 
TNFAIP2 0.034834576 20 CTSL 0.028144706 70 
ADM 0.034558569 21 
CTD-
2303H24.2 0.028024837 71 
IL1RN 0.034497212 22 VCAN 0.027997839 72 
FPR1 0.034276824 23 JDP2 0.027793213 73 
CXCL2 0.034252954 24 CD14 0.027770132 74 
TREM1 0.034020456 25 ZNF683 0.027607461 75 
CTB-61M7.2 0.033906973 26 EGR3 0.02756121 76 
CLEC7A 0.03379109 27 MS4A6A 0.027448848 77 
FFAR2 0.033624425 28 CD36 0.027372058 78 
KIR3DL1 0.03342716 29 ALPL 0.027348023 79 
LRRK2 0.032874463 30 HCAR3 0.027243408 80 
GPR84 0.032622855 31 WDFY3 0.027230761 81 
LYZ 0.032501323 32 CD300E 0.027209143 82 
CSF3R 0.032489089 33 RP11-443B7.3 0.027123718 83 
TRIB1 0.032471461 34 PLAU 0.026949121 84 
APOBEC3A 0.032241561 35 BASP1 0.026769882 85 
GNA15 0.032155158 36 SGK1 0.026750555 86 
RNU1-34P 0.032102292 37 MGLL 0.026717902 87 
DUSP4 0.031772339 38 VDR 0.026706643 88 
S100A12 0.031687864 39 RBM47 0.026696244 89 
TGFBI 0.031597074 40 PID1 0.026660303 90 
S100A8 0.031259906 41 ICOSLG 0.026625361 91 
PTGS2 0.031232339 42 OLR1 0.026599181 92 
CAMK2A 0.031168223 43 RNU5F-1 0.026594636 93 
CXCL16 0.030985889 44 ZMAT4 0.026584874 94 
SDC2 0.030640419 45 CTB-114C7.4 0.026560423 95 
SIRPA 0.030564235 46 SELENBP1 0.026524697 96 
PTX3 0.030388862 47 MME 0.026432205 97 
HCAR2 0.030237623 48 DEFA3 0.026354172 98 
LRG1 0.030138753 49 PTGES 0.026346759 99 






Appendix 8 Genes differentially expressed between nonlicensed, licensed and 
memory-like ex vivo stage 5 NK populations identified from top 100 genes using 
ANOVA analysis  
Expression levels are indicated in Log2 domain. 
8.1 Genes differentially expressed between nonlicensed and licensed samples. 
All identified genes are higher expressed in nonlicensed samples.  
GeneID p Value 
Expression levels 


























AMICA1 0.017310103 7.89 4.50 MNDA 0.036935536 5.99 3.01 
CD4 0.018416018 6.41 3.11 MS4A6A 0.012419481 6.34 3.01 
FAM20C 0.012196882 5.32 1.37 NAPSB 0.015336566 6.91 3.33 
GNA15 0.046179566 6.16 2.83 PLD4 0.010970554 6.01 2.67 
HCK 0.026177292 6.64 3.42 PTGS2 0.029512842 5.84 2.32 
IL1B 0.028955093 7.68 2.94 RP11-443B7.3 0.040515378 4.22 1.18 
IL1RN 0.042781891 5.02 1.51 SLC8A1 0.036845802 6.79 3.64 
JDP2 0.027446496 4.83 1.73 SPI1 0.037400647 6.38 2.76 
KCTD12 0.018728145 7.22 3.72 TGFBI 0.006044786 8.15 4.14 
LILRA5 0.041437349 6.41 3.13 TNFAIP2 0.040965892 8.20 4.46 
LYZ 0.031494793 10.64 6.54 WDFY4 0.016001568 7.60 4.54 
 
8.2 Genes differentially expressed between licensed and memory-like samples. 
Genes with higher expression in licensed samples are marked in green. 
GeneID p Value 
Expression 
levels 




















ADGRA3 0.000362118 6.78 1.85 HCAR3 0.007034287 0.56 4.00 
ZMAT4 0.010841639 5.71 1.50 HCK 0.00852025 3.42 6.72 
ADM 0.006639844 1.67 5.86 IL1B 0.00402717 2.94 8.37 
AIF1 0.012708486 3.67 6.94 IL1RN 0.001224724 1.51 6.44 
ANPEP 0.037673756 2.29 5.62 JDP2 0.003534086 1.73 5.31 
APOBEC3A 0.011131988 1.94 6.01 KCTD12 0.037786526 3.72 6.42 
AQP9 0.03566371 1.61 5.66 LILRA5 0.00668812 3.13 6.89 
BANK1 0.037663273 4.20 6.37 LRG1 0.00499452 0.83 4.46 
C5AR1 0.007449463 2.72 7.33 LTF 0.000848569 1.93 7.95 
CD14 0.002721083 3.19 7.30 LYZ 0.00691872 6.54 10.99 
CD1D 0.024198792 2.10 5.77 MAFB 0.009714003 2.71 6.76 





CD4 0.00508166 3.11 6.52 MPEG1 0.013888814 4.31 7.96 
CLEC7A 0.018381993 3.27 7.41 MS4A1 0.029387246 4.95 7.44 
CSF3R 0.002881093 4.00 8.50 MS4A6A 0.011036874 3.01 5.94 
CTB-114C7.4 0.00238312 0.96 4.88 PTGS2 0.002151916 2.32 6.67 
CTB-61M7.2 0.04675631 0.79 4.20 PTX3 0.02015828 1.02 4.37 
CTSL 0.022884927 1.14 4.42 RAB20 0.002948134 1.24 5.25 
CXCL16 0.02174077 2.08 5.76 RP11-443B7.3 0.002839788 1.18 5.03 
CXCL8 0.00488742 5.12 11.68 S100A12 0.001824637 1.41 5.75 
CYBB 0.014355388 5.45 8.48 S100A8 0.001184547 4.17 9.27 
CYP27A1 0.01126043 1.32 4.88 S100A9 0.002490332 5.77 10.62 
DGAT2 0.016979779 1.14 4.35 SDC2 0.04257517 0.85 3.98 
EREG 0.008680707 2.94 7.54 SERPINA1 0.002142821 3.52 8.21 
FAM20C 0.009816509 1.37 4.90 SIRPA 0.013335425 1.71 5.41 
FCAR 0.001280308 1.33 6.82 SLC8A1 0.044459555 3.64 6.27 
FCN1 0.004944217 4.96 9.32 SPI1 0.004790846 2.76 7.01 
FFAR2 0.008995255 1.33 5.33 TGFBI 0.006922601 4.14 7.55 
FPR1 0.006778137 2.45 6.99 TNFAIP2 0.007174018 4.46 8.69 
G0S2 0.003957594 3.12 8.95 TREM1 0.00425362 2.89 7.62 
GNA15 0.029189105 2.83 5.96 TRIB1 0.007907009 3.29 7.47 
GPR84 0.009054005 1.16 5.10 VCAN 0.021883606 5.78 9.27 
HBEGF 0.007256206 1.83 6.24 WDFY4 0.024770358 4.54 7.01 
HCAR2 0.007329884 0.96 4.79         
 
8.3 Genes differentially expressed between nonlicensed and memory-like 
samples. The gene with higher expression in nonlicensed samples is marked in green. 
GeneID p Value 
Expression levels 
























ADGRA3 0.017992673 5.88 1.85 LTF 0.017889801 2.60 7.95 
 
Appendix 9 Genes differentially expressed between nonlicensed, licensed and 
memory-like ex vivo stage 5 NK populations (excluding samples from the donor 6) 
identified from top 400 genes using ANOVA analysis 
Expression levels are indicated in Log2 domain. 
9.1 Genes differentially expressed between nonlicensed and licensed samples. 
All identified genes are higher expressed in nonlicensed samples. 





























ALDH2 0.019756039 5.96 2.72 MEFV 0.042740551 4.71 2.17 
CD4 0.048825127 5.80 2.76 MS4A6A 0.039622601 5.93 2.70 
CFP 0.044028532 6.47 3.21 NAPSB 0.043232221 6.86 3.10 
CLEC10A 0.041427478 5.56 1.85 PLD4 0.042811678 6.19 2.62 
FLT3 0.005461092 5.41 1.39 SEMA4A 0.036546325 5.86 2.37 
IFI30 0.046531008 6.11 2.65 TGFBI 0.016728485 7.69 3.78 
IL1RN 0.032653486 3.64 0.95 TNS3 0.033987674 4.88 2.05 
KCTD12 0.046912382 6.98 3.39         
 
9.2 Genes differentially expressed between nonlicensed and memory-like 
samples. Genes with higher expression in nonlicensed samples are marked in green. 
GeneID p Value 
Expression levels 
























AC009505.2 0.027433182 3.56 0.68 CAMP 0.000879347 1.05 6.75 
AC010886.2 0.024800011 5.22 0.99 CEACAM8 0.000901707 0.48 5.65 
ADGRA3 0.031749081 6.83 2.48 DEFA3 0.000270012 0.05 8.17 
DUTP1 0.012906403 3.78 1.27 DEFA4 7.90E-05 0.00 5.90 
MGAM2 0.004072577 5.17 0.10 FCAR 0.041827861 2.67 5.31 
MPPED2 0.003327628 4.40 0.00 FPR2 0.032052052 0.37 2.84 
MYO1H 0.021001958 4.59 1.46 IL10 0.03493464 1.72 5.15 
RASGRF2 0.009361244 8.62 4.75 LAG3 0.041672348 2.44 6.91 
RP11-
588K22.2 0.001940757 5.84 0.58 LCN2 0.000428392 0.00 6.35 
RP11-
706O15.3 0.045795177 4.47 0.00 LTF 0.00063943 0.70 9.20 
SARDH 0.009948945 6.16 1.33 MPO 0.030842798 1.71 6.32 
TRAT1 0.049303543 4.06 0.86 SELENBP1 0.012812314 1.42 5.88 
WSCD1 0.025893635 4.44 0.86 TCN1 0.018736252 1.57 4.85 
BPI 0.000294287 0.26 6.49 ZNF683 0.03906203 4.90 9.12 
                
 
9.3 Genes differentially expressed between licensed and memory-like samples. 
Genes with higher expression in licensed samples are marked in green. 
GeneID p Value 
Expression levels 
























AC009505.2 0.029071684 2.95 0.68 HK3 0.028067068 2.76 6.01 
AC010886.2 0.047819505 3.97 0.99 HLA-DQA2 0.017708629 2.97 8.65 
ADGRA3 0.005578575 7.05 2.48 HLA-DRB6 0.014870348 4.40 8.70 
C1QTNF7 0.04512044 4.54 1.94 IFI30 0.034336294 2.65 6.32 
DIO1 0.013493943 3.20 0.84 IGHV1-3 0.038941597 1.89 5.10 
GJB7 0.01172082 4.30 1.00 IL10 0.003486882 1.25 5.15 
MPPED2 0.027335908 2.56 0.00 IL1B 0.03133587 2.36 7.02 
RASGRF2 0.036438926 7.21 4.75 IL1RN 0.001469331 0.95 5.17 
RP11-
588K22.2 0.005871095 4.22 0.58 KB-1615E4.3 0.02003347 1.58 4.50 
RP11-
706O15.3 0.044894366 3.58 0.00 LAG3 0.005447808 1.96 6.91 
RP11-
873E20.1 0.030648154 3.85 0.58 LCN2 0.000130518 0.62 6.35 
SARDH 0.037394314 4.41 1.33 LILRA5 0.032802459 2.69 5.78 
TAS2R50 0.027184442 4.85 1.72 LILRB2 0.014852505 2.13 5.40 
BPI 7.62E-05 0.80 6.49 LINC00384 0.045907086 2.45 5.26 
BTBD19 0.029351751 2.12 5.16 LINC00877 0.012985086 2.53 6.23 
C6orf99 0.048250825 5.57 8.35 LTF 0.000190775 1.49 9.20 
CAMP 3.94E-05 0.51 6.75 LYZ 0.047472132 6.07 10.24 
CCDC144A 0.033959705 2.03 5.93 MEFV 0.03741949 2.17 4.77 
CD4 0.040208376 2.76 5.92 MPO 0.01144651 1.98 6.32 
CDA 0.015253614 0.73 3.30 PAX5 0.025461976 2.73 5.61 
CEACAM8 0.000260916 0.93 5.65 PTMS 0.009293334 2.83 6.86 
CFD 0.021990616 2.40 5.42 RP11-159J3.1 0.028213187 4.81 7.71 
CFP 0.023872987 3.21 6.87 RP11-443B7.3 0.011337436 0.77 4.13 
CSF3R 0.010244388 3.48 7.33 
RP11-
689B22.2 0.044481994 2.35 5.00 
CTD-
2562J15.6 0.041796946 3.29 6.31 RXRG 0.030573467 1.24 4.60 
CXCL8 0.020211892 4.33 9.44 S100A8 0.003601321 3.75 9.39 
DEFA3 8.18E-05 0.87 8.17 S100A9 0.010120386 5.31 10.33 
DEFA4 2.46E-05 0.65 5.90 SELENBP1 0.002943572 1.51 5.88 
FCAR 9.64E-05 0.68 5.31 SERPINA1 0.006362658 3.04 7.53 
FCN1 0.020629501 4.49 8.54 SLC34A1 0.012251396 2.80 6.33 
FMR1-AS1 0.02281783 1.63 5.04 SLC4A1 0.008788832 2.89 6.89 
FPR1 0.02826293 1.89 5.30 SPATA22 0.028400685 1.36 4.72 
FPR2 0.019208331 0.68 2.84 SPI1 0.027304489 2.29 5.87 
G0S2 0.003194579 2.42 7.04 TAS2R63P 0.009431207 5.14 2.05 
HBA1 0.021566674 6.53 11.09 TCN1 0.001331981 1.08 4.85 
HBA2 0.032073681 8.54 12.71 TNFAIP2 0.049648127 3.96 7.43 
HCK 0.04979665 3.10 6.45 TRIB1 0.035694725 2.76 5.83 
HEMGN 0.035318619 2.90 5.62 ZNF683 0.033706893 5.66 9.12 
 
Appendix 10 Genes differentially expressed between ex vivo and in vitro stage 





Expression levels are indicated in Log2 domain. Genes with higher expression in in 
vitro samples are marked in green. 
GeneID p Value 
Expression levels 




















ASPM 0.001757709 7.51 12.67 KIR2DL4 0.008265714 2.34 6.75 
SLFN12L 0.007565211 7.56 11.69 KLRC4 0.000979751 1.84 6.74 
MYO18B 0.005352704 6.82 11.61 
KLRC4-
KLRK1 0.004846741 2.35 6.74 
NCAM1 0.027386606 6.02 11.53 NOSTRIN 0.005882118 2.28 6.72 
CENPE 0.00589387 7.01 11.29 HLA-V 0.006307461 1.89 6.69 
CDK1 0.003167144 6.13 10.96 FBXO43 0.010586229 2.38 6.31 
CFH 0.001164924 6.21 10.81 AMPH 0.000674115 1.87 6.23 
ARHGAP11
A 0.002894541 6.09 10.79 RNA5SP390 0.000125648 1.29 6.22 
KIF14 0.00106013 5.75 10.72 LDB2 0.028897802 2.56 6.18 
RASSF8 0.005942996 6.84 10.70 SGCE 0.000862963 1.76 6.13 
GZMA 5.22E-05 3.03 10.59 AC092580.1 0.005863426 1.57 5.70 
PTGER3 0.00376404 6.02 10.29 
RP11-
799B12.2 0.034997144 2.50 5.49 
TMEM200A 0.007448746 5.14 10.23 VSTM4 0.041437639 2.22 5.48 
HJURP 0.004484735 5.11 9.94 SIK1 0.003435981 9.19 6.23 
BUB1B 0.024450973 5.91 9.92 CD300LF 0.007326864 9.32 4.33 
ADGRL2 0.000403131 3.52 9.92 CDH1 0.006806712 8.24 3.64 
AFAP1L2 0.000124148 4.21 9.88 
RP11-
307C12.13 0.037303753 6.54 2.92 
KIF18A 0.023548809 6.06 9.81 RP4-765C7.2 0.014912757 6.19 2.89 
RP11-
1094M14.5 0.001449569 3.31 9.54 SEMA3C 0.042358593 5.48 2.57 
LZTS1 4.95E-06 2.17 9.51 EREG 9.00E-07 9.71 2.49 
RP11-
1094M14.8 0.002847264 4.08 9.47 RRAD 0.037927553 6.00 2.49 
B4GALNT1 0.049607825 5.10 9.38 NUAK2 0.017550491 5.02 2.44 
PEG10 0.000166902 2.28 9.31 AREG 0.014439112 6.05 2.05 
IGF2BP3 0.001553652 2.77 9.29 A2M-AS1 0.001517961 5.46 1.96 
NTRK2 8.18E-07 1.12 9.27 AKR1C3 0.021980398 5.93 1.85 
DRAXIN 3.01E-08 1.70 9.24 AF213884.2 0.003927121 6.31 1.72 
NDFIP2 0.011519835 4.66 9.02 C17orf107 0.00376429 5.61 1.66 
RP11-
277P12.20 0.012629887 5.04 8.99 MSRB3 0.000226098 6.47 1.43 
RNF165 0.003193698 3.85 8.94 C1QTNF1 0.031765431 4.81 1.23 
DEPDC1 0.008097417 4.34 8.88 
RP11-
44N11.2 0.001444691 6.50 1.22 
E2F3P1 0.007612725 3.84 8.87 NELL2 0.018406665 7.03 1.19 
CENPI 0.009730398 4.61 8.79 LINC00612 0.003868064 4.98 1.12 
CLECL1 0.001301643 3.26 8.76 ADGRE1 0.017518438 4.48 0.85 
TOMM20P2 0.007000877 4.27 8.76 NCF1 0.012215451 4.10 0.83 






NEK2 0.008592297 4.26 8.61 NFIX 2.12E-05 6.08 0.70 
E2F8 0.01643722 4.26 8.58 BEX5 0.012240932 5.12 0.70 
THRA1/BT
R 0.035823687 5.07 8.54 UPB1 0.013121344 3.37 0.58 
PTGIS 1.26E-07 0.63 8.45 
RP11-
252C15.1 0.019035142 5.03 0.53 
PVRL3 0.019278926 4.58 8.40 A2MP1 0.026483283 3.39 0.53 
AK4 0.000332975 2.09 8.39 IL5RA 0.005842729 4.15 0.52 
PBK 0.01290095 3.03 8.33 HLA-U 0.001938466 6.10 0.49 
KLRC2 0.001137854 2.56 8.32 CACNA1D 0.031633645 3.22 0.49 
ERCC6L 0.038711474 4.71 8.23 BTG1P1 0.039814816 3.19 0.49 
ITGA1 0.013994977 3.89 8.12 KRT17P8 0.042201187 3.27 0.49 
MYO6 0.026833354 4.87 7.80 ALS2CL 0.004079629 3.89 0.46 
RP11-
70L8.4 0.03038884 4.97 7.65 CYP2F1 0.028210804 3.78 0.16 
OMD 0.007422255 3.23 7.51 LINC00309 0.010292542 4.50 0.16 
ASPN 0.011855546 3.17 7.45 AC012307.2 0.023731202 3.88 0.16 
SPC25 0.004589728 2.99 7.43 EVPL 0.033548827 3.41 0.16 
ALDH1A3 3.06E-05 1.77 7.41 DTX1 0.003035575 6.60 0.10 
LINC01146 0.005959369 3.59 7.37 AC022182.1 0.002732063 5.51 0.00 
IL26 0.006537708 2.70 7.32 EDARADD 0.01232804 3.11 0.00 
CTA-
125H2.2 1.42E-05 1.58 7.25 IGHG1 0.016847725 7.59 0.00 
PRKCA-
AS1 0.013649211 3.51 7.17 CH25H 0.019515034 4.64 0.00 
ABLIM3 5.69E-06 1.22 7.08 PCDH20 0.023501069 3.72 0.00 
KLRC3 0.000435018 2.23 6.93 IGHG4 0.036326526 5.29 0.00 
CYP1A1 9.82E-05 1.44 6.76         
 
Appendix 11 Genes differentially expressed between ex vivo and in vitro stage 
4 NK populations identified from top 400 genes using ANOVA analysis 
Expression levels are indicated in Log2 domain. Genes with higher expression in in 
vitro samples are marked in green. 
GeneID p Value 
Expression levels 




















AC020571.3 0.010554827 1.85 6.01 SLC7A11 0.000122661 1.43 6.54 
AFAP1L2 0.010273428 5.07 10.27 SOS1-IT1 0.00271236 3.69 7.81 
AMPH 0.006154799 2.91 6.94 TAS2R43 0.016817182 2.97 6.46 
ASPM 0.001172334 7.00 12.28 TAS2R64P 0.025780473 3.51 7.62 
BCAT1 0.004659351 4.26 9.15 TDRD15 0.00080337 1.87 6.69 
C10orf128 0.00175295 1.96 7.25 THEMIS 0.000183037 3.62 10.19 
C18orf54 0.003541747 3.58 7.48 TMEM200A 0.019881808 5.98 9.88 





CCDC150 0.007310545 3.37 7.45 TTLL7 0.000807138 2.41 7.11 
CDK1 0.00454538 4.56 10.31 BEX5 0.008738484 4.18 0.78 
CDKN2B 0.001295273 2.23 7.69 CD2 0.000342337 10.46 5.80 
CENPA 0.004390287 3.27 7.63 COL16A1 0.001670428 4.48 0.00 
DEPDC1 0.000398382 2.47 8.54 CYGB 0.000178752 5.29 0.28 
DIAPH3 0.007251608 4.42 8.26 EDARADD 0.000103799 4.91 0.70 
DLGAP5 0.005140536 4.43 9.88 ETNK2 0.005998641 3.53 0.39 
DSCC1 0.007564444 3.21 7.04 FCRL1 0.029697826 4.36 0.18 
E2F7 0.000753758 3.37 7.93 FCRL3 0.008851847 7.92 1.28 
E2F8 0.005633857 3.43 7.72 HBA1 0.008359766 6.14 0.04 
EGLN3 0.001380868 4.07 9.32 HBA2 0.001886636 7.43 0.45 
ESCO2 0.009446238 3.58 8.04 HBB 0.002754031 10.16 2.27 
GPR15 0.000980635 2.85 8.78 HID1 0.003884196 4.03 0.00 
GSG2 0.016159942 3.08 6.91 HOXA-AS3 0.006004183 4.31 0.21 
HLA-V 0.003350906 1.97 7.34 IFNG-AS1 0.000114308 7.88 2.52 
HMMR 0.000605365 4.73 9.42 IGHM 0.009239485 7.30 2.63 
IGF2BP3 0.01181309 5.69 9.24 IGLV3-13 0.002942657 3.10 0.00 
IKBIP 0.020018107 4.83 8.46 IL21R-AS1 0.000133906 7.12 2.15 
IL7R 0.000111365 11.65 7.07 KCNK17 0.005811878 5.21 0.77 
KCNK5 0.02305587 2.73 6.18 KIAA1211L 0.009890233 3.69 0.08 
KDELC1 0.004516924 3.31 7.80 L3MBTL4 0.000493433 7.14 0.92 
KIF14 0.001796609 4.89 10.19 LARGE 0.011181527 5.04 0.41 
KIF20A 0.002954548 3.77 9.07 LINC00925 0.001923865 4.70 0.00 
KIZ-AS1 0.010516244 2.32 6.16 LINGO2 0.00335457 4.23 0.03 
KLRF2 0.005624246 4.35 9.25 LMNA 0.000152129 10.97 6.12 
KNSTRN 0.014351063 4.80 8.37 MS4A1 0.001711099 7.22 1.67 
LILRP2 0.007144067 2.00 6.17 MUC16 0.01167359 3.78 0.41 
LINC01355 0.007216156 3.78 8.03 NKX3-1 0.018567559 3.25 0.51 
MYO5B 0.000537664 2.96 8.00 PMEPA1 0.007668535 4.45 1.02 
NCR2 0.001834598 1.16 6.00 
RP11-
44N11.2 0.000152996 7.10 1.89 
NDFIP2 0.000994266 4.06 10.93 RP11-545P6.2 0.017442561 3.13 0.03 
NUF2 0.007174789 3.96 9.03 SDPR 0.0103272 4.52 0.21 
PBK 0.001053652 1.93 7.72 SH3BP4 0.000196451 6.93 1.95 
PRKCA-
AS1 0.001148395 3.22 7.72 SLC4A1 0.021005154 4.53 0.00 
RP11-21J7.1 0.002488062 2.39 7.45 SNORD3B-1 0.010274656 8.54 5.20 
RP11-28F1.2 0.000186709 1.78 7.19 T 0.012970318 3.22 0.03 
RP11-
328K2.1 0.005608019 2.28 6.31 TMEM204 0.017371895 5.99 3.35 
RP11-
563D10.1 0.002076368 1.91 6.37 TNFSF9 0.004536794 8.01 3.59 
RP11-
932O9.10 0.001318369 1.54 5.99 WWC2-AS2 0.001685186 4.87 0.00 
RP11-
98G13.1 0.001003641 2.25 8.23 ZDHHC20P1 0.00771788 3.34 0.00 
RPL23AP22 0.00045306 1.63 6.89 ZMAT4 0.000635 8.06 2.95 






Appendix 12 Ranked top 100 protein-genes differentially expressed within ex 
vivo NK samples 
Genes identified from the total number of 14177 genes using LoD1. 
GeneID Score (PC1-3) Rank GeneID Score (PC1-3) Rank 
ENPP1 0.054752916 1 PRSS23 0.038967922 51 
IL23R 0.054545918 2 SPINK2 0.038809767 52 
RORC 0.054213487 3 CTSG 0.038738028 53 
IL7R 0.052599853 4 B3GALT5 0.038733592 54 
S1PR5 0.051887348 5 KLRF1 0.038693149 55 
MPO 0.050715683 6 MS4A3 0.038543886 56 
FGFBP2 0.049178562 7 DEFA3 0.038202797 57 
XCL1 0.048513928 8 S100A12 0.03793209 58 
LIF 0.047318836 9 FEZ1 0.037894379 59 
ARSI 0.046889232 10 CLC 0.037885662 60 
TNFSF11 0.046831308 11 TOX2 0.037800911 61 
DUSP4 0.046767582 12 CXCL8 0.037683811 62 
GPR55 0.04652845 13 FFAR2 0.037664656 63 
SLC4A10 0.046490401 14 THEM5 0.037655324 64 
IL4I1 0.04568056 15 CDH1 0.037536095 65 
GZMH 0.045637846 16 KLRF2 0.037498171 66 
KRT81 0.045627665 17 BCAS1 0.037481396 67 
PRTN3 0.045165573 18 DTX1 0.03746515 68 
KRT86 0.045087726 19 HBG2 0.037388629 69 
DTHD1 0.044790453 20 RHAG 0.037264379 70 
AZU1 0.04424315 21 CPNE7 0.037233014 71 
LINGO4 0.043954412 22 FCAR 0.037176649 72 
KLRD1 0.043631485 23 CSPG4 0.037128125 73 
ELANE 0.043423083 24 CAMK2A 0.037056427 74 
LTF 0.043375786 25 TGFBR3 0.036987477 75 
FCGR3A 0.04337522 26 PKDCC 0.036978542 76 
HBD 0.043358476 27 N4BP3 0.036915877 77 
GZMA 0.042300228 28 PRSS57 0.036787298 78 
LPAR1 0.042006769 29 TNFSF9 0.036640388 79 
GZMM 0.04180026 30 VWDE 0.03661077 80 
KIAA1211L 0.041663323 31 HBB 0.036438067 81 
IFNG 0.041566923 32 LTB 0.036420826 82 
IL1R1 0.041191723 33 HBG1 0.036358759 83 
DLL1 0.04110398 34 MAP7 0.036351706 84 
MYO7A 0.040790579 35 ITGB3 0.036302531 85 
GZMB 0.040763344 36 B4GALNT1 0.036220613 86 
SMIM10L2A 0.040701178 37 IL22 0.036099059 87 
KIAA1324 0.040475128 38 CSF2 0.036079662 88 





MYB 0.040440553 40 EOMES 0.035964139 90 
ACAN 0.04033615 41 SORCS1 0.035856048 91 
PYHIN1 0.040300451 42 TNFRSF18 0.035815999 92 
BNC2 0.039937801 43 CPA3 0.035729712 93 
SPTA1 0.03964422 44 TNFAIP8L2 0.035678744 94 
TBX21 0.03953964 45 PDZD4 0.03567442 95 
IGFBP4 0.039194002 46 B3GAT1 0.03566897 96 
C5AR1 0.039185552 47 CD200R1 0.035653068 97 
XCL2 0.039132871 48 RNASE2 0.035603947 98 
AHSP 0.039095362 49 KIR3DX1 0.035532949 99 
PRF1 0.03908271 50 NELL2 0.035521544 100 
 
Appendix 13 Ranked top 100 non-protein genes differentially expressed within 
ex vivo NK samples 
Genes identified from the total number of 6613 genes using LoD1. 
GeneID Score (PC1-3) Rank GeneID Score (PC1-3) Rank 
LINC00892 0.058799913 1 AP001171.1 0.038234855 51 
RP11-98G13.1 0.055845921 2 AC004791.2 0.038167016 52 
RP11-21J7.1 0.050096205 3 RP11-463J10.2 0.037918677 53 
AL450992.2 0.04939482 4 RP3-467K16.4 0.037852336 54 
RP11-563D10.1 0.048783287 5 LPAL2 0.037764726 55 
RP6-91H8.3 0.048270487 6 RP1-206D15.6 0.037718527 56 
RP11-330A16.1 0.04733271 7 AMZ2P2 0.037639982 57 
LINC01132 0.04728287 8 RP11-624C23.1 0.037454564 58 
RP11-354E11.2 0.04629156 9 XXbac-BPG181B23.6 0.037442059 59 
RPL23AP22 0.046228632 10 RP5-1028K7.2 0.037408791 60 
AC092580.4 0.04553675 11 RP11-705C15.5 0.037379497 61 
EDDM3CP 0.045018206 12 AF131217.1 0.037330811 62 
RP11-973H7.1 0.043704866 13 HSPE1P18 0.037163487 63 
HLA-DQB1-AS1 0.043562304 14 LINC00309 0.037138922 64 
AC017104.6 0.043350433 15 AC022182.1 0.037026399 65 
RP1-131F15.2 0.043310571 16 RP11-305O6.3 0.036936453 66 
GATA2-AS1 0.04330196 17 RP11-693J15.5 0.036901389 67 
RP11-15B24.5 0.043140309 18 RP4-738P11.3 0.036822959 68 
LINC00299 0.042441564 19 FCGR2C 0.036811323 69 
RP11-104L21.3 0.042305008 20 KIAA0125 0.036791233 70 
AC007278.2 0.042039656 21 RP11-475O6.1 0.036600145 71 
RP11-158I9.5 0.04201662 22 RP11-456H18.2 0.036486872 72 
MAGI2-AS3 0.041594372 23 RP11-277P12.20 0.036462396 73 
AC092667.2 0.04158054 24 TVP23CP1 0.036452761 74 
FTH1P22 0.041559638 25 RP11-121A8.1 0.036337256 75 
RP11-326C3.2 0.041541675 26 RP11-47L3.1 0.036250539 76 





LINC01268 0.041233947 28 RP11-686D22.10 0.036193839 78 
RP11-104L21.2 0.04113833 29 HCP5 0.036026386 79 
AOX2P 0.041121305 30 RPS20P2 0.035945755 80 
AC002454.1 0.04109729 31 CASC15 0.035938704 81 
RP11-252C15.1 0.041032289 32 RP11-567M16.1 0.035876267 82 
RP11-520A21.1 0.040856994 33 RP11-347C18.3 0.035807167 83 
AC020571.3 0.040596058 34 AC007319.1 0.03577111 84 
RP11-389C8.2 0.040435381 35 RP11-794P6.1 0.03572974 85 
RP11-366L20.2 0.040123848 36 TOMM20P2 0.035698244 86 
RP11-222K16.2 0.040042764 37 NAPSB 0.035674891 87 
IGF2BP2-AS1 0.039933586 38 RP11-796E2.4 0.035637531 88 
RP1-18D14.7 0.039901388 39 RP11-1094M14.5 0.035556444 89 
LINC00880 0.039861751 40 RP11-424C20.2 0.03553821 90 
LINC00877 0.039747578 41 AL356585.1 0.035528516 91 
AC005083.1 0.039632494 42 RP11-693N9.2 0.035441543 92 
RP11-20I20.4 0.039513625 43 RP11-678G14.3 0.035390647 93 
RP13-786C16.1 0.039269059 44 KIAA0087 0.035240211 94 
AC010761.14 0.039101463 45 RP11-44N11.3 0.035125387 95 
SRGAP3-AS2 0.039013378 46 C10orf91 0.03510002 96 
AC010886.2 0.038877675 47 B3GALT5-AS1 0.035026045 97 
SCART1 0.038576601 48 PCED1B-AS1 0.03485257 98 
RP11-342I1.2 0.038341606 49 PLA2G4E-AS1 0.034813687 99 
RP11-6F2.5 0.038235569 50 EGFEM1P 0.03480097 100 
 
Appendix 14 Correlation coefficients between expression of protein-coding 
and non-protein coding genes 
Only correlation coefficients >0.8 or <-0.8 (p<0.05) and only genes involved in at 
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Appendix 15 Correlation coefficients between expression of non-protein 
coding and those of closely localized protein-coding genes 
Only correlation coefficients >0.5 or <-0.5 (p<0.05) and only genes involved in at 
least one correlation are shown 
15.1. Correlation coefficients between expression of non-protein coding and 
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15.2. Correlation coefficients between expression of non-protein coding and 
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15.3. Correlation coefficients between expression of non-protein coding and 
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15.4. Correlation coefficients between expression of non-protein coding and 
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15.5. Correlation coefficients between expression of non-protein coding and 
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Appendix 16 NK-specific genes used for single cell analysis  
Protein-coding Non-protein-coding 
ADAMTS1 FGR PDGFD A2MP1 LUCAT1 
ATP8B4 FOSL2 PDGFRB AC017104.6 PLCB1-IT1 
B3GAT1 GNLY PRF1 AC092580.4 RP11-1094M14.5 
BNC2 GZMA PRSS23 AF131217.1 RP11-183I6.2 
C1orf21 GZMB PTGDR ANKRD20A11P RP11-222K16.2 
CCNJL GZMH RASSF4 FCGR2C RP11-277P12.20 
CD300A HOPX RNF165 GS1-115G20.1 RP11-305L7.1 
CLIC3 IL18RAP S1PR5 HLA-DRB6 RP11-452D12.1 
CMKLR1 ITGAM SH2D1A LINC00299 RP11-456D7.1 
COL13A1 ITK SH2D1B LINC00861 RP11-81H14.2 
CST7 KIR3DX1 SIGLEC7 LINC00877 RP13-516M14.2 
CX3CR1 KLRD1 SLAMF7 LINC01108 SIGLEC17P 
CXCR2 KLRF1 SLC1A7 LPAL2 U91324.1 
DAB2 L3MBTL4 SLC4A4 
  DTHD1 LINGO2 SLCO4C1 
  FAT4 NCAM1 TRDC 
  FCGR3A NCR1 TRDJ1 
  FCRL6 NKG7 TRGV9 
  FEZ1 NME8 TTC38 
  FGFBP2 PCDH1 TYROBP 
   
Appendix 17 Ranked top 89 genes differentially expressed within single cell 
samples 
Genes identified from the total number of 172 genes using LoD1. 
GeneID Score (PC1-3) Rank GeneID Score (PC1-3) Rank 
RP11-277P12.20 0.299472148 1 CX3CR1 0.137893714 46 
LINC00299 0.261794142 2 IGLL5 0.13705548 47 
CST7 0.253418982 3 SLAMF7 0.136352997 48 
AC092580.4 0.236154646 4 IGHM 0.134048472 49 
KLRD1 0.233888096 5 RP11-452D12.1 0.133816264 50 





CD52 0.219360474 7 IGHA2 0.125868851 52 
CLIC3 0.218038909 8 IGHG1 0.120504667 53 
IL6ST 0.216909275 9 GZMH 0.119713812 54 
NKG7 0.214374081 10 NELL2 0.118108594 55 
FCGR3A 0.212705178 11 IGLV6-57 0.11563056 56 
CD37 0.211009942 12 CD19 0.112480522 57 
PRF1 0.207685164 13 IGLC2 0.110738037 58 
GZMB 0.207636059 14 L3MBTL4 0.108641719 59 
TRDJ1 0.206808793 15 IGHMBP2 0.106941898 60 
IL32 0.204479471 16 IGHG3 0.105174127 61 
SH2D1A 0.197002444 17 IGLC3 0.104732575 62 
ITK 0.196889663 18 FEZ1 0.10295379 63 
TYROBP 0.196845947 19 LINC00861 0.099697808 64 
CD59 0.196802894 20 ANKRD20A11P 0.098024219 65 
CD3D 0.194678508 21 NCR1 0.097355715 66 
TRDC 0.193499757 22 CCR7 0.085949742 67 
IGKC 0.192615816 23 FGR 0.085158447 68 
GNLY 0.187869334 24 IGHV1-3 0.078918547 69 
RP11-81H14.2 0.187684034 25 IGF2R 0.073016456 70 
IL7R 0.186110755 26 IGBP1 0.072450968 71 
CD3E 0.182619866 27 FCGR2C 0.072379785 72 
GZMA 0.182606671 28 DTHD1 0.069269068 73 
AF131217.1 0.175067402 29 TRGV9 0.068354073 74 
IGJ 0.173851 30 IGHG4 0.06353194 75 
IGHV5-51 0.173795501 31 RP11-1094M14.5 0.051424615 76 
IGHA1 0.172992872 32 TTC38 0.050187768 77 
IGLV3-19 0.169290032 33 ADAMTS1 0.045409684 78 
HOPX 0.168971947 34 GS1-115G20.1 0.044262823 79 
IL27RA 0.165765091 35 DAB2 0.04248583 80 
C1orf21 0.160622497 36 NCAM1 0.041222876 81 
CD82 0.159271777 37 ITGAM 0.03912345 82 
FGFBP2 0.158105365 38 RP11-456D7.1 0.036664183 83 
SH2D1B 0.157642569 39 ATP8B4 0.036534158 84 
IGLC1 0.15281992 40 LEF1 0.033533177 85 
IL18RAP 0.151770948 41 IGIP 0.032284662 86 
KLRF1 0.150570604 42 IGHV1OR15-1 0.029346265 87 
RP11-222K16.2 0.150133842 43 CMKLR1 0.028405811 88 
SLCO4C1 0.14532052 44 CD300A 0.024991681 89 
AHR 0.141135408 45       
 
Appendix 18 Correlation between expression of non-protein coding genes and 
those of protein-coding genes within single NK cells 
Only significant correlation coefficients (r>0.5 or r<-0.5, p<0.05) and only genes 





















































































ATP8B5                        0.66          
BNC3 0.50                        0.54       
C1orf22    0.59                     0.68       
CCNJL       0.57                           
CLIC4 0.58       0.51    0.52                  
CMKLR2                           0.53       
CST8                              0.51    
DAB3                        0.68          
DTX2       0.62                           
DUSP5       0.55                           
FCGR3A          0.66                        
FEZ2                                    
GNLY    0.62    0.50                        
GZMA    0.53                              
GZMB    0.66                              
IL18RAP                0.53    -0.69             
IL23R             0.69                     
ITGAM                           0.55       
KLRD2          0.65    0.52                  
L3MBTL5       0.82                           
MYO7A                   0.54               
N4BP4                        0.51          
NCAM2    0.57                              
NCR2                                 0.52 
PCDH2             0.69                     
PDGFD                                    
PDGFRB             0.69                     
PRF2                              0.52    
PYHIN2    0.58                              
SH2D1A 0.57 0.58                              
SLC4A5             0.69                     
SLCO4C2                              0.70    
SPINK3                                    
TBX22                                    
TGFBR4                              0.65    
TTC39                           0.53       
XCL2                        0.75 0.51 0.63    
XCL3                              0.52    







































































































ADAMTS2                0.53                   
BNC3                      0.51             
C1orf22          0.52                         
CAMK2A 0.72 0.84          0.58          0.84       
CLIC4             0.65    0.51                
CMKLR2    0.72 0.52       0.58          0.72       
CX3CR2          0.57 0.52          0.51          
DTX2                   0.56                
DUSP5 0.64    0.59                            
FCGR3A             0.69                      
FEZ2             0.51 0.50                   
GNLY             0.71                      
GZMA             0.59       0.54             
GZMB                      0.50             
GZMH                0.60                   
IL18RAP             0.58                      
IL23R    0.50                               
KLRD2             0.52                      
NCAM2    0.69    0.54    0.65          0.70       
NELL3    0.72                      0.72       
NKG8       0.53             0.51             
PCDH2    0.50                               
PDGFD    1.00          0.59          0.99       
PDGFRB    0.50                               
SH2D1A             0.65                      
SLC4A11                               0.53    
SLC4A5    0.50                               
SPINK3                         0.53          
TBX22    0.61          0.59          0.61    0.57 
TTC39    0.63                      0.63       
TYROBP                                     
VWDE    1.00          0.59          0.99       
XCL2                                  0.61 
FOSL2               -0.56         
NFIL4       0.59                 
 
Appendix 19 Correlation between expression of non-protein coding genes and 





Only significant correlation coefficients (r>0.5 or r<-0.5, p<0.05) and only genes 
involved in at least one significant correlation are shown. 
19.1 Correlation coefficients between expression of protein-coding and non-












































































ADAMTS1       0.72 0.51 -0.56    0.51 0.75       0.55 
BNC2       0.70 0.58 -0.57    0.69 0.75       0.63 
C1orf21       0.74 0.53 -0.57    0.61 0.83       0.56 
CCNJL    0.61 0.73             0.51 0.50 0.60    
CLIC3    0.60 0.78    -0.60    0.66 0.56 0.69 0.67 0.68 
CMKLR1       0.59 0.56       0.63 0.59    0.56 0.57 
CST7       0.68 0.55 -0.63    0.59 0.64 0.54    0.61 
CXCR1       0.53 0.60 -0.52    0.56 0.53       0.57 
DAB2                   0.57 0.56          
FCGR3A       0.75 0.51 -0.63    0.77 0.74       0.62 
FEZ1       0.74 0.63 -0.60    0.60 0.63 0.58    0.66 
FOSL2       0.53       -0.50 0.58 0.59          
GNLY    0.69 0.77    -0.64    0.53 0.60 0.52 0.60 0.62 
GZMA    0.57 0.79    -0.67    0.58 0.75       0.66 
GZMB    0.61 0.72 0.53 -0.61    0.64 0.72 0.53 0.64 0.62 
GZMH       0.78 0.55 -0.66    0.63 0.75       0.71 
IL18RAP    0.55 0.81    -0.57    0.56 0.68 0.54 0.61 0.61 
IL23R    0.54                      0.51    
ITGAM       0.58          0.72 0.54          
KLRD1    0.65 0.83 0.53 -0.61    0.56 0.68 0.61 0.57 0.69 
L3MBTL4 0.58    0.62 0.65             0.66    0.51 
NCAM1    0.68 0.72    -0.54       0.58    0.64 0.53 
NCR1    0.66 0.79    -0.57    0.54 0.50 0.65 0.68 0.65 
NKG7       0.76    -0.61    0.66 0.71    0.50 0.64 
PCDH1       0.63 0.71       0.53 0.63 0.52    0.59 
PDGFD       0.80    -0.55    0.58 0.79       0.57 
PDGFRB          0.57       0.58 0.54    0.50    
PRF1    0.59 0.81    -0.68    0.61 0.69 0.59 0.57 0.72 
PYHIN1       0.84 0.54 -0.74    0.56 0.74 0.51    0.78 
SH2D1A       0.59             0.54          
SLC4A10    0.57                      0.56    
SLC4A4       0.80 0.51 -0.57    0.57 0.78       0.62 
SLCO4C1       0.66 0.54 -0.55    0.72 0.79    0.54 0.58 
SPINK2             0.54                -0.55 





TGFBR3       0.79 0.63 -0.72    0.60 0.74 0.55    0.78 
TRGV9    0.79 0.65                0.52 0.73    
TTC38    0.53 0.71 0.57 -0.58    0.65 0.67 0.57 0.62 0.56 
TYROBP       0.60          0.66    0.57 0.58    
VWDE       -0.51    0.58    -0.63    -0.62    -0.51 
XCL1    0.67                      0.69    




















































































 ADAMTS1    0.65 0.75 0.61    0.68 0.50 0.66 0.51 0.55 
 ATP8B4                0.58             
 BNC2    0.59 0.72 0.60    0.57    0.62 0.55 0.70 
 C1orf21    0.54 0.75 0.63    0.59    0.60 0.56 0.69 
 CAMK2A 0.66                            
 CCNJL       0.73 0.60    0.75    0.63    0.57 
 CLIC3    0.50 0.78 0.56    0.65    0.59 0.65 0.78 
 CMKLR1       0.64       0.55       0.53 0.73 
 CST7       0.74 0.50          0.55 0.56 0.68 
 CXCR1       0.61                0.51 0.66 
 DAB2                            0.55 
 FCGR3A    0.58 0.82 0.61    0.56    0.63 0.62 0.70 
 FEZ1    0.54 0.73 0.51          0.55 0.69 0.67 
 FOSL2       0.58 0.52                   
 GNLY    0.61 0.82 0.73    0.75    0.69 0.53 0.61 
 GZMA    0.80 0.86 0.72    0.72 0.58 0.81 0.61 0.59 
 GZMB    0.65 0.78 0.65    0.67    0.71 0.63 0.76 
 GZMH    0.61 0.81 0.64    0.52    0.62 0.67 0.69 
 IL18RAP    0.60 0.80 0.63    0.70    0.71 0.63 0.70 
 ITGAM       0.64                   0.62 
 KLRD1    0.68 0.86 0.71    0.70    0.73 0.67 0.72 
 L3MBTL4       0.55                0.56 0.76 
 NCAM1    0.67 0.76 0.78    0.84    0.74    0.53 
 NCR1    0.55 0.81 0.59    0.70    0.67 0.59 0.68 
 NKG7    0.54 0.81 0.64    0.58    0.61 0.56 0.71 
 PCDH1       0.60                0.60 0.70 
 PDGFD    0.55 0.81 0.64    0.66    0.58 0.59 0.67 
 PDGFRB                            0.68 
 PRF1    0.72 0.85 0.65    0.68    0.77 0.67 0.70 
 PYHIN1    0.83 0.80 0.63    0.59 0.70 0.82 0.77 0.60 
 SH2D1A    0.58 0.53 0.55       0.65 0.58 0.57    
 SLC4A10                0.61             






SLCO4C1    0.60 0.73 0.65    0.64    0.63    0.70 
 SPINK2             0.57          -0.55    
 TBX21    0.64 0.82 0.60    0.57    0.70 0.76 0.76 
 TGFBR3    0.72 0.80 0.61    0.54 0.56 0.76 0.74 0.72 
 TRGV9    0.51 0.67 0.56    0.77    0.60    0.62 
 TTC38       0.73 0.53    0.63    0.56 0.58 0.83 
 TYROBP       0.64       0.56          0.68 
 VWDE       -0.52                -0.58 -0.52 
 XCL1          0.56    0.73    0.51       
 XCL2       0.57 0.59    0.77    0.55       
   
19.2 Correlation coefficients between expression of protein-coding and non-





































































ADAMTS1    0.79 0.75 -0.59    0.56 0.67    0.71    
BNC2    0.73 0.71 -0.65    0.75 0.84    0.77    
C1orf21    0.74 0.67 -0.70    0.69 0.77    0.70    
CAMK2A                            0.69 
CCNJL    0.62                0.55       
CLIC3    0.82 0.58 -0.67    0.68 0.52 0.60 0.85    
CMKLR1    0.69 0.74 -0.58    0.65 0.64    0.79    
CST7    0.55 0.70 -0.67    0.59 0.52 0.54 0.69    
CXCR1    0.56 0.77 -0.52    0.66 0.58    0.76    
DAB2       0.66       0.66 0.65          
DTX1       -0.53                      
DUSP4       -0.66                      
FCGR3A    0.76 0.72 -0.70    0.73 0.79    0.80    
FEZ1    0.70 0.77 -0.68    0.66 0.70 0.57 0.71    
FOSL2          -0.52 -0.55    0.52          
GNLY    0.73    -0.64          0.59 0.70    
GPR55                   -0.53          
GZMA    0.82 0.72 -0.69    0.66 0.71    0.81    
GZMB    0.66 0.74 -0.69    0.67 0.64 0.66 0.78    
GZMH    0.67 0.65 -0.71    0.68 0.70    0.83    
IL18RAP    0.79    -0.57    0.53 0.63    0.55    
IL23R             0.51    -0.53          
ITGAM    0.66          0.55 0.54    0.67    
KLRD1    0.73 0.74 -0.63    0.53 0.54 0.72 0.73    
L3MBTL4    0.72 0.75             0.53 0.62    





NCAM1    0.77    -0.56             0.68    
NCR1    0.71    -0.56          0.68 0.73    
NKG7    0.74 0.65 -0.70    0.69 0.59 0.58 0.88    
PCDH1    0.57 0.73       0.69 0.69    0.65    
PDGFD    0.84 0.60 -0.61    0.63 0.79    0.74    
PDGFRB       0.69       0.61       0.60    
PRF1    0.78 0.75 -0.66    0.69 0.64 0.63 0.83    
PYHIN1    0.81 0.79 -0.68    0.73 0.81    0.80    
SH2D1A    0.63 0.52 -0.61       0.74    0.50    
SLC4A10             0.55                
SLC4A4    0.81 0.54 -0.62    0.64 0.77    0.73    
SLCO4C1    0.74 0.75 -0.65    0.79 0.81    0.84    
SPINK2    -0.53 -0.71 0.72    -0.70 -0.76    -0.67    
TBX21    0.72 0.74 -0.73    0.69 0.72 0.53 0.76    
TGFBR3    0.64 0.69 -0.71    0.71 0.78    0.76    
TRGV9 0.69 0.55                0.75 0.56    
TTC38    0.70 0.76 -0.70    0.68 0.71 0.55 0.76    
TYROBP    0.64    -0.59    0.51    0.50 0.71    
VWDE    -0.57    0.78    -0.65 -0.62 -0.58 -0.65    





















































































ADAMTS1    0.69 0.69          0.58 0.64 0.62 0.68 
BNC2    0.80 0.67 0.56 -0.54    0.69 0.77 0.64 0.79 
C1orf21 -0.55 0.79 0.68 0.51 -0.50    0.58 0.79 0.76 0.71 
CCNJL -0.51    0.54             0.56       
CLIC3 -0.54 0.68 0.78    -0.58    0.57 0.67 0.73 0.63 
CMKLR1    0.77 0.68    -0.53    0.56 0.69 0.76 0.80 
CST7    0.60 0.60    -0.52       0.59 0.65 0.65 
CXCR1    0.64 0.55          0.51 0.53 0.59 0.74 
DAB2    0.58                0.57    0.67 
DUSP4                            -0.53 
FCGR3A -0.58 0.82 0.77 0.55 -0.52    0.61 0.76 0.78 0.76 
FEZ1 -0.51 0.80 0.69    -0.54    0.51 0.82 0.77 0.77 
FOSL2                      0.54       
GNLY       0.72 0.61       0.55    0.53    
GZMA -0.53 0.85 0.86 0.57 -0.51    0.63 0.77 0.80 0.73 
GZMB -0.60 0.75 0.68    -0.65       0.75 0.76 0.80 
GZMH    0.71 0.71 0.55 -0.56    0.59 0.64 0.73 0.72 
IL18RAP -0.57 0.69 0.70 0.52          0.80 0.57    
ITGAM    0.52 0.56             0.59       





L3MBTL4    0.53 0.59          0.50    0.57 0.63 
MYO7A    -0.57                -0.59 -0.54 -0.58 
NCAM1 -0.51 0.57 0.69 0.70    0.58 0.59 0.56       
NCR1 -0.53 0.51 0.68             0.56 0.59    
NKG7    0.66 0.74    -0.51    0.55 0.61 0.70 0.70 
PCDH1    0.67 0.53             0.60 0.59 0.73 
PDGFD -0.52 0.84 0.85 0.61       0.63 0.74 0.75 0.58 
PDGFRB    0.57                   0.54 0.71 
PRF1 -0.59 0.78 0.77    -0.56    0.55 0.73 0.77 0.74 
PYHIN1 -0.62 0.90 0.73 0.61 -0.56 0.56 0.71 0.86 0.79 0.81 
SH2D1A    0.67 0.63 0.75       0.59 0.73 0.66 0.58 
SLC4A4    0.83 0.81 0.63       0.63 0.78 0.76 0.59 
SLCO4C1    0.82 0.68 0.57 -0.51    0.69 0.75 0.67 0.77 
SPINK2 0.52 -0.69 -0.53    0.64    -0.53 -0.73 -0.64 -0.78 
TBX21 -0.62 0.76 0.69 0.54 -0.60    0.60 0.75 0.77 0.80 
TGFBR3 -0.54 0.80 0.66 0.57 -0.61    0.59 0.81 0.74 0.78 
TRGV9       0.54                0.52    
TTC38 -0.58 0.75 0.66    -0.64    0.56 0.76 0.77 0.83 
TYROBP       0.54          0.52          
VWDE 0.51 -0.56 -0.57    0.68       -0.67 -0.61 -0.72 
 
19.3 Correlation coefficients between expression of protein-coding and non-














































































ADAMTS1          0.76 0.75 0.71 0.51       0.64 0.57 
ATP8B4          0.79    0.54                
BNC2          0.55 0.64 0.55    0.64          
C1orf21          0.56 0.64 0.55 0.51       0.56    
CAMK2A          -0.54    -0.53          -0.73 -0.57 
CCNJL -0.54                               
CLIC3          0.53 0.56    0.58       0.71 0.77 
CMKLR1          0.51 0.76 0.52          0.76 0.68 
CST7       0.59    0.58          0.60       
CXCR1             0.70    0.52       0.62 0.71 
DAB2          0.70 0.75 0.62 0.64 0.57    0.61    
DTX1             -0.57                   
DUSP4          -0.58 -0.62 -0.72 -0.57       -0.63 -0.62 
FCGR3A             0.70 0.58 0.50       0.66 0.57 
FEZ1             0.67                   





GZMB             0.58          0.56    0.52 
GZMH       0.51                   0.51 0.76 
IL18RAP -0.55       0.59                      
ITGAM          0.52                0.60    
KLRD1             0.53          0.52       
L3MBTL4          0.76 0.66 0.72 0.63       0.59 0.65 
MYO7A             -0.67                   
N4BP3          -0.60 -0.63 -0.73 -0.54       -0.63 -0.67 
NCAM1          0.61                0.66    
NCR1                            0.53 0.51 
NELL2             -0.53    -0.56       -0.61    
NKG7    -0.53 0.55    0.58             0.64 0.84 
PCDH1             0.56    0.59       0.67 0.60 
PDGFD          0.67 0.61 0.58 0.62 0.58    0.68 0.50 
PDGFRB             0.71             0.74 0.80 
PRF1          0.53 0.74    0.52       0.76 0.77 
PYHIN1          0.66 0.77 0.64 0.56 0.53    0.52    
SH2D1A                            -0.58    
SLCO4C1          0.62 0.73 0.64 0.63 0.52    0.73 0.65 
SLC4A4          0.61 0.54 0.55 0.55       0.60    
TBX21             0.61    0.52       0.57    
TGFBR3             0.60                   
TTC38             0.60             0.64 0.62 
FOSL2          -0.59 -0.55 -0.74          -0.59 -0.66 




















































































 ADAMTS1    0.67 0.53    0.63 0.51       0.52 -0.62 
 ATP8B4             0.81 0.54             
 BNC2    0.71 0.58    0.51 0.54          -0.58 
 C1orf21 -0.53 0.86 0.62          0.57 0.67 0.65    
 CAMK2A 0.78 -0.59 -0.75                      
 CLIC3 -0.74    0.56                      
 CMKLR1 -0.68 0.73 0.68             0.59 0.71    
 CST7                      0.55       
 CXCR1 -0.58                            
 DAB2    0.82 0.56    0.54             -0.62 
 DTX1    -0.51    -0.57    -0.53       -0.61    
 DUSP4 0.53 -0.72 -0.68    -0.59 -0.62    -0.58 -0.72 0.55 
 FCGR3A -0.62 0.78 0.74             0.68 0.76    
 FEZ1    0.69             0.64 0.57       






GZMB          -0.56                   
 GZMH -0.52                            
 IL18RAP                   0.64          
 ITGAM -0.54                            
 L3MBTL4    0.58 0.58    0.60             -0.58 
 MYO7A    -0.78             -0.57 -0.68 -0.71    
 N4BP3 0.54 -0.71 -0.73    -0.66 -0.68    -0.61 -0.70 0.54 
 NCAM1 -0.60          0.59                
 NCR1 -0.57                            
 NKG7 -0.57    0.58                      
 PCDH1 -0.68 0.52                         
 PDGFD -0.69 0.81 0.75    0.66 0.56          -0.57 
 PDGFRB -0.59 0.54                   0.62    
 PRF1 -0.67 0.59 0.59                      
 PYHIN1 -0.55 0.96 0.71    0.62 0.55 0.59 0.60 0.56 -0.60 
 SLCO4C1 -0.65 0.81 0.68    0.58 0.55       0.60 -0.60 
 SPINK2                         -0.58    
 SLC4A4 -0.75 0.80 0.79    0.57       0.55       
 TBX21    0.64                0.57 0.56    
 TGFBR3    0.57                   0.62    
 TTC38 -0.58 0.64 0.62             0.63 0.67    
 XCL1                         -0.58    
 FOSL2 0.55 -0.67 -0.75    -0.64 -0.60    -0.58 -0.64    
 TRGV9 -0.55       -0.57                   
  
19.4 Correlation coefficients between expression of protein-coding and non-






































































ADAMTS1 0.66 0.77 0.54          0.52          
ATP8B4 0.84    0.73    0.51                
BNC2 0.56 0.56       0.60    0.60          
C1orf21 0.57 0.53                         
CAMK2A                         0.77    
CLIC3 0.53       0.50       0.60 0.78 -0.57    
CMKLR1 0.61 0.62             0.78 0.72 -0.58    
CST7    0.60          0.61             
CXCR1    0.68             0.67 0.70       
DAB2 0.74 0.66 0.52 0.57       0.74          
DTX1    -0.60                         





FCGR3A 0.54 0.54             0.69 0.57       
FEZ1    0.66                         
FOSL2 -0.52    -0.68                      
GZMA 0.62 0.56 0.51          0.52          
GZMB    0.53          0.58 0.56          
IL18RAP 0.58                            
ITGAM 0.54                0.73 0.62       
KLRD1    0.66                         
L3MBTL4 0.71 0.68 0.61 0.52          0.54       
MYO7A                            0.50 
N4BP3 -0.54 -0.66 -0.63          -0.59 -0.58       
NCAM1 0.68    0.56 0.58       0.68 0.70 -0.58    
NCR1                      0.63 -0.63    
NELL2    -0.57    -0.51       -0.64          
NKG7                   0.65 0.83       
PCDH1                   0.70 0.58 -0.53    
PDGFD 0.78    0.63          0.50    -0.70    
PDGFRB    0.66             0.76 0.81       
PRF1 0.51 0.70             0.71 0.69 -0.56    
PYHIN1 0.73 0.73 0.60          0.63          
SH2D1A                   -0.57 -0.56 0.54    
SLC4A10                         -0.51    
SLC4A4 0.71    0.64                -0.65    
SLCO4C1 0.69 0.62 0.58 0.63       0.85 0.73       
SPINK2                               
TBX21    0.58             0.54          
TRGV9                0.66    0.55       
TTC38    0.59             0.70 0.58       






















































































ADAMTS1             0.61          0.50    
ATP8B4 0.61 0.60       0.78 0.60          -0.65 
BNC2             0.56 0.52             
C1orf21 0.75          0.51    0.50 0.50 0.57    
CAMK2A -0.50 -0.77                         
CMKLR1 0.59 0.56       0.52          0.52    
CST7       -0.54                      
DAB2 0.64          0.58                
DTX1                         -0.60    
DUSP4             -0.67 -0.64       -0.67    





FEZ1                   0.57          
FOSL2    -0.54       -0.64                
GZMA 0.69 0.71                         
GZMB       -0.65                      
IL18RAP                   0.65          
L3MBTL4             0.61                
MYO7A -0.57                -0.56          
N4BP3             -0.67 -0.62       -0.65    
NCAM1 0.60 0.52       0.57 0.52             
NELL2                         -0.59    
NKG7                               
PCDH1                               
PDGFD 0.70 0.78       0.68             -0.53 
PDGFRB                         0.57    
PYHIN1 0.77          0.70    0.52          
SH2D1A       0.50                      
SLC4A4 0.76 0.80       0.59                
SLCO4C1 0.65          0.67 0.58             
SPINK2          0.54             -0.50    
TTC38                         0.56    
TYROBP                               
XCL1                         -0.50    
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19.7 Correlation coefficients between expression of protein-coding and non-


















































































ADAMTS1       0.82                            
ATP8B4 0.79                                  
C1orf21    0.82    0.86                0.86 0.86    
CAMK2A    -0.93    -0.82          0.82 -0.85 -0.85 -0.93    
CLIC3          0.86                0.82       
CMKLR1    0.79    0.79          -0.86 0.82 0.82 0.79    
CST7    0.86                -0.82 0.86 0.86 0.86    
CXCR1    0.82    0.82             0.89 0.89 0.93    
DAB2       0.86                            
DUSP4    -0.86    -0.86             -0.86 -0.86 -0.96    
FCGR3A    1.00                -0.86 0.82    0.82 -0.79 
FEZ1          0.86                0.79       
FOSL2    -0.96                0.93 -0.86       0.89 
GZMA    0.93    0.79                0.82 0.89    
GZMB          0.93                1.00 0.93    
GZMH    0.93                -0.96 0.89       -0.82 
IL18RAP       0.82                            
ITGAM          0.86          -0.79 0.86 0.86 0.86    
KLRD1          0.96                0.86 0.86    
L3MBTL4          0.93                0.93 0.79    





N4BP3    -1.00                0.86 -0.82    -0.82 0.79 
NCAM1    0.93                   0.79 0.79 0.93    
NCR1    0.79    0.89             0.82 0.82 0.89    
NELL2          -0.79                -0.86       
NKG7    0.82    0.82             0.89 0.89 0.93    
PCDH1          0.96                0.96 0.86    
PDGFD    0.79                -0.86 0.93       -0.93 
PDGFRB    0.79    0.86             0.82 0.96 0.96    
PRF1          0.96                0.96 0.86    
PYHIN1    0.79    0.79                0.79 0.93    
SH2D1A    -0.79                0.96 -0.93       0.82 
SLC4A4    0.89                -0.89 0.82       -0.93 
SLCO4C1    0.86    0.86             0.86 0.86 0.96    
SPINK2          -0.76    -0.80          -0.76       
TBX21             -0.85       -0.86 0.82          
TGFBR3          0.86                0.82 0.89    
TRGV9                   0.86    0.79       -0.93 
TTC38          0.96                0.96 0.86    





























































































 ADAMTS1                      0.79          
 BNC2                      0.93          
 C1orf21    0.79    -0.79    -0.86          0.82    
 CAMK2A 0.78                0.85    -0.78 -0.93    
 CLIC3 -0.79       -0.96    -0.86                
 CMKLR1 -0.89                -0.96       0.86    
 CST7 -0.79             -0.79 -0.89    0.79 0.93    
 CXCR1                   -0.86       0.96    
 DUSP4                   0.79       -0.93    
 FCGR3A       0.82                0.89 0.79 0.86 
 FEZ1 -0.82       -0.86    -0.86                
 FOSL2       -0.89          0.79    -0.93       
 GPR55       -0.86                -0.79       
 GZMA                -0.79          0.86 0.86 
 GZMB          -0.93    -0.93          0.96    
 GZMH -0.79    0.86          -0.86    0.96       
 ITGAM -0.82       -0.79       -0.93       0.89    
 KLRD1 -0.79 0.86    -0.86    -0.79          0.79    
 L3MBTL4          -1.00    -0.93          0.82    
 MYO7A    -0.82    0.93    0.82          -0.86    






NCAM1                            0.86 0.79 
 NCR1 -0.79                -0.86       0.86    
 NELL2          0.86    0.79                
 NKG7                   -0.86       0.96    
 PCDH1 -0.79       -0.96    -0.89 -0.79       0.89    
 PDGFD                   -0.86             
 PDGFRB          -0.82    -0.86          1.00    
 PRF1 -0.79       -0.96    -0.89 -0.79       0.89    
 PYHIN1    0.89                      0.82    
 SH2D1A 0.86                0.96    -0.86       
 SLC4A4       0.86             -0.79 0.86       
 SLCO4C1                   -0.79       0.93    
 SPINK2    -0.76    0.80    0.80                
 TBX21 -0.82                -0.96             
 TGFBR3    0.96                      0.79    
 TRGV9          -0.79                      
 TTC38 -0.79       -0.96    -0.89 -0.79       0.89    
 TYROBP                   -0.79       0.79    
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